index,title,abstract,Master Ref#,PubMed ID,Journal,Primary Author,Publication Year,Volume / Issue,Pages,Priority Journal,PubMed ID:,Full Reference:,"Study Outcome ($/QALY, $/DALY, Both):",Study Country:,Disease Classification:,Intervention Type(s):,Intervention Phrase vs. Comparator Phrase:,Target Characteristics:,Max Target Age:,Min Target Age:,Target Genders:,Review:,Time Horizon:,Discounting Rate (Costs):,Discounting Rate (QALYs):,Incremental Cost-Effectiveness Ratio (Original currency and year):,Currency Country:,Currency Year:,Incremental Cost-Effectiveness Ratio (Converted to current $USD):
10401,Establishing the cost-effectiveness of percutaneous coronary intervention for chronic total occlusion in stable angina: a decision-analytic model,"In the setting of chronic stable angina, successful percutaneous coronary intervention (PCI) of chronic total occlusions (CTO) has been shown to produce significant symptom improvement with some evidence for survival benefit. However, the economic basis for this procedure has not been established compared with optimal medical treatment (OMT) of chronic stable angina.The aim of this study was to determine the cost-effectiveness of CTO-PCI in chronic stable angina using a Markov model.The transition probabilities, utilities and costs related to CTO-PCI and OMT used to inform the model were derived from literature and our experience. Implications with respect to cost and quality of life were calculated. Sensitivity analyses were based on factors noted to influence model outcome.In the reference case, mean age 60 years, rate of successful CTO-PCI 67.9%, and mean transition probabilities, utilities and costs as defined by literature and clinical experience, the strategy of CTO-PCI incurred higher costs relative to OMT (US$31 512 vs US$27 805), but also accumulated greater quality-adjusted life-years (QALYs) (2.38 vs 1.99), yielding a cost-effectiveness ratio of US$9505 per QALY. Sensitivity analyses showed the utility of OMT and utilities postsuccessful and postunsuccessful CTO-PCI to be the most influential drivers of outcome. Procedural success held limited influence over model outcome at particular utility threshold values.On the basis of the supporting evidence, this decision-analytic model suggests that CTO-PCI is cost-effective in a patient population with severe symptoms. Quality-of-life metrics should be employed in future appropriateness criteria developed for CTO-PCI.",2012-01-09905,23038791,Heart,Hemal Gada,2012,98 / 24,1790-7,No,23038791,"Hemal Gada; Patrick L Whitlow; Thomas H Marwick; Establishing the cost-effectiveness of percutaneous coronary intervention for chronic total occlusion in stable angina: a decision-analytic model, Heart, ; 98(24):1468-201X; 1790-7",QALY,Canada,Not Stated,Not Stated,Percutaneous coronary intervention (PCI) of chronic total occlusions (CTO) (CTO-PCI) vs. Optimal medical treatment (OMT),Not Stated,60 Years,60 Years,"Female, Male",Full,5 Years,5.00,5.00,9505,United States,2012,10714.56
10402,A model of the cost-effectiveness of intensity-modulated radiotherapy in comparison with three-dimensional conformal radiotherapy for the treatment of localised prostate cancer,"To determine the cost-effectiveness of intensity-modulated radiotherapy (IMRT) compared with three-dimensional conformal radiotherapy (3DCRT) for men with localised prostate cancer from a UK National Health Service perspective.A discrete event simulation model was developed to simulate the progress of patients through advancing disease states until death from prostate cancer or other causes. Clinical effectiveness data for IMRT and 3DCRT were derived from a systematic review. Four scenarios were modelled based on different clinical studies. A probabilistic sensitivity analysis was undertaken and the incremental cost per quality adjusted life years (ICER) calculated.In scenarios where estimated survival was greater for IMRT than 3DCRT, IMRT was clearly cost-effective (ICER <?20 000). For scenarios where only a difference in late gastrointestinal toxicity was assumed, the ICER was highly sensitive to uncertain model parameters, including the magnitude of the difference, the duration of gastrointestinal toxicity and the cost difference between treatments. For the most likely scenario, a 15% difference in late gastrointestinal toxicity, the ICER was ?35 000, with a 20% probability that it is cost-effective at a maximum threshold of ?20 000 and a 48% probability at a threshold of ?30 000.If IMRT can be used to prolong survival, it is very cost-effective. Otherwise cost-effectiveness is uncertain.",2012-01-09907,23040143,Clin Oncol (R Coll Radiol),S R Hummel,2012,24 / 10,e159-67,No,23040143,"S R Hummel; M D Stevenson; E L Simpson; J Staffurth; A model of the cost-effectiveness of intensity-modulated radiotherapy in comparison with three-dimensional conformal radiotherapy for the treatment of localised prostate cancer, Clin Oncol (R Coll Radiol), ; 24(10):0936-6555; e159-67",QALY,Not Stated,Not Stated,Not Stated,Intensity-modulated radiotherapy (IMRT) vs. 3-dimensional conformal radiotherapy (3DCRT),Not Stated,Not Stated,70 Years,Male,Full,Lifetime,3.50,3.50,104066,United Kingdom,2009,181775.87
10403,A model of the cost-effectiveness of intensity-modulated radiotherapy in comparison with three-dimensional conformal radiotherapy for the treatment of localised prostate cancer,"To determine the cost-effectiveness of intensity-modulated radiotherapy (IMRT) compared with three-dimensional conformal radiotherapy (3DCRT) for men with localised prostate cancer from a UK National Health Service perspective.A discrete event simulation model was developed to simulate the progress of patients through advancing disease states until death from prostate cancer or other causes. Clinical effectiveness data for IMRT and 3DCRT were derived from a systematic review. Four scenarios were modelled based on different clinical studies. A probabilistic sensitivity analysis was undertaken and the incremental cost per quality adjusted life years (ICER) calculated.In scenarios where estimated survival was greater for IMRT than 3DCRT, IMRT was clearly cost-effective (ICER <?20 000). For scenarios where only a difference in late gastrointestinal toxicity was assumed, the ICER was highly sensitive to uncertain model parameters, including the magnitude of the difference, the duration of gastrointestinal toxicity and the cost difference between treatments. For the most likely scenario, a 15% difference in late gastrointestinal toxicity, the ICER was ?35 000, with a 20% probability that it is cost-effective at a maximum threshold of ?20 000 and a 48% probability at a threshold of ?30 000.If IMRT can be used to prolong survival, it is very cost-effective. Otherwise cost-effectiveness is uncertain.",2012-01-09907,23040143,Clin Oncol (R Coll Radiol),S R Hummel,2012,24 / 10,e159-67,No,23040143,"S R Hummel; M D Stevenson; E L Simpson; J Staffurth; A model of the cost-effectiveness of intensity-modulated radiotherapy in comparison with three-dimensional conformal radiotherapy for the treatment of localised prostate cancer, Clin Oncol (R Coll Radiol), ; 24(10):0936-6555; e159-67",QALY,Not Stated,Not Stated,Not Stated,Intensity-modulated radiotherapy (IMRT) vs. 3-dimensional conformal radiotherapy (3DCRT),Not Stated,Not Stated,70 Years,Male,Full,Lifetime,3.50,3.50,31162,United Kingdom,2009,54431.8
10404,A model of the cost-effectiveness of intensity-modulated radiotherapy in comparison with three-dimensional conformal radiotherapy for the treatment of localised prostate cancer,"To determine the cost-effectiveness of intensity-modulated radiotherapy (IMRT) compared with three-dimensional conformal radiotherapy (3DCRT) for men with localised prostate cancer from a UK National Health Service perspective.A discrete event simulation model was developed to simulate the progress of patients through advancing disease states until death from prostate cancer or other causes. Clinical effectiveness data for IMRT and 3DCRT were derived from a systematic review. Four scenarios were modelled based on different clinical studies. A probabilistic sensitivity analysis was undertaken and the incremental cost per quality adjusted life years (ICER) calculated.In scenarios where estimated survival was greater for IMRT than 3DCRT, IMRT was clearly cost-effective (ICER <?20 000). For scenarios where only a difference in late gastrointestinal toxicity was assumed, the ICER was highly sensitive to uncertain model parameters, including the magnitude of the difference, the duration of gastrointestinal toxicity and the cost difference between treatments. For the most likely scenario, a 15% difference in late gastrointestinal toxicity, the ICER was ?35 000, with a 20% probability that it is cost-effective at a maximum threshold of ?20 000 and a 48% probability at a threshold of ?30 000.If IMRT can be used to prolong survival, it is very cost-effective. Otherwise cost-effectiveness is uncertain.",2012-01-09907,23040143,Clin Oncol (R Coll Radiol),S R Hummel,2012,24 / 10,e159-67,No,23040143,"S R Hummel; M D Stevenson; E L Simpson; J Staffurth; A model of the cost-effectiveness of intensity-modulated radiotherapy in comparison with three-dimensional conformal radiotherapy for the treatment of localised prostate cancer, Clin Oncol (R Coll Radiol), ; 24(10):0936-6555; e159-67",QALY,Not Stated,Not Stated,Not Stated,Intensity-modulated radiotherapy (IMRT) vs. 3-dimensional conformal radiotherapy (3DCRT),Not Stated,Not Stated,70 Years,Male,Full,Lifetime,3.50,3.50,5295,United Kingdom,2009,9248.97
10405,A model of the cost-effectiveness of intensity-modulated radiotherapy in comparison with three-dimensional conformal radiotherapy for the treatment of localised prostate cancer,"To determine the cost-effectiveness of intensity-modulated radiotherapy (IMRT) compared with three-dimensional conformal radiotherapy (3DCRT) for men with localised prostate cancer from a UK National Health Service perspective.A discrete event simulation model was developed to simulate the progress of patients through advancing disease states until death from prostate cancer or other causes. Clinical effectiveness data for IMRT and 3DCRT were derived from a systematic review. Four scenarios were modelled based on different clinical studies. A probabilistic sensitivity analysis was undertaken and the incremental cost per quality adjusted life years (ICER) calculated.In scenarios where estimated survival was greater for IMRT than 3DCRT, IMRT was clearly cost-effective (ICER <?20 000). For scenarios where only a difference in late gastrointestinal toxicity was assumed, the ICER was highly sensitive to uncertain model parameters, including the magnitude of the difference, the duration of gastrointestinal toxicity and the cost difference between treatments. For the most likely scenario, a 15% difference in late gastrointestinal toxicity, the ICER was ?35 000, with a 20% probability that it is cost-effective at a maximum threshold of ?20 000 and a 48% probability at a threshold of ?30 000.If IMRT can be used to prolong survival, it is very cost-effective. Otherwise cost-effectiveness is uncertain.",2012-01-09907,23040143,Clin Oncol (R Coll Radiol),S R Hummel,2012,24 / 10,e159-67,No,23040143,"S R Hummel; M D Stevenson; E L Simpson; J Staffurth; A model of the cost-effectiveness of intensity-modulated radiotherapy in comparison with three-dimensional conformal radiotherapy for the treatment of localised prostate cancer, Clin Oncol (R Coll Radiol), ; 24(10):0936-6555; e159-67",QALY,Not Stated,Not Stated,Not Stated,Intensity-modulated radiotherapy (IMRT) vs. 3-dimensional conformal radiotherapy (3DCRT),Not Stated,Not Stated,70 Years,Male,Full,Lifetime,3.50,3.50,-2939.64,United Kingdom,2009,-5134.78
10406,Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium,"To evaluate the cost-utility of adding tiotropium to usual care versus usual care alone for patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in the UK and Belgium.A four-state Markov model was developed with three disease severity states (moderate, severe, very severe) and death. Severity was based on post-bronchodilator FEV1 and transitions were based on outcomes of the Understanding Potential Long Term Impacts on Function with Tiotropium (UPLIFT?) trial. Utilities were derived from EQ-5D scores for a subset of UPLIFT? patients. UK costs were evaluated separately for England (E), and for Scotland, Wales and Northern Ireland (SWNI). Belgian (B) costs were obtained from local sources. Uncertainty was assessed by deterministic and probabilistic sensitivity analysis (PSA).Adding tiotropium to usual care resulted in an incremental cost per patient of ?969 (B), ?796 (E), and ?812 (SWNI), and incremental QALYs of 0.052 (B), and 0.051 (E, SWNI). The four-year incremental cost-effectiveness ratios (ICER) were ?18,617 (B), ?15,567 (E) and ?15,890 (SWNI) per QALY. Probability of tiotropium being cost-effective at ?30,000 (?50,000) per QALY gained was greater than 60%.At willingness to pay thresholds of ?(?) 30,000 per QALY gained, adding tiotropium to usual care is cost-effective.",2012-01-09908,23040833,Respir Med,Robert Hettle,2012,106 / 12,1722-33,No,23040833,"Robert Hettle; Hanne Wouters; Jon Ayres; Ray Gani; Steve Kelly; Michaela Lion; Marc Decramer; Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium, Respir Med, ; 106(12):0954-6111; 1722-33",QALY,Not Stated,Not Stated,Not Stated,Tiotropium plus usual care vs. Usual care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,4 Years,3.50,3.50,15567,United Kingdom,2011,28734.86
10407,Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium,"To evaluate the cost-utility of adding tiotropium to usual care versus usual care alone for patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in the UK and Belgium.A four-state Markov model was developed with three disease severity states (moderate, severe, very severe) and death. Severity was based on post-bronchodilator FEV1 and transitions were based on outcomes of the Understanding Potential Long Term Impacts on Function with Tiotropium (UPLIFT?) trial. Utilities were derived from EQ-5D scores for a subset of UPLIFT? patients. UK costs were evaluated separately for England (E), and for Scotland, Wales and Northern Ireland (SWNI). Belgian (B) costs were obtained from local sources. Uncertainty was assessed by deterministic and probabilistic sensitivity analysis (PSA).Adding tiotropium to usual care resulted in an incremental cost per patient of ?969 (B), ?796 (E), and ?812 (SWNI), and incremental QALYs of 0.052 (B), and 0.051 (E, SWNI). The four-year incremental cost-effectiveness ratios (ICER) were ?18,617 (B), ?15,567 (E) and ?15,890 (SWNI) per QALY. Probability of tiotropium being cost-effective at ?30,000 (?50,000) per QALY gained was greater than 60%.At willingness to pay thresholds of ?(?) 30,000 per QALY gained, adding tiotropium to usual care is cost-effective.",2012-01-09908,23040833,Respir Med,Robert Hettle,2012,106 / 12,1722-33,No,23040833,"Robert Hettle; Hanne Wouters; Jon Ayres; Ray Gani; Steve Kelly; Michaela Lion; Marc Decramer; Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium, Respir Med, ; 106(12):0954-6111; 1722-33",QALY,Not Stated,Not Stated,Not Stated,Tiotropium plus usual care vs. Usual care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,4 Years,3.50,3.50,15890,United Kingdom,2011,29331.08
10408,Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium,"To evaluate the cost-utility of adding tiotropium to usual care versus usual care alone for patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in the UK and Belgium.A four-state Markov model was developed with three disease severity states (moderate, severe, very severe) and death. Severity was based on post-bronchodilator FEV1 and transitions were based on outcomes of the Understanding Potential Long Term Impacts on Function with Tiotropium (UPLIFT?) trial. Utilities were derived from EQ-5D scores for a subset of UPLIFT? patients. UK costs were evaluated separately for England (E), and for Scotland, Wales and Northern Ireland (SWNI). Belgian (B) costs were obtained from local sources. Uncertainty was assessed by deterministic and probabilistic sensitivity analysis (PSA).Adding tiotropium to usual care resulted in an incremental cost per patient of ?969 (B), ?796 (E), and ?812 (SWNI), and incremental QALYs of 0.052 (B), and 0.051 (E, SWNI). The four-year incremental cost-effectiveness ratios (ICER) were ?18,617 (B), ?15,567 (E) and ?15,890 (SWNI) per QALY. Probability of tiotropium being cost-effective at ?30,000 (?50,000) per QALY gained was greater than 60%.At willingness to pay thresholds of ?(?) 30,000 per QALY gained, adding tiotropium to usual care is cost-effective.",2012-01-09908,23040833,Respir Med,Robert Hettle,2012,106 / 12,1722-33,No,23040833,"Robert Hettle; Hanne Wouters; Jon Ayres; Ray Gani; Steve Kelly; Michaela Lion; Marc Decramer; Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium, Respir Med, ; 106(12):0954-6111; 1722-33",QALY,Belgium,Not Stated,Not Stated,Tiotropium plus usual care vs. Usual care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,4 Years,3.50,3.50,18617,United Kingdom,2011,34364.8
10409,Cost-effectiveness analysis of primary arthroscopic stabilization versus nonoperative treatment for first-time anterior glenohumeral dislocations,"The purpose of this study was to compare the cost-effectiveness of initial observation versus surgery for first-time anterior shoulder dislocation.The clinical scenario of first-time anterior glenohumeral dislocation was simulated using a Markov model (where variables change over time depending on previous states). Nonoperative outcomes include success (no recurrence) and recurrence; surgical outcomes include success, recurrence, and complications of infection or stiffness. Probabilities for outcomes were determined from published literature. Costs were tabulated from Medicare Current Procedural Terminology data, as well as hospital and office billing records. We performed microsimulation and probabilistic sensitivity analysis running 6 models for 1,000 patients over a period of 15 years. The 6 models tested were male versus female patients aged 15 years versus 25 years versus 35 years.Primary surgery was less costly and more effective for 15-year-old boys, 15-year-old girls, and 25-year-old men. For the remaining scenarios (25-year-old women and 35-year-old men and women), primary surgery was also more effective but was more costly. However, for these scenarios, primary surgery was still very cost-effective (cost per quality-adjusted life-year, <$25,000). After 1 recurrence, surgery was less costly and more effective for all scenarios.Primary arthroscopic stabilization is a clinically effective and cost-effective treatment for first-time anterior shoulder dislocations in the cohorts studied. By use of a willingness-to-pay threshold of $25,000 per quality-adjusted life-year, surgery was more cost-effective than nonoperative treatment for the majority of patients studied in the model.Level II, economic and decision analysis.",2012-01-09909,23040837,Arthroscopy,Timothy S Crall,2012,28 / 12,1755-65,No,23040837,"Timothy S Crall; Julius A Bishop; Dan Guttman; Mininder Kocher; Kevin Bozic; James H Lubowitz; Cost-effectiveness analysis of primary arthroscopic stabilization versus nonoperative treatment for first-time anterior glenohumeral dislocations, Arthroscopy , ; 28(12):1526-3231; 1755-65",QALY,Not Stated,Not Stated,Not Stated,Standard noncontrast magnetic resonance imaging followed by an arthroscopic Bankart repair vs. Nonoperative treatment,Not Stated,15 Years,15 Years,Male,Full,15 Years,5.00,5.00,-15499.13,United States,2010,-18395.94
10410,Cost-effectiveness analysis of primary arthroscopic stabilization versus nonoperative treatment for first-time anterior glenohumeral dislocations,"The purpose of this study was to compare the cost-effectiveness of initial observation versus surgery for first-time anterior shoulder dislocation.The clinical scenario of first-time anterior glenohumeral dislocation was simulated using a Markov model (where variables change over time depending on previous states). Nonoperative outcomes include success (no recurrence) and recurrence; surgical outcomes include success, recurrence, and complications of infection or stiffness. Probabilities for outcomes were determined from published literature. Costs were tabulated from Medicare Current Procedural Terminology data, as well as hospital and office billing records. We performed microsimulation and probabilistic sensitivity analysis running 6 models for 1,000 patients over a period of 15 years. The 6 models tested were male versus female patients aged 15 years versus 25 years versus 35 years.Primary surgery was less costly and more effective for 15-year-old boys, 15-year-old girls, and 25-year-old men. For the remaining scenarios (25-year-old women and 35-year-old men and women), primary surgery was also more effective but was more costly. However, for these scenarios, primary surgery was still very cost-effective (cost per quality-adjusted life-year, <$25,000). After 1 recurrence, surgery was less costly and more effective for all scenarios.Primary arthroscopic stabilization is a clinically effective and cost-effective treatment for first-time anterior shoulder dislocations in the cohorts studied. By use of a willingness-to-pay threshold of $25,000 per quality-adjusted life-year, surgery was more cost-effective than nonoperative treatment for the majority of patients studied in the model.Level II, economic and decision analysis.",2012-01-09909,23040837,Arthroscopy,Timothy S Crall,2012,28 / 12,1755-65,No,23040837,"Timothy S Crall; Julius A Bishop; Dan Guttman; Mininder Kocher; Kevin Bozic; James H Lubowitz; Cost-effectiveness analysis of primary arthroscopic stabilization versus nonoperative treatment for first-time anterior glenohumeral dislocations, Arthroscopy , ; 28(12):1526-3231; 1755-65",QALY,Not Stated,Not Stated,Not Stated,Standard noncontrast magnetic resonance imaging followed by an arthroscopic Bankart repair vs. Nonoperative treatment,Not Stated,15 Years,15 Years,Female,Full,15 Years,5.00,5.00,-1601.11,United States,2010,-1900.36
10411,Cost-effectiveness analysis of primary arthroscopic stabilization versus nonoperative treatment for first-time anterior glenohumeral dislocations,"The purpose of this study was to compare the cost-effectiveness of initial observation versus surgery for first-time anterior shoulder dislocation.The clinical scenario of first-time anterior glenohumeral dislocation was simulated using a Markov model (where variables change over time depending on previous states). Nonoperative outcomes include success (no recurrence) and recurrence; surgical outcomes include success, recurrence, and complications of infection or stiffness. Probabilities for outcomes were determined from published literature. Costs were tabulated from Medicare Current Procedural Terminology data, as well as hospital and office billing records. We performed microsimulation and probabilistic sensitivity analysis running 6 models for 1,000 patients over a period of 15 years. The 6 models tested were male versus female patients aged 15 years versus 25 years versus 35 years.Primary surgery was less costly and more effective for 15-year-old boys, 15-year-old girls, and 25-year-old men. For the remaining scenarios (25-year-old women and 35-year-old men and women), primary surgery was also more effective but was more costly. However, for these scenarios, primary surgery was still very cost-effective (cost per quality-adjusted life-year, <$25,000). After 1 recurrence, surgery was less costly and more effective for all scenarios.Primary arthroscopic stabilization is a clinically effective and cost-effective treatment for first-time anterior shoulder dislocations in the cohorts studied. By use of a willingness-to-pay threshold of $25,000 per quality-adjusted life-year, surgery was more cost-effective than nonoperative treatment for the majority of patients studied in the model.Level II, economic and decision analysis.",2012-01-09909,23040837,Arthroscopy,Timothy S Crall,2012,28 / 12,1755-65,No,23040837,"Timothy S Crall; Julius A Bishop; Dan Guttman; Mininder Kocher; Kevin Bozic; James H Lubowitz; Cost-effectiveness analysis of primary arthroscopic stabilization versus nonoperative treatment for first-time anterior glenohumeral dislocations, Arthroscopy , ; 28(12):1526-3231; 1755-65",QALY,Not Stated,Not Stated,Not Stated,Standard noncontrast magnetic resonance imaging followed by an arthroscopic Bankart repair vs. Nonoperative treatment,Not Stated,25 Years,25 Years,Male,Full,15 Years,5.00,5.00,-3046.32,United States,2010,-3615.68
10412,Cost-effectiveness analysis of primary arthroscopic stabilization versus nonoperative treatment for first-time anterior glenohumeral dislocations,"The purpose of this study was to compare the cost-effectiveness of initial observation versus surgery for first-time anterior shoulder dislocation.The clinical scenario of first-time anterior glenohumeral dislocation was simulated using a Markov model (where variables change over time depending on previous states). Nonoperative outcomes include success (no recurrence) and recurrence; surgical outcomes include success, recurrence, and complications of infection or stiffness. Probabilities for outcomes were determined from published literature. Costs were tabulated from Medicare Current Procedural Terminology data, as well as hospital and office billing records. We performed microsimulation and probabilistic sensitivity analysis running 6 models for 1,000 patients over a period of 15 years. The 6 models tested were male versus female patients aged 15 years versus 25 years versus 35 years.Primary surgery was less costly and more effective for 15-year-old boys, 15-year-old girls, and 25-year-old men. For the remaining scenarios (25-year-old women and 35-year-old men and women), primary surgery was also more effective but was more costly. However, for these scenarios, primary surgery was still very cost-effective (cost per quality-adjusted life-year, <$25,000). After 1 recurrence, surgery was less costly and more effective for all scenarios.Primary arthroscopic stabilization is a clinically effective and cost-effective treatment for first-time anterior shoulder dislocations in the cohorts studied. By use of a willingness-to-pay threshold of $25,000 per quality-adjusted life-year, surgery was more cost-effective than nonoperative treatment for the majority of patients studied in the model.Level II, economic and decision analysis.",2012-01-09909,23040837,Arthroscopy,Timothy S Crall,2012,28 / 12,1755-65,No,23040837,"Timothy S Crall; Julius A Bishop; Dan Guttman; Mininder Kocher; Kevin Bozic; James H Lubowitz; Cost-effectiveness analysis of primary arthroscopic stabilization versus nonoperative treatment for first-time anterior glenohumeral dislocations, Arthroscopy , ; 28(12):1526-3231; 1755-65",QALY,Not Stated,Not Stated,Not Stated,Standard noncontrast magnetic resonance imaging followed by an arthroscopic Bankart repair vs. Nonoperative treatment,Not Stated,25 Years,25 Years,Female,Full,15 Years,5.00,5.00,14394,United States,2010,17084.26
10413,Cost-effectiveness analysis of primary arthroscopic stabilization versus nonoperative treatment for first-time anterior glenohumeral dislocations,"The purpose of this study was to compare the cost-effectiveness of initial observation versus surgery for first-time anterior shoulder dislocation.The clinical scenario of first-time anterior glenohumeral dislocation was simulated using a Markov model (where variables change over time depending on previous states). Nonoperative outcomes include success (no recurrence) and recurrence; surgical outcomes include success, recurrence, and complications of infection or stiffness. Probabilities for outcomes were determined from published literature. Costs were tabulated from Medicare Current Procedural Terminology data, as well as hospital and office billing records. We performed microsimulation and probabilistic sensitivity analysis running 6 models for 1,000 patients over a period of 15 years. The 6 models tested were male versus female patients aged 15 years versus 25 years versus 35 years.Primary surgery was less costly and more effective for 15-year-old boys, 15-year-old girls, and 25-year-old men. For the remaining scenarios (25-year-old women and 35-year-old men and women), primary surgery was also more effective but was more costly. However, for these scenarios, primary surgery was still very cost-effective (cost per quality-adjusted life-year, <$25,000). After 1 recurrence, surgery was less costly and more effective for all scenarios.Primary arthroscopic stabilization is a clinically effective and cost-effective treatment for first-time anterior shoulder dislocations in the cohorts studied. By use of a willingness-to-pay threshold of $25,000 per quality-adjusted life-year, surgery was more cost-effective than nonoperative treatment for the majority of patients studied in the model.Level II, economic and decision analysis.",2012-01-09909,23040837,Arthroscopy,Timothy S Crall,2012,28 / 12,1755-65,No,23040837,"Timothy S Crall; Julius A Bishop; Dan Guttman; Mininder Kocher; Kevin Bozic; James H Lubowitz; Cost-effectiveness analysis of primary arthroscopic stabilization versus nonoperative treatment for first-time anterior glenohumeral dislocations, Arthroscopy , ; 28(12):1526-3231; 1755-65",QALY,Not Stated,Not Stated,Not Stated,Standard noncontrast magnetic resonance imaging followed by an arthroscopic Bankart repair vs. Nonoperative treatment,Not Stated,35 Years,35 Years,Male,Full,15 Years,5.00,5.00,13359,United States,2010,15855.82
10414,Cost-effectiveness analysis of primary arthroscopic stabilization versus nonoperative treatment for first-time anterior glenohumeral dislocations,"The purpose of this study was to compare the cost-effectiveness of initial observation versus surgery for first-time anterior shoulder dislocation.The clinical scenario of first-time anterior glenohumeral dislocation was simulated using a Markov model (where variables change over time depending on previous states). Nonoperative outcomes include success (no recurrence) and recurrence; surgical outcomes include success, recurrence, and complications of infection or stiffness. Probabilities for outcomes were determined from published literature. Costs were tabulated from Medicare Current Procedural Terminology data, as well as hospital and office billing records. We performed microsimulation and probabilistic sensitivity analysis running 6 models for 1,000 patients over a period of 15 years. The 6 models tested were male versus female patients aged 15 years versus 25 years versus 35 years.Primary surgery was less costly and more effective for 15-year-old boys, 15-year-old girls, and 25-year-old men. For the remaining scenarios (25-year-old women and 35-year-old men and women), primary surgery was also more effective but was more costly. However, for these scenarios, primary surgery was still very cost-effective (cost per quality-adjusted life-year, <$25,000). After 1 recurrence, surgery was less costly and more effective for all scenarios.Primary arthroscopic stabilization is a clinically effective and cost-effective treatment for first-time anterior shoulder dislocations in the cohorts studied. By use of a willingness-to-pay threshold of $25,000 per quality-adjusted life-year, surgery was more cost-effective than nonoperative treatment for the majority of patients studied in the model.Level II, economic and decision analysis.",2012-01-09909,23040837,Arthroscopy,Timothy S Crall,2012,28 / 12,1755-65,No,23040837,"Timothy S Crall; Julius A Bishop; Dan Guttman; Mininder Kocher; Kevin Bozic; James H Lubowitz; Cost-effectiveness analysis of primary arthroscopic stabilization versus nonoperative treatment for first-time anterior glenohumeral dislocations, Arthroscopy , ; 28(12):1526-3231; 1755-65",QALY,Not Stated,Not Stated,Not Stated,Standard noncontrast magnetic resonance imaging followed by an arthroscopic Bankart repair vs. Nonoperative treatment,Not Stated,35 Years,35 Years,Female,Full,15 Years,5.00,5.00,22101,United States,2010,26231.71
10415,Cost-effectiveness analysis of pancreatin minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitis,"Chronic pancreatitis (CP) is the most common cause of pancreatic exocrine insufficiency (PEI). Management of PEI due to CP is achieved through lifelong treatment with pancreatic enzyme replacement therapy (PERT). To the authors' knowledge, no cost-effectiveness analysis on the benefit of PERT in CP patients with PEI has been performed to date. The objective of this analysis was to examine the cost-effectiveness of Creon (pancreatin minimicrospheres [MMS]), one of the main PERTs available in Poland, in treating patients with CP-related PEI.The cost-effectiveness of pancreatin MMS in the treatment of patients with CP-related PEI vs no PERT treatment was estimated using a decision analysis based on clinical data from relevant studies. The model horizon was 20 years. Main outcomes included the percentage of patients with controlled PEI, survival, total medical costs, number of quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio (ICER). All costs were analysed from the Polish payer perspective.The model included clinical data from 176 patients treated in five pancreatin MMS randomized trials. Treatment with pancreatin MMS resulted in a considerably higher proportion of patients with controlled PEI compared to those not treated with any PERT. Over a horizon of 20 years, the total treatment cost and the ICER for pancreatin MMS was ?8223 and ?6312 per QALY, respectively.Important limitations include the lack of long-term and comparative clinical data available. The use of 'no PERT treatment' as a comparator against pancreatin MMS treatment may not accurately reflect current practice in Poland.Treatment of CP-related PEI with pancreatin MMS is cost-effective from a Polish payer perspective, with an ICER below the accepted 'willingness to pay' threshold of 3-times gross domestic product (GDP) per capita. These results are likely to apply to other European countries.",2012-01-09916,23043594,J Med Econ,J H Morawski,2012,15Suppl1 /,15-25,Yes,23043594,"J H Morawski; A Pr?fert; A van Engen; D Foerster; S Sander-Struckmeier; E Malecka-Panas; R Pezzilli; Cost-effectiveness analysis of pancreatin minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitis, J Med Econ, ; 15Suppl1():1369-6998; 15-25",QALY,Not Stated,Not Stated,Not Stated,Pancreatic enzyme replacement therapy (PERT) with pancreatin minimicrospheres [MMS] vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,20 Years,5.00,3.50,6312,Euro,2011,10106.31
10416,Cost-effectiveness analysis of pancreatin minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitis,"Chronic pancreatitis (CP) is the most common cause of pancreatic exocrine insufficiency (PEI). Management of PEI due to CP is achieved through lifelong treatment with pancreatic enzyme replacement therapy (PERT). To the authors' knowledge, no cost-effectiveness analysis on the benefit of PERT in CP patients with PEI has been performed to date. The objective of this analysis was to examine the cost-effectiveness of Creon (pancreatin minimicrospheres [MMS]), one of the main PERTs available in Poland, in treating patients with CP-related PEI.The cost-effectiveness of pancreatin MMS in the treatment of patients with CP-related PEI vs no PERT treatment was estimated using a decision analysis based on clinical data from relevant studies. The model horizon was 20 years. Main outcomes included the percentage of patients with controlled PEI, survival, total medical costs, number of quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio (ICER). All costs were analysed from the Polish payer perspective.The model included clinical data from 176 patients treated in five pancreatin MMS randomized trials. Treatment with pancreatin MMS resulted in a considerably higher proportion of patients with controlled PEI compared to those not treated with any PERT. Over a horizon of 20 years, the total treatment cost and the ICER for pancreatin MMS was ?8223 and ?6312 per QALY, respectively.Important limitations include the lack of long-term and comparative clinical data available. The use of 'no PERT treatment' as a comparator against pancreatin MMS treatment may not accurately reflect current practice in Poland.Treatment of CP-related PEI with pancreatin MMS is cost-effective from a Polish payer perspective, with an ICER below the accepted 'willingness to pay' threshold of 3-times gross domestic product (GDP) per capita. These results are likely to apply to other European countries.",2012-01-09916,23043594,J Med Econ,J H Morawski,2012,15Suppl1 /,15-25,Yes,23043594,"J H Morawski; A Pr?fert; A van Engen; D Foerster; S Sander-Struckmeier; E Malecka-Panas; R Pezzilli; Cost-effectiveness analysis of pancreatin minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitis, J Med Econ, ; 15Suppl1():1369-6998; 15-25",QALY,Not Stated,Not Stated,Not Stated,Pancreatic enzyme replacement therapy (PERT) with pancreatin minimicrospheres [MMS] vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,20 Years,5.00,3.50,17443,Euro,2011,27928.44
10417,Estimated health and economic impact of quadrivalent HPV (types 6/11/16/18) vaccination in Brazil using a transmission dynamic model,"ABSTRACT:Cervical cancer is the second most common cancer among women in Brazil. We examined the health and economic impacts of quadrivalent HPV vaccination in Brazil.We adapted a previously developed transmission dynamic model to estimate the effectiveness of HPV vaccination on cervical cancer, cervical intraepithelial neoplasia grades 2 and 3 (CIN2/3), CIN1, and genital warts. We evaluated following vaccination strategies: routine vaccination of 12-year-old girls and routine vaccination in combination with a catch-up vaccination of 12 to 26-year-old women.The model projected that the vaccination would reduce the incidence rates of HPV 6/11/16/18-related cervical cancer, CIN2/3, CIN1, and female genital warts by 94% to 98% at year 100. Routine vaccination in combination with a catch-up vaccination could prevent approximately 163,000 cases of cervical cancer, 48,000 deaths from cervical cancer, 2.3 million cases of CIN2/3, and 11.4 million genital warts in the next 50 years. The incremental cost-effectiveness ratios for female vaccination strategies ranged from R$350 to R$720 (US$219 to US$450) per quality-adjusted life year (QALY) gained.Our study demonstrates that quadrivalent HPV female vaccination can be a cost-effective public health intervention that can substantially reduce the burden of cervical diseases and genital warts in Brazil.",2012-01-09918,23046886,BMC Infect Dis,Kosuke Kawai,2012,12 / 1,250,No,23046886,"Kosuke Kawai; Gabriela Tannus Branco de Araujo; Marcelo Fonseca; Matthew Pillsbury; Puneet K Singhal; Estimated health and economic impact of quadrivalent HPV (types 6/11/16/18) vaccination in Brazil using a transmission dynamic model, BMC Infect Dis, ; 12(1):1471-2334; 250",QALY,Brazil,Not Stated,Not Stated,Routine vaccination of 12 year-old girls combined with a catch-up vaccination of 12 to 26 year olds vs. Routine vaccination of 12 year-old girls,Not Stated,Not Stated,Not Stated,Female,Full,100 Years,3.00,3.00,450,United States,2011,517.76
10418,Estimated health and economic impact of quadrivalent HPV (types 6/11/16/18) vaccination in Brazil using a transmission dynamic model,"ABSTRACT:Cervical cancer is the second most common cancer among women in Brazil. We examined the health and economic impacts of quadrivalent HPV vaccination in Brazil.We adapted a previously developed transmission dynamic model to estimate the effectiveness of HPV vaccination on cervical cancer, cervical intraepithelial neoplasia grades 2 and 3 (CIN2/3), CIN1, and genital warts. We evaluated following vaccination strategies: routine vaccination of 12-year-old girls and routine vaccination in combination with a catch-up vaccination of 12 to 26-year-old women.The model projected that the vaccination would reduce the incidence rates of HPV 6/11/16/18-related cervical cancer, CIN2/3, CIN1, and female genital warts by 94% to 98% at year 100. Routine vaccination in combination with a catch-up vaccination could prevent approximately 163,000 cases of cervical cancer, 48,000 deaths from cervical cancer, 2.3 million cases of CIN2/3, and 11.4 million genital warts in the next 50 years. The incremental cost-effectiveness ratios for female vaccination strategies ranged from R$350 to R$720 (US$219 to US$450) per quality-adjusted life year (QALY) gained.Our study demonstrates that quadrivalent HPV female vaccination can be a cost-effective public health intervention that can substantially reduce the burden of cervical diseases and genital warts in Brazil.",2012-01-09918,23046886,BMC Infect Dis,Kosuke Kawai,2012,12 / 1,250,No,23046886,"Kosuke Kawai; Gabriela Tannus Branco de Araujo; Marcelo Fonseca; Matthew Pillsbury; Puneet K Singhal; Estimated health and economic impact of quadrivalent HPV (types 6/11/16/18) vaccination in Brazil using a transmission dynamic model, BMC Infect Dis, ; 12(1):1471-2334; 250",QALY,Brazil,Not Stated,Not Stated,Routine vaccination of 12 year-old girls vs. None,Not Stated,Not Stated,Not Stated,Female,Full,100 Years,3.00,3.00,349.21,United States,2011,401.79
10419,Cost-effectiveness of problem-solving treatment in comparison with usual care for primary care patients with mental health problems: a randomized trial,"ABSTRACT:Mental health problems are common and are associated with increased disability and health care costs. Problem-Solving Treatment (PST) delivered to these patients by nurses in primary care might be efficient. The aim of this study was to evaluate the cost-effectiveness of PST by mental health nurses compared with usual care (UC) by the general practitioner for primary care patients with mental health problems.An economic evaluation from a societal perspective was performed alongside a randomized clinical trial. Patients with a positive General Health Questionnaire score (score = 4) and who visited their general practitioner at least three times during the past 6 months were eligible. Outcome measures were improvement on the Hospital Anxiety and Depression Scale and QALYs based on the EQ-5D. Resource use was measured using a validated questionnaire. Missing cost and effect data were imputed using multiple imputation techniques. Bootstrapping was used to analyze costs and cost-effectiveness of PST compared with UC.There were no statistically significant differences in clinical outcomes at 9 months. Mean total costs were ?4795 in the PST group and ?6857 in the UC group. Costs were not statistically significantly different between the two groups (95% CI -4698;359). The cost-effectiveness analysis showed that PST was cost-effective in comparison with UC. Sensitivity analyses confirmed these findings.PST delivered by nurses seems cost-effective in comparison with UC. However, these results should be interpreted with caution, since the difference in total costs was mainly caused by 3 outliers with extremely high indirect costs in the UC group.Nederlands Trial Register ISRCTN51021015.",2012-01-09920,23052105,BMC Fam Pract,Judith E Bosmans,2012,13 /,98,No,23052105,"Judith E Bosmans; Bettine Schreuders; Harm W J van Marwijk; Jan H Smit; Patricia van Oppen; Maurits W van Tulder; Cost-effectiveness of problem-solving treatment in comparison with usual care for primary care patients with mental health problems: a randomized trial, BMC Fam Pract, ; 13():1471-2296; 98",QALY,Netherlands,Not Stated,Not Stated,"Problem-solving treatment (PST) by mental health nurses (brief treatment focused on practical skill building, education & managing depressive symptoms) vs. Usual care by general practitioner",Not Stated,Not Stated,Not Stated,"Female, Male",Full,9 Months,Not Stated,Not Stated,-68733.34,Euro,2012,-99629.53
10420,Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents,"Influenza affects all age groups and is common in children. Between 15% and 42% of preschool- and school-aged children experience influenza each season. Recently, intranasal live attenuated influenza vaccine, trivalent (LAIV) has been approved in Canada.The objective of this study was to determine the cost-effectiveness of LAIV compared with that of the injectable inactivated influenza vaccine, trivalent (TIV) in Canadian children and adolescents from both a payer (eg. Ministry of Health) perspective and a societal perspective.A cost-effectiveness model comparing LAIV and TIV in children aged 24-59 months old was supplemented by primary (ie, a survey of 144 Canadian physicians) and secondary (eg, literature) data to model children aged 2-17 years old. Parameter uncertainty was addressed through univariate and probability analyses.Although LAIV increased vaccination costs when compared to TIV, LAIV reduced the number of influenza cases and lowered the number of hospitalizations, emergency room visits, outpatient visits, and parents' days lost from work. The estimated offsets in direct and societal costs saved were CAD$4.20 and CAD$35.34, respectively, per vaccinated child aged 2-17 years old. When costs and outcomes were considered, LAIV when compared to TIV, was the dominant strategy. At a willingness to pay of CAD$50,000 per quality adjusted life year gained, or CAD$100,000 per quality adjusted life year gained, the probabilistic results indicated that the probability of LAIV being cost-effective was almost 1.LAIV reduces the burden of influenza in children and adolescents. Consistent with previously reported results, vaccinating children with LAIV, rather than TIV, is the dominant strategy from both a societal perspective and a Ministry of Health perspective.",2012-01-09922,23055756,Clinicoecon Outcomes Res,Jean-Eric Tarride,2012,4 /,287-98,No,23055756,"Jean-Eric Tarride; Natasha Burke; Camilla Von Keyserlingk; Daria O'Reilly; Feng Xie; Ron Goeree; Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents, Clinicoecon Outcomes Res , ; 4 ():1178-6981; 287-98",QALY,Canada,Not Stated,Not Stated,"Intranasal live attenuated influenza vaccine, trivalent (LAIV) vs. Injectable inactivated influenza vaccine, trivalent (TIV)",Not Stated,17 Years,2 Years,"Female, Male",Full,12 Months,Not Stated,Not Stated,Not Stated,Canada,2010,Not Stated
10421,Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china,"To analyse the cost-effectiveness of traditional disease-modifying anti-rheumatic drugs (tDMARDs) compared to biological therapies from the perspective of Chinese society.A mathematical model was developed by incorporating the clinical trial data and Chinese unit costs and treatment sequences from a lifetime perspective. Hypothetical cohorts with moderate to severe RA were simulated. The primary outcome measure-quality-adjusted life years (QALYs)-was derived from disease severity (HAQ scores). Primary analysis included drug costs, monitoring costs, and other costs. Probabilistic and one-way sensitivity analyses were performed. Treatment sequences that included TNF antagonists and rituximab produced a greater number of QALYs than tDMARDs alone or TNF antagonists plus DMARDs. In comparison with tDMARDs, the incremental cost-effectiveness ratios (ICERs) for etanercept, infliximab, and adalimumab without rituximab were $77,357.7, $26,562.4 and $57,838.4 per QALY and $66,422.9, $28,780.6 and $50,937.6 per QALY, for etanercept, infliximab, and adalimumab with rituximab. No biotherapy was cost-effective under the willingness to pay threshold when the threshold was 3 times the per capita GDP of China. When 3 times the per capita GDP of Shanghai used as the threshold, infliximab and rituximab could yield nearly 90% cost-effective simulations in probabilistic sensitivity analysis.tDMARD was the most cost-effective option in the Chinese healthcare setting. In some relatively developed regions in China, infliximab and rituximab may be a favorable cost-effective alternative for moderate to severe RA.",2012-01-09925,23056637,PLoS One,Bin Wu,2012,7 / 10,e47373,No,23056637,"Bin Wu; Alisa Wilson; Fang-fang Wang; Su-li Wang; Daniel J Wallace; Michael H Weisman; Liang-jing Lu; Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china, PLoS One , ; 7(10):1932-6203; e47373",QALY,China,Not Stated,Not Stated,Initiation with etanercept followed by tDMARD vs. Traditional disease modifying antirheumatic drugs (tDMARDs),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,77357.7,United States,2011,89006.46
10422,Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china,"To analyse the cost-effectiveness of traditional disease-modifying anti-rheumatic drugs (tDMARDs) compared to biological therapies from the perspective of Chinese society.A mathematical model was developed by incorporating the clinical trial data and Chinese unit costs and treatment sequences from a lifetime perspective. Hypothetical cohorts with moderate to severe RA were simulated. The primary outcome measure-quality-adjusted life years (QALYs)-was derived from disease severity (HAQ scores). Primary analysis included drug costs, monitoring costs, and other costs. Probabilistic and one-way sensitivity analyses were performed. Treatment sequences that included TNF antagonists and rituximab produced a greater number of QALYs than tDMARDs alone or TNF antagonists plus DMARDs. In comparison with tDMARDs, the incremental cost-effectiveness ratios (ICERs) for etanercept, infliximab, and adalimumab without rituximab were $77,357.7, $26,562.4 and $57,838.4 per QALY and $66,422.9, $28,780.6 and $50,937.6 per QALY, for etanercept, infliximab, and adalimumab with rituximab. No biotherapy was cost-effective under the willingness to pay threshold when the threshold was 3 times the per capita GDP of China. When 3 times the per capita GDP of Shanghai used as the threshold, infliximab and rituximab could yield nearly 90% cost-effective simulations in probabilistic sensitivity analysis.tDMARD was the most cost-effective option in the Chinese healthcare setting. In some relatively developed regions in China, infliximab and rituximab may be a favorable cost-effective alternative for moderate to severe RA.",2012-01-09925,23056637,PLoS One,Bin Wu,2012,7 / 10,e47373,No,23056637,"Bin Wu; Alisa Wilson; Fang-fang Wang; Su-li Wang; Daniel J Wallace; Michael H Weisman; Liang-jing Lu; Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china, PLoS One , ; 7(10):1932-6203; e47373",QALY,China,Not Stated,Not Stated,Initiation with infliximab followed by tDMARD vs. Traditional disease modifying antirheumatic drugs (tDMARDs),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,26562.4,United States,2011,30562.25
10423,Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china,"To analyse the cost-effectiveness of traditional disease-modifying anti-rheumatic drugs (tDMARDs) compared to biological therapies from the perspective of Chinese society.A mathematical model was developed by incorporating the clinical trial data and Chinese unit costs and treatment sequences from a lifetime perspective. Hypothetical cohorts with moderate to severe RA were simulated. The primary outcome measure-quality-adjusted life years (QALYs)-was derived from disease severity (HAQ scores). Primary analysis included drug costs, monitoring costs, and other costs. Probabilistic and one-way sensitivity analyses were performed. Treatment sequences that included TNF antagonists and rituximab produced a greater number of QALYs than tDMARDs alone or TNF antagonists plus DMARDs. In comparison with tDMARDs, the incremental cost-effectiveness ratios (ICERs) for etanercept, infliximab, and adalimumab without rituximab were $77,357.7, $26,562.4 and $57,838.4 per QALY and $66,422.9, $28,780.6 and $50,937.6 per QALY, for etanercept, infliximab, and adalimumab with rituximab. No biotherapy was cost-effective under the willingness to pay threshold when the threshold was 3 times the per capita GDP of China. When 3 times the per capita GDP of Shanghai used as the threshold, infliximab and rituximab could yield nearly 90% cost-effective simulations in probabilistic sensitivity analysis.tDMARD was the most cost-effective option in the Chinese healthcare setting. In some relatively developed regions in China, infliximab and rituximab may be a favorable cost-effective alternative for moderate to severe RA.",2012-01-09925,23056637,PLoS One,Bin Wu,2012,7 / 10,e47373,No,23056637,"Bin Wu; Alisa Wilson; Fang-fang Wang; Su-li Wang; Daniel J Wallace; Michael H Weisman; Liang-jing Lu; Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china, PLoS One , ; 7(10):1932-6203; e47373",QALY,China,Not Stated,Not Stated,Initiation with adalimumab followed by tDMARD vs. Traditional disease modifying antirheumatic drugs (tDMARDs),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,57838.4,United States,2011,66547.88
10424,Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china,"To analyse the cost-effectiveness of traditional disease-modifying anti-rheumatic drugs (tDMARDs) compared to biological therapies from the perspective of Chinese society.A mathematical model was developed by incorporating the clinical trial data and Chinese unit costs and treatment sequences from a lifetime perspective. Hypothetical cohorts with moderate to severe RA were simulated. The primary outcome measure-quality-adjusted life years (QALYs)-was derived from disease severity (HAQ scores). Primary analysis included drug costs, monitoring costs, and other costs. Probabilistic and one-way sensitivity analyses were performed. Treatment sequences that included TNF antagonists and rituximab produced a greater number of QALYs than tDMARDs alone or TNF antagonists plus DMARDs. In comparison with tDMARDs, the incremental cost-effectiveness ratios (ICERs) for etanercept, infliximab, and adalimumab without rituximab were $77,357.7, $26,562.4 and $57,838.4 per QALY and $66,422.9, $28,780.6 and $50,937.6 per QALY, for etanercept, infliximab, and adalimumab with rituximab. No biotherapy was cost-effective under the willingness to pay threshold when the threshold was 3 times the per capita GDP of China. When 3 times the per capita GDP of Shanghai used as the threshold, infliximab and rituximab could yield nearly 90% cost-effective simulations in probabilistic sensitivity analysis.tDMARD was the most cost-effective option in the Chinese healthcare setting. In some relatively developed regions in China, infliximab and rituximab may be a favorable cost-effective alternative for moderate to severe RA.",2012-01-09925,23056637,PLoS One,Bin Wu,2012,7 / 10,e47373,No,23056637,"Bin Wu; Alisa Wilson; Fang-fang Wang; Su-li Wang; Daniel J Wallace; Michael H Weisman; Liang-jing Lu; Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china, PLoS One , ; 7(10):1932-6203; e47373",QALY,China,Not Stated,Not Stated,Etanercept therapy followed by rituximab and tDMARD vs. Traditional disease modifying antirheumatic drugs (tDMARDs),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,66422.9,United States,2011,76425.06
10425,Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china,"To analyse the cost-effectiveness of traditional disease-modifying anti-rheumatic drugs (tDMARDs) compared to biological therapies from the perspective of Chinese society.A mathematical model was developed by incorporating the clinical trial data and Chinese unit costs and treatment sequences from a lifetime perspective. Hypothetical cohorts with moderate to severe RA were simulated. The primary outcome measure-quality-adjusted life years (QALYs)-was derived from disease severity (HAQ scores). Primary analysis included drug costs, monitoring costs, and other costs. Probabilistic and one-way sensitivity analyses were performed. Treatment sequences that included TNF antagonists and rituximab produced a greater number of QALYs than tDMARDs alone or TNF antagonists plus DMARDs. In comparison with tDMARDs, the incremental cost-effectiveness ratios (ICERs) for etanercept, infliximab, and adalimumab without rituximab were $77,357.7, $26,562.4 and $57,838.4 per QALY and $66,422.9, $28,780.6 and $50,937.6 per QALY, for etanercept, infliximab, and adalimumab with rituximab. No biotherapy was cost-effective under the willingness to pay threshold when the threshold was 3 times the per capita GDP of China. When 3 times the per capita GDP of Shanghai used as the threshold, infliximab and rituximab could yield nearly 90% cost-effective simulations in probabilistic sensitivity analysis.tDMARD was the most cost-effective option in the Chinese healthcare setting. In some relatively developed regions in China, infliximab and rituximab may be a favorable cost-effective alternative for moderate to severe RA.",2012-01-09925,23056637,PLoS One,Bin Wu,2012,7 / 10,e47373,No,23056637,"Bin Wu; Alisa Wilson; Fang-fang Wang; Su-li Wang; Daniel J Wallace; Michael H Weisman; Liang-jing Lu; Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china, PLoS One , ; 7(10):1932-6203; e47373",QALY,China,Not Stated,Not Stated,Infliximab therapy followed by rituximab and tDMARD vs. Traditional disease modifying antirheumatic drugs (tDMARDs),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,28780.6,United States,2011,33114.47
10426,Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china,"To analyse the cost-effectiveness of traditional disease-modifying anti-rheumatic drugs (tDMARDs) compared to biological therapies from the perspective of Chinese society.A mathematical model was developed by incorporating the clinical trial data and Chinese unit costs and treatment sequences from a lifetime perspective. Hypothetical cohorts with moderate to severe RA were simulated. The primary outcome measure-quality-adjusted life years (QALYs)-was derived from disease severity (HAQ scores). Primary analysis included drug costs, monitoring costs, and other costs. Probabilistic and one-way sensitivity analyses were performed. Treatment sequences that included TNF antagonists and rituximab produced a greater number of QALYs than tDMARDs alone or TNF antagonists plus DMARDs. In comparison with tDMARDs, the incremental cost-effectiveness ratios (ICERs) for etanercept, infliximab, and adalimumab without rituximab were $77,357.7, $26,562.4 and $57,838.4 per QALY and $66,422.9, $28,780.6 and $50,937.6 per QALY, for etanercept, infliximab, and adalimumab with rituximab. No biotherapy was cost-effective under the willingness to pay threshold when the threshold was 3 times the per capita GDP of China. When 3 times the per capita GDP of Shanghai used as the threshold, infliximab and rituximab could yield nearly 90% cost-effective simulations in probabilistic sensitivity analysis.tDMARD was the most cost-effective option in the Chinese healthcare setting. In some relatively developed regions in China, infliximab and rituximab may be a favorable cost-effective alternative for moderate to severe RA.",2012-01-09925,23056637,PLoS One,Bin Wu,2012,7 / 10,e47373,No,23056637,"Bin Wu; Alisa Wilson; Fang-fang Wang; Su-li Wang; Daniel J Wallace; Michael H Weisman; Liang-jing Lu; Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china, PLoS One , ; 7(10):1932-6203; e47373",QALY,China,Not Stated,Not Stated,Adalimumab therapy followed by rituximab and tDMARD vs. Traditional disease modifying antirheumatic drugs (tDMARDs),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,50937.6,United States,2011,58607.94
10427,Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation,"Apixaban was shown to be superior to adjusted-dose warfarin in preventing stroke or systemic embolism in patients with atrial fibrillation (AF) and at least one additional risk factor for stroke, and associated with reduced rates of hemorrhage. We sought to determine the cost-effectiveness of using apixaban for stroke prevention.Based on the results from the Apixaban Versus Warfarin in Patients with Atrial Fibrillation (ARISTOTLE) trial and other published studies, we constructed a Markov model to evaluate the cost-effectiveness of apixaban versus warfarin from the Medicare perspective. The base-case analysis assumed a cohort of 65-year-old patients with a CHADS(2) score of 2.1 and no contraindication to oral anticoagulation. We utilized a 2-week cycle length and a lifetime time horizon. Outcome measures included costs in 2012 US$, quality-adjusted life-years (QALYs), life years saved and incremental cost-effectiveness ratios.Under base case conditions, quality adjusted life expectancy was 10.69 and 11.16 years for warfarin and apixaban, respectively. Total costs were $94,941 for warfarin and $86,007 for apixaban, demonstrating apixaban to be a dominant economic strategy. Upon one-way sensitivity analysis, these results were sensitive to variability in the drug cost of apixaban and various intracranial hemorrhage related variables. In Monte Carlo simulation, apixaban was a dominant strategy in 57% of 10,000 simulations and cost-effective in 98% at a willingness-to-pay threshold of $50,000 per QALY.In patients with AF and at least one additional risk factor for stroke and a baseline risk of ICH risk of about 0.8%, treatment with apixaban may be a cost-effective alternative to warfarin.",2012-01-09926,23056642,PLoS One,Soyon Lee,2012,7 / 10,e47473,No,23056642,"Soyon Lee; Rachel Mullin; Jon Blazawski; Craig I Coleman; Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation, PLoS One , ; 7(10):1932-6203; e47473",QALY,Not Stated,Not Stated,Not Stated,Apixaban (5 mg twice daily) vs. Adjusted-dose warfarin with target INR of 2 to 3,Not Stated,65 Years,65 Years,"Female, Male",Full,Lifetime,3.00,3.00,-7744.12,United States,2012,-8729.6
10428,Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada,"In Canada, two vaccines that have demonstrated high efficacy against infection with human papillomavirus (HPV) types -16 and -18 are available. The HPV-6/11/16/18 vaccine provides protection against genital warts (GW) while the HPV-16/18 vaccine may provide better protection against other oncogenic HPV types. In this analysis, the estimated clinical and economic benefit of each of these vaccines was compared in the Canadian setting.A Markov model of the natural history of HPV infection among women, cervical cancer (CC) and GW was used to estimate the impact of vaccinating a cohort of 100,000 12-year-old females on lifetime outcomes and healthcare system costs (no indirect benefit in males included). A budget impact model was used to estimate the impact of each vaccine by province.In the base case, vaccination with the HPV-16/18 vaccine was predicted to prevent 48 additional CC cases, and 16 additional CC deaths, while vaccination with the HPV-6/11/16/18 vaccine was predicted to prevent 6,933 additional GW cases. Vaccination with the HPV-16/18 vaccine was estimated to save 1 additional discounted quality adjusted life year (QALY) at an overall lower lifetime cost to the healthcare system compared to the HPV-6/11/16/18 vaccine (assuming vaccine price parity). In sensitivity analyses, the HPV-6/11/16/18 vaccine was associated with greater QALYs saved when the cross-protection efficacy of the HPV-16/18 vaccine was reduced, or the burden of GW due to HPV-6/11 was increased. In most scenarios with price parity, the lifetime healthcare cost of the strategy with the HPV-16/18 vaccine was predicted to be lower than the HPV-6/11/16/18 vaccine. In the probabilistic sensitivity analyses, the HPV-16/18 vaccine provided more QALY benefit than the HPV-6/11/16/18 vaccine in 49.2% of scenarios, with lower relative lifetime costs in 83.5% of scenarios.Overall, the predicted lifetime healthcare costs and QALYs saved by implementing each of the vaccines are similar. Vaccination with the HPV-16/18 vaccine is expected to be associated with reduced CC disease morbidity and mortality compared to vaccination with the HPV-6/11/16/18 vaccine. Differences in these outcomes depend on the extent of cervical disease prevented by cross-protection and the burden of GW caused by HPV-6/11.",2012-01-09930,23061913,BMC Public Health,Michele Kohli,2012,12 /,872,No,23061913,"Michele Kohli; Donna Lawrence; Jennifer Haig; Andrea Anonychuk; Nadia Demarteau; Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada, BMC Public Health, ; 12():1471-2458; 872",QALY,Canada,Not Stated,Not Stated,Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine plus screening vs. Human papillomavirus (HPV)-6/11/16/18 vaccine plus screening,Not Stated,12 Years,12 Years,Female,Full,Lifetime,3.00,3.00,-683107,Canada,2006,-773526.11
10429,Cost-effectiveness of a European preventive cardiology programme in primary care: a Markov modelling approach,"OBJECTIVE: To investigate the longer-term cost-effectiveness of a nurse-coordinated preventive cardiology programme for primary prevention of cardiovascular disease (CVD) compared to routine practice from a health service perspective. DESIGN: A matched, paired cluster-randomised controlled trial. SETTING: Six pairs of general practices in six countries. PARTICIPANTS: 1019 patients were randomised to the EUROACTION intervention programme and 1005 patients to usual care (UC) and who completed the 1-year follow-up. OUTCOME MEASURES: Evidence on health outcomes and costs was based on patient-level data from the study, which had a 1-year follow-up period. Future risk of CVD events was modelled, using published risk models based on patient characteristics. An individual-level Markov model for each patient was used to extrapolate beyond the end of the trial, which was populated with data from published sources. We used an 11-year time horizon and investigated the impact on the cost-effectiveness of varying the duration of the effect of the intervention beyond the end of the trial. Results are expressed as incremental cost per quality-adjusted life-year gained. RESULTS: Unadjusted results found the intervention to be more costly and also more effective than UC. However, after adjusting for differences in age, gender, country and baseline risk factors, the intervention was dominated by UC, but this analysis was not able to take into account the lifestyle changes in terms of diet and physical activity. CONCLUSIONS: Although the EUROACTION study achieved healthier lifestyle changes and improvements in management of blood pressure and lipids for patients at high risk of CVD, compared to UC, it was not possible to show, using available risk equations which do not incorporate diet and physical activity, that the intervention reduced longer-term cardiovascular risk cost-effectively. Whether or not an intervention such as that offered by EUROACTION is cost-effective requires a longer-term trial with major cardiovascular events as the outcome. TRIAL REGISTRATION NUMBER: ISRCTN 71715857.",2012-01-09934,23065443,BMJ Open,Hema Mistry,2012,2 / 5,,No,23065443,"Hema Mistry; Stephen Morris; Matthew Dyer; Kornelia Kotseva; David Wood; Martin Buxton; EUROACTION study group; Cost-effectiveness of a European preventive cardiology programme in primary care: a Markov modelling approach, BMJ Open , ; 2(5):2044-6055",QALY,Netherlands,Not Stated,Not Stated,EUROACTION: a nurse-coordinated preventive cardiology programme for coronary patients in hospital and high-risk individuals in general practice vs. Usual care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,11 Years,3.50,3.50,Not Stated,United Kingdom,2007,Not Stated
10430,Cost-effectiveness of total hip arthroplasty versus resurfacing arthroplasty: economic evaluation alongside a clinical trial,"To report on the relative cost-effectiveness of total hip arthroplasty and resurfacing arthroplasty (replacement of articular surface of femoral head only) in patients with severe arthritis suitable for hip joint resurfacing arthroplasty.Cost-effectiveness analysis on an intention-to-treat basis of a single-centre, single-blind randomised controlled trial of 126 adult patients within 12 months of treatment. Missing data were imputed using multiple imputations with differences in baseline quality of life and gender adjusted using regression techniques.A large teaching hospital trust in the UK.A total of 126 adult patients with severe arthritis of the hip joint suitable for a resurfacing arthroplasty of the hip.Data were received for 126 patients, 4 of whom did not provide any resource use data. For the remainder, data were imputed for costs or quality of life in at least one time point (baseline, 3, 6 months and 1 year) for 18 patients. Patients in the resurfacing arm had higher quality of life at 12 months (0.795 vs 0.727) and received 0.032 more QALYs within the first 12 months postoperation. At an additional cost of ?564, resurfacing arthroplasty offers benefits at ?17 451 per QALY within the first 12 months of treatment. When covariates are considered, the health economic case is stronger in men than in women.Resurfacing arthroplasty appears to offer very short-term efficiency benefits over total hip arthroplasty within a selected patient group. The short-term follow-up in this trial should be noted, particularly in light of the concerns raised regarding adverse reactions to metal debris from metal-on-metal bearing surfaces in the longer term. Longer-term follow-up of resurfacing arthroplasty patients and decision analytic modelling is also advised.Current controlled Trials ISRCTN33354155. UKCRN 4093.",2012-01-09935,23065450,BMJ Open,Richard Edlin,2012,2 / 5,,No,23065450,"Richard Edlin; Sandy Tubeuf; Juul Achten; Nicholas Parsons; Matthew Costa; Cost-effectiveness of total hip arthroplasty versus resurfacing arthroplasty: economic evaluation alongside a clinical trial, BMJ Open , ; 2(5):2044-6055",QALY,Not Stated,Not Stated,Not Stated,Resurfacing arthroplasty (RSA) vs. Total hip arthroplasty,Not Stated,Not Stated,Not Stated,"Female, Male",Full,1 Year,Not Stated,Not Stated,17451,United Kingdom,2009,30482.3
10431,Cost-effectiveness of total hip arthroplasty versus resurfacing arthroplasty: economic evaluation alongside a clinical trial,"To report on the relative cost-effectiveness of total hip arthroplasty and resurfacing arthroplasty (replacement of articular surface of femoral head only) in patients with severe arthritis suitable for hip joint resurfacing arthroplasty.Cost-effectiveness analysis on an intention-to-treat basis of a single-centre, single-blind randomised controlled trial of 126 adult patients within 12 months of treatment. Missing data were imputed using multiple imputations with differences in baseline quality of life and gender adjusted using regression techniques.A large teaching hospital trust in the UK.A total of 126 adult patients with severe arthritis of the hip joint suitable for a resurfacing arthroplasty of the hip.Data were received for 126 patients, 4 of whom did not provide any resource use data. For the remainder, data were imputed for costs or quality of life in at least one time point (baseline, 3, 6 months and 1 year) for 18 patients. Patients in the resurfacing arm had higher quality of life at 12 months (0.795 vs 0.727) and received 0.032 more QALYs within the first 12 months postoperation. At an additional cost of ?564, resurfacing arthroplasty offers benefits at ?17 451 per QALY within the first 12 months of treatment. When covariates are considered, the health economic case is stronger in men than in women.Resurfacing arthroplasty appears to offer very short-term efficiency benefits over total hip arthroplasty within a selected patient group. The short-term follow-up in this trial should be noted, particularly in light of the concerns raised regarding adverse reactions to metal debris from metal-on-metal bearing surfaces in the longer term. Longer-term follow-up of resurfacing arthroplasty patients and decision analytic modelling is also advised.Current controlled Trials ISRCTN33354155. UKCRN 4093.",2012-01-09935,23065450,BMJ Open,Richard Edlin,2012,2 / 5,,No,23065450,"Richard Edlin; Sandy Tubeuf; Juul Achten; Nicholas Parsons; Matthew Costa; Cost-effectiveness of total hip arthroplasty versus resurfacing arthroplasty: economic evaluation alongside a clinical trial, BMJ Open , ; 2(5):2044-6055",QALY,Not Stated,Not Stated,Not Stated,Resurfacing arthroplasty (RSA) vs. Total hip arthroplasty,Not Stated,Not Stated,Not Stated,"Female, Male",Full,1 Year,Not Stated,Not Stated,19435,United Kingdom,2009,33947.82
10432,Which long-acting bronchodilator is most cost-effective for the treatment of COPD?,"The aim of this study was to estimate the cost-effectiveness of tiotropium versus salmeterol to inform decision making within the Dutch healthcare setting.A previously published, validated COPD progression model was updated with new exacerbation data and adapted to the Dutch setting by including Dutch estimates of healthcare use for COPD maintenance treatment and Dutch unit costs. Exacerbation data from the POET-COPD trial were combined with evidence from earlier tiotropium studies using Bayesian meta-analysis. The model-based analysis was performed using a one- and five-year time horizon. Main health outcomes were the number of exacerbations and quality-adjusted life years (QALYs).One-year costs per patient from the healthcare perspective were v1370 for tiotropium and v1359 for salmeterol; a difference of v11 (95% uncertainty interval (UI): -198-212). The annual number of exacerbations was 0.068 (-0.005-0.140) lower in the tiotropium group. The number of QALYs in the tiotropium group was 0.011 (-0.019-0.049) higher, resulting in an incremental cost-effectiveness ratio (ICER) of v1015 per QALY. After five years, the difference in exacerbations, QALYs and costs between the tiotropium and salmeterol group were -0.435 (-0.915-0.107), 0.079 (-0.272-0.520) and v-277 (-1586-1074), respectively, indicating that tiotropium was more effective and less costly. Using a societal perspective, tiotropium dominated salmeterol both after one and five years.Tiotropium reduced exacerbations and exacerbation-related costs. After one year the cost per QALY of tiotropium compared with salmeterol was very low, while after five years tiotropium was found to dominate salmeterol.",2012-01-09936,23065983,Neth J Med,M Hoogendoorn,2012,70 / 8,357-64,No,23065983,"M Hoogendoorn; B S Kappelhoff; J A Overbeek; E F M Wouters; M P M H Rutten-van M?lken; Which long-acting bronchodilator is most cost-effective for the treatment of COPD?, Neth J Med, ; 70(8):0300-2977; 357-64",QALY,Netherlands,Not Stated,Not Stated,Tiotropium vs. Salmeterol,Not Stated,Not Stated,Not Stated,"Female, Male",Full,5 Years,4.00,1.50,-3506.33,Euro,2011,-5614.07
10433,Which long-acting bronchodilator is most cost-effective for the treatment of COPD?,"The aim of this study was to estimate the cost-effectiveness of tiotropium versus salmeterol to inform decision making within the Dutch healthcare setting.A previously published, validated COPD progression model was updated with new exacerbation data and adapted to the Dutch setting by including Dutch estimates of healthcare use for COPD maintenance treatment and Dutch unit costs. Exacerbation data from the POET-COPD trial were combined with evidence from earlier tiotropium studies using Bayesian meta-analysis. The model-based analysis was performed using a one- and five-year time horizon. Main health outcomes were the number of exacerbations and quality-adjusted life years (QALYs).One-year costs per patient from the healthcare perspective were v1370 for tiotropium and v1359 for salmeterol; a difference of v11 (95% uncertainty interval (UI): -198-212). The annual number of exacerbations was 0.068 (-0.005-0.140) lower in the tiotropium group. The number of QALYs in the tiotropium group was 0.011 (-0.019-0.049) higher, resulting in an incremental cost-effectiveness ratio (ICER) of v1015 per QALY. After five years, the difference in exacerbations, QALYs and costs between the tiotropium and salmeterol group were -0.435 (-0.915-0.107), 0.079 (-0.272-0.520) and v-277 (-1586-1074), respectively, indicating that tiotropium was more effective and less costly. Using a societal perspective, tiotropium dominated salmeterol both after one and five years.Tiotropium reduced exacerbations and exacerbation-related costs. After one year the cost per QALY of tiotropium compared with salmeterol was very low, while after five years tiotropium was found to dominate salmeterol.",2012-01-09936,23065983,Neth J Med,M Hoogendoorn,2012,70 / 8,357-64,No,23065983,"M Hoogendoorn; B S Kappelhoff; J A Overbeek; E F M Wouters; M P M H Rutten-van M?lken; Which long-acting bronchodilator is most cost-effective for the treatment of COPD?, Neth J Med, ; 70(8):0300-2977; 357-64",QALY,Netherlands,Not Stated,Not Stated,Tiotropium vs. Salmeterol,Not Stated,Not Stated,Not Stated,"Female, Male",Full,5 Years,4.00,1.50,Not Stated,Euro,2011,Not Stated
10434,Cost-effectiveness of diagnostic strategies for evaluation of suspected subarachnoid hemorrhage in the emergency department,"Diagnosing subarachnoid hemorrhage (SAH) in emergency department (ED) patients is challenging. Potential diagnostic strategies include computed tomography (CT) only, CT followed by lumbar puncture (CT/LP), CT followed by magnetic resonance imaging and angiography (CT/MRA), and CT followed by CT angiography (CT/CTA). The objective was to determine the relative cost-effectiveness of diagnostic strategies for SAH. The authors created a decision model to evaluate the cost-effectiveness of SAH diagnostic strategies in ED patients with suspected SAH. Clinical probabilities were obtained from published data; sensitivity analyses were conducted across plausible ranges. In the base-case scenario, CT-only had a cost of $10,339 and effectiveness of 20.25 quality-adjusted life-years (QALYs), and CT/LP had a cost of $15,120 and effectiveness of 20.366 QALYs. Among the alternative strategies, CT/CTA had a cost of $12,840 and effectiveness of 20.24 QALYs, and CT/MRA had a cost of $16,207 and effectiveness of 20.27 QALYs. In sensitivity analyses, probability of severe disability from SAH, sensitivity of noncontrast CT, and specificity of LP and MRA were key drivers of the model, and CT-only and CT/LP were preferable.In the base-case scenario, CT-only was preferable to the CT/CTA and CT/MRA strategies. When considering sensitivity analyses and the current medicolegal environment, there are no overwhelming differences between the cost-effectiveness of CT/LP and the alternative strategies to suggest that clinicians should abandon the standard CT/LP approach.",2012-01-09937,23067018,Acad Emerg Med,Michael J Ward,2012,19 / 10,1134-44,No,23067018,"Michael J Ward; Jordan B Bonomo; Opeolu Adeoye; Ali S Raja; Jesse M Pines; Cost-effectiveness of diagnostic strategies for evaluation of suspected subarachnoid hemorrhage in the emergency department, Acad Emerg Med, ; 19(10):1069-6563; 1134-44",QALY,Not Stated,Not Stated,Not Stated,Computed tomography (CT) and CT angiogram (CTA) vs. Computed tomography (CT) only,Not Stated,45 Years,45 Years,"Female, Male",Full,Lifetime,3.00,3.00,-208416.67,United States,2009,-251427.62
10435,Cost-effectiveness of diagnostic strategies for evaluation of suspected subarachnoid hemorrhage in the emergency department,"Diagnosing subarachnoid hemorrhage (SAH) in emergency department (ED) patients is challenging. Potential diagnostic strategies include computed tomography (CT) only, CT followed by lumbar puncture (CT/LP), CT followed by magnetic resonance imaging and angiography (CT/MRA), and CT followed by CT angiography (CT/CTA). The objective was to determine the relative cost-effectiveness of diagnostic strategies for SAH. The authors created a decision model to evaluate the cost-effectiveness of SAH diagnostic strategies in ED patients with suspected SAH. Clinical probabilities were obtained from published data; sensitivity analyses were conducted across plausible ranges. In the base-case scenario, CT-only had a cost of $10,339 and effectiveness of 20.25 quality-adjusted life-years (QALYs), and CT/LP had a cost of $15,120 and effectiveness of 20.366 QALYs. Among the alternative strategies, CT/CTA had a cost of $12,840 and effectiveness of 20.24 QALYs, and CT/MRA had a cost of $16,207 and effectiveness of 20.27 QALYs. In sensitivity analyses, probability of severe disability from SAH, sensitivity of noncontrast CT, and specificity of LP and MRA were key drivers of the model, and CT-only and CT/LP were preferable.In the base-case scenario, CT-only was preferable to the CT/CTA and CT/MRA strategies. When considering sensitivity analyses and the current medicolegal environment, there are no overwhelming differences between the cost-effectiveness of CT/LP and the alternative strategies to suggest that clinicians should abandon the standard CT/LP approach.",2012-01-09937,23067018,Acad Emerg Med,Michael J Ward,2012,19 / 10,1134-44,No,23067018,"Michael J Ward; Jordan B Bonomo; Opeolu Adeoye; Ali S Raja; Jesse M Pines; Cost-effectiveness of diagnostic strategies for evaluation of suspected subarachnoid hemorrhage in the emergency department, Acad Emerg Med, ; 19(10):1069-6563; 1134-44",QALY,Not Stated,Not Stated,Not Stated,Computed tomography (CT) and lumbar puncture (LP) vs. Computed tomography (CT) only,Not Stated,45 Years,45 Years,"Female, Male",Full,Lifetime,3.00,3.00,41239,United States,2009,49749.49
10436,Cost-effectiveness of diagnostic strategies for evaluation of suspected subarachnoid hemorrhage in the emergency department,"Diagnosing subarachnoid hemorrhage (SAH) in emergency department (ED) patients is challenging. Potential diagnostic strategies include computed tomography (CT) only, CT followed by lumbar puncture (CT/LP), CT followed by magnetic resonance imaging and angiography (CT/MRA), and CT followed by CT angiography (CT/CTA). The objective was to determine the relative cost-effectiveness of diagnostic strategies for SAH. The authors created a decision model to evaluate the cost-effectiveness of SAH diagnostic strategies in ED patients with suspected SAH. Clinical probabilities were obtained from published data; sensitivity analyses were conducted across plausible ranges. In the base-case scenario, CT-only had a cost of $10,339 and effectiveness of 20.25 quality-adjusted life-years (QALYs), and CT/LP had a cost of $15,120 and effectiveness of 20.366 QALYs. Among the alternative strategies, CT/CTA had a cost of $12,840 and effectiveness of 20.24 QALYs, and CT/MRA had a cost of $16,207 and effectiveness of 20.27 QALYs. In sensitivity analyses, probability of severe disability from SAH, sensitivity of noncontrast CT, and specificity of LP and MRA were key drivers of the model, and CT-only and CT/LP were preferable.In the base-case scenario, CT-only was preferable to the CT/CTA and CT/MRA strategies. When considering sensitivity analyses and the current medicolegal environment, there are no overwhelming differences between the cost-effectiveness of CT/LP and the alternative strategies to suggest that clinicians should abandon the standard CT/LP approach.",2012-01-09937,23067018,Acad Emerg Med,Michael J Ward,2012,19 / 10,1134-44,No,23067018,"Michael J Ward; Jordan B Bonomo; Opeolu Adeoye; Ali S Raja; Jesse M Pines; Cost-effectiveness of diagnostic strategies for evaluation of suspected subarachnoid hemorrhage in the emergency department, Acad Emerg Med, ; 19(10):1069-6563; 1134-44",QALY,Not Stated,Not Stated,Not Stated,Computed tomography (CT) and magnetic resonance angiography (MRA) vs. Computed tomography (CT) and lumbar puncture (LP),Not Stated,45 Years,45 Years,"Female, Male",Full,Lifetime,3.00,3.00,-10870,United States,2009,-13113.24
10437,Future impact of various interventions on the burden of COPD in canada: a dynamic population model,"Chronic obstructive pulmonary disease (COPD) is a growing economic burden worldwide. Smoking cessation is thought to be the single most effective way of reducing the economic burden of COPD. The impact of other strategies such as interventions that predict risk of disease, reduce progression of disease, or reduce exacerbations has not been systematically studied.We estimated the economic and clinical burden of COPD over the next 25 years in Canada and the impact of three potential interventions (screening test for predisposition to COPD, new drugs to avoid progression into more severe disease stages, and predictive test for exacerbations) on COPD burden.Using a dynamic simulation model, we projected the total burden of COPD (cost, morbidity, and mortality) from 2011 to 2035 using the population of Canada as a case study. The model stratified population based on sex, age, smoking status, respiratory symptoms, and their COPD stage. The cost and quality adjusted life years (QALYs) associated with each intervention were estimated.The model indicates that annual societal cost of COPD is $4.52 billion (B) Canadian dollars in 2011 and will reach $3.61B ($7.33B undiscounted) per year in 2035. Over the next 25 years, COPD will be responsible for approximately $101.4B in societal costs ($147.5B undiscounted) and 12.9 million QALYs lost (19.0 million undiscounted). Our results suggested that the best strategy to reduce the financial burden of COPD is by reducing exacerbations. Smoking cessation, while it is the cornerstone of COPD prevention, has only a modest effect in attenuating the financial burden of COPD over the next 25 years in Western countries such as Canada.Our data suggest that any intervention that can reduce the number of exacerbations has a substantial impact on morbidity and costs of COPD and should be considered in conjunction with the ongoing efforts to reduce smoking rates.",2012-01-09940,23071626,PLoS One,Mehdi Najafzadeh,2012,7 / 10,e46746,No,23071626,"Mehdi Najafzadeh; Carlo A Marra; Larry D Lynd; Mohsen Sadatsafavi; J Mark FitzGerald; Bruce McManus; Don Sin; Future impact of various interventions on the burden of COPD in canada: a dynamic population model, PLoS One , ; 7(10):1932-6203; e46746",QALY,Canada,Not Stated,Not Stated,Decreasing smoking start rate by testing for COPD predisposition in early smokers vs. Usual care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,25 Years,3.00,3.00,881.25,Canada,2011,1025.58
10438,Future impact of various interventions on the burden of COPD in canada: a dynamic population model,"Chronic obstructive pulmonary disease (COPD) is a growing economic burden worldwide. Smoking cessation is thought to be the single most effective way of reducing the economic burden of COPD. The impact of other strategies such as interventions that predict risk of disease, reduce progression of disease, or reduce exacerbations has not been systematically studied.We estimated the economic and clinical burden of COPD over the next 25 years in Canada and the impact of three potential interventions (screening test for predisposition to COPD, new drugs to avoid progression into more severe disease stages, and predictive test for exacerbations) on COPD burden.Using a dynamic simulation model, we projected the total burden of COPD (cost, morbidity, and mortality) from 2011 to 2035 using the population of Canada as a case study. The model stratified population based on sex, age, smoking status, respiratory symptoms, and their COPD stage. The cost and quality adjusted life years (QALYs) associated with each intervention were estimated.The model indicates that annual societal cost of COPD is $4.52 billion (B) Canadian dollars in 2011 and will reach $3.61B ($7.33B undiscounted) per year in 2035. Over the next 25 years, COPD will be responsible for approximately $101.4B in societal costs ($147.5B undiscounted) and 12.9 million QALYs lost (19.0 million undiscounted). Our results suggested that the best strategy to reduce the financial burden of COPD is by reducing exacerbations. Smoking cessation, while it is the cornerstone of COPD prevention, has only a modest effect in attenuating the financial burden of COPD over the next 25 years in Western countries such as Canada.Our data suggest that any intervention that can reduce the number of exacerbations has a substantial impact on morbidity and costs of COPD and should be considered in conjunction with the ongoing efforts to reduce smoking rates.",2012-01-09940,23071626,PLoS One,Mehdi Najafzadeh,2012,7 / 10,e46746,No,23071626,"Mehdi Najafzadeh; Carlo A Marra; Larry D Lynd; Mohsen Sadatsafavi; J Mark FitzGerald; Bruce McManus; Don Sin; Future impact of various interventions on the burden of COPD in canada: a dynamic population model, PLoS One , ; 7(10):1932-6203; e46746",QALY,Canada,Not Stated,Not Stated,Decreasing progression rates by access to new pharmacogenomic agents vs. Usual care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,25 Years,3.00,3.00,4383.65,Canada,2011,5101.57
10439,Future impact of various interventions on the burden of COPD in canada: a dynamic population model,"Chronic obstructive pulmonary disease (COPD) is a growing economic burden worldwide. Smoking cessation is thought to be the single most effective way of reducing the economic burden of COPD. The impact of other strategies such as interventions that predict risk of disease, reduce progression of disease, or reduce exacerbations has not been systematically studied.We estimated the economic and clinical burden of COPD over the next 25 years in Canada and the impact of three potential interventions (screening test for predisposition to COPD, new drugs to avoid progression into more severe disease stages, and predictive test for exacerbations) on COPD burden.Using a dynamic simulation model, we projected the total burden of COPD (cost, morbidity, and mortality) from 2011 to 2035 using the population of Canada as a case study. The model stratified population based on sex, age, smoking status, respiratory symptoms, and their COPD stage. The cost and quality adjusted life years (QALYs) associated with each intervention were estimated.The model indicates that annual societal cost of COPD is $4.52 billion (B) Canadian dollars in 2011 and will reach $3.61B ($7.33B undiscounted) per year in 2035. Over the next 25 years, COPD will be responsible for approximately $101.4B in societal costs ($147.5B undiscounted) and 12.9 million QALYs lost (19.0 million undiscounted). Our results suggested that the best strategy to reduce the financial burden of COPD is by reducing exacerbations. Smoking cessation, while it is the cornerstone of COPD prevention, has only a modest effect in attenuating the financial burden of COPD over the next 25 years in Western countries such as Canada.Our data suggest that any intervention that can reduce the number of exacerbations has a substantial impact on morbidity and costs of COPD and should be considered in conjunction with the ongoing efforts to reduce smoking rates.",2012-01-09940,23071626,PLoS One,Mehdi Najafzadeh,2012,7 / 10,e46746,No,23071626,"Mehdi Najafzadeh; Carlo A Marra; Larry D Lynd; Mohsen Sadatsafavi; J Mark FitzGerald; Bruce McManus; Don Sin; Future impact of various interventions on the burden of COPD in canada: a dynamic population model, PLoS One , ; 7(10):1932-6203; e46746",QALY,Canada,Not Stated,Not Stated,Decreasing exacerbations by using predictive test for exacerbations vs. Usual care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,25 Years,3.00,3.00,8997.39,Canada,2011,10470.92
10440,Cost effectiveness of oromucosal cannabis-based medicine (sativex?) for spasticity in multiple sclerosis,"Spasticity is common in patients with multiple sclerosis (MS) and is a major contributor to disability. Sativex?, an oromucosal spray containing cannabis-based medicinal products, has been found to be effective in reducing spasticity symptoms.Our objective was to estimate the cost effectiveness of Sativex? plus oral anti-spasticity medicines compared with the current standard treatment for moderate or severe spasticity in MS in the UK.A Markov model was used to assess the costs and benefits of Sativex? plus oral anti-spasticity medicines or current standard treatment based on their effects on the quality of life of patients. The main outcome was the incremental cost-effectiveness ratio (ICER) in terms of costs per additional QALY gained over 5 years of treatment. One-way, multi-way and probabilistic sensitivity analyses were conducted to explore the impact of uncertainties on the findings. Results: In the base case, Sativex? plus oral anti-spasticity medicines resulted in incremental costs of ?7600 and a QALY gain of 0.15 per person over 5 years (ICER?=??49?300 per QALY).[year 2009 data for costs]. Findings were sensitive to the costs of Sativex? (price and dose) and differences in utilities between responders and non-responders.Using a willingness-to-pay threshold of ?30?000 per QALY, Sativex? appears unlikely to be considered cost effective by UK funders of healthcare for spasticity in MS. This is unfortunate, since it appears that Sativex? use is likely to benefit some patients in the management of this common consequence of MS.",2012-01-09942,23072659,Pharmacoeconomics,Lanting Lu,2012,30 / 12,1157-71,Yes,23072659,"Lanting Lu; Hilary Pearce; Chris Roome; James Shearer; Iain A Lang; Ken Stein; Cost effectiveness of oromucosal cannabis-based medicine (sativex?) for spasticity in multiple sclerosis, Pharmacoeconomics, Dec/1/2012; 30(12):1179-2027; 1157-71",QALY,Not Stated,Not Stated,Not Stated,Sativex (oromucosal spray containing cannabis-based medicinal products) plus oral anti-spasticity medicines vs. Standard of care,Not Stated,50 Years,50 Years,"Female, Male",Full,5 Years,3.50,3.50,49257,United Kingdom,2009,86039
10441,Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases,"Perioperative intravesical chemotherapy following transurethral resection of bladder tumor has been underused despite level 1 evidence supporting its performance. The primary objective of this study was to estimate the economic and humanistic consequences associated with preventable recurrences in patients initially diagnosed with nonmuscle invasive bladder cancer.Using population based estimates of nonmuscle invasive bladder cancer incidence, a 2-year model was developed to estimate the number of preventable recurrences in eligible patients untreated with perioperative intravesical chemotherapy. Therapy utilization rates were obtained from a retrospective database analysis and a chart review study of 1,010 patients with nonmuscle invasive bladder cancer. Recurrence rates of nonmuscle invasive bladder cancer were obtained from a randomized clinical trial comparing transurethral resection of bladder tumor with or without perioperative mitomycin C. Costs were estimated using prevailing Medicare reimbursement rates. Quality adjusted life-year estimates and disutilities for complications were obtained from the literature.The model estimated that 7,827 bladder recurrences could be avoided if all patients received immediate intravesical chemotherapy. It estimated an economic savings of $3,847 per avoidable recurrence, resulting in an aggregate savings of $30.1 million. The model also estimated that 1,025 quality adjusted life-years are lost every 2 years due to preventable recurrences, resulting in 0.13 quality adjusted life-years (48 quality adjusted days) lost per avoidable recurrence. This translates into 0.02 quality adjusted life-years (8.1 quality adjusted days) lost per patient not receiving immediate intravesical chemotherapy.Greater use of immediate intravesical chemotherapy in the United States has the potential to substantially decrease the economic and humanistic burdens of nonmuscle invasive bladder cancer.",2012-01-09950,23083857,J Urol,Cheryl T Lee,2012,188 / 6,2114-9,No,23083857,"Cheryl T Lee; Daniel Barocas; Denise R Globe; Michael G Oefelein; Danielle C Colayco; Amanda Bruno; Ken O'Day; Thomas Bramley; Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases, J Urol, ; 188(6):0022-5347; 2114-9",QALY,Not Stated,Not Stated,Not Stated,Adjuvant perioperative intravesical chemotherapy vs. Usual care (resection only),Not Stated,Not Stated,Not Stated,"Female, Male",Full,2 Years,Not Stated,Not Stated,-24750,United States,2011,-28476.93
10442,Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised controlled trial in primary care,"ABSTRACT: BACKGROUND: There is insufficient evidence to determine whether acupuncture is a cost-effective treatment for irritable bowel syndrome. The objective of this study is to assess the cost-effectiveness of acupuncture as an adjunct to usual care versus usual care alone for the treatment of Irritable Bowel Syndrome (IBS). METHODS: Cost-utility analysis conducted alongside a pragmatic, multicentre, randomised controlled trial. 233 patients with irritable bowel syndrome were randomly allocated to either acupuncture plus usual care, or usual care alone. Cost-effectiveness outcomes are expressed in terms of incremental cost per quality adjusted life year (QALY) at one year after randomisation. Costs were estimated from the UK National Health Service perspective for a time horizon of one year. Cost-utility ratios were estimated based on complete case analysis for the base case analysis, where only patients with available EQ-5D and cost data were included. Sensitivity analyses comprised a multiple imputation approach for missing data and a subgroup analysis for the more severe cases of IBS. RESULTS: The base case analysis showed acupuncture to be marginally more effective than usual care (gain of 0.0035 QALYs, 95% CI: -0.00395 to 0.0465) and more expensive (incremental cost of GBP218 per patient (95% CI: 55.87 to 492.87) resulting in an incremental cost-effectiveness ratio of approximately GBP62,500. Sensitivity analysis using multiple imputation for missing data resulted in acupuncture appearing less effective and more costly than usual care, so usual care is dominant. Subgroup analysis selecting the most severe cases of IBS (Symptom Severity Score of over 300) suggested that acupuncture may be a cost-effective treatment option for this group, with a cost-per-QALY of GBP6,500. CONCLUSIONS: Acupuncture as an adjunct to usual care is not a cost-effective option for the whole IBS population; however it may be cost-effective for those with more severe irritable bowel syndrome. Trial Registration Current Controlled Trials ISRCTN08827905.",2012-01-09960,23095351,BMC Gastroenterol,Eugena Stamuli,2012,12 / 1,149,No,23095351,"Eugena Stamuli; Karen Bloor; Hugh Macpherson; Helen Tilbrook; Tracy Stuardi; Sally Brabyn; David Torgerson; Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised controlled trial in primary care, BMC Gastroenterol, Oct/24/2012; 12(1):1471-230X; 149",QALY,Not Stated,Not Stated,Not Stated,Acupuncture plus usual care vs. Usual care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,1 Year,Not Stated,Not Stated,69933,United Kingdom,2010,128139.75
10443,Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised controlled trial in primary care,"ABSTRACT: BACKGROUND: There is insufficient evidence to determine whether acupuncture is a cost-effective treatment for irritable bowel syndrome. The objective of this study is to assess the cost-effectiveness of acupuncture as an adjunct to usual care versus usual care alone for the treatment of Irritable Bowel Syndrome (IBS). METHODS: Cost-utility analysis conducted alongside a pragmatic, multicentre, randomised controlled trial. 233 patients with irritable bowel syndrome were randomly allocated to either acupuncture plus usual care, or usual care alone. Cost-effectiveness outcomes are expressed in terms of incremental cost per quality adjusted life year (QALY) at one year after randomisation. Costs were estimated from the UK National Health Service perspective for a time horizon of one year. Cost-utility ratios were estimated based on complete case analysis for the base case analysis, where only patients with available EQ-5D and cost data were included. Sensitivity analyses comprised a multiple imputation approach for missing data and a subgroup analysis for the more severe cases of IBS. RESULTS: The base case analysis showed acupuncture to be marginally more effective than usual care (gain of 0.0035 QALYs, 95% CI: -0.00395 to 0.0465) and more expensive (incremental cost of GBP218 per patient (95% CI: 55.87 to 492.87) resulting in an incremental cost-effectiveness ratio of approximately GBP62,500. Sensitivity analysis using multiple imputation for missing data resulted in acupuncture appearing less effective and more costly than usual care, so usual care is dominant. Subgroup analysis selecting the most severe cases of IBS (Symptom Severity Score of over 300) suggested that acupuncture may be a cost-effective treatment option for this group, with a cost-per-QALY of GBP6,500. CONCLUSIONS: Acupuncture as an adjunct to usual care is not a cost-effective option for the whole IBS population; however it may be cost-effective for those with more severe irritable bowel syndrome. Trial Registration Current Controlled Trials ISRCTN08827905.",2012-01-09960,23095351,BMC Gastroenterol,Eugena Stamuli,2012,12 / 1,149,No,23095351,"Eugena Stamuli; Karen Bloor; Hugh Macpherson; Helen Tilbrook; Tracy Stuardi; Sally Brabyn; David Torgerson; Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised controlled trial in primary care, BMC Gastroenterol, Oct/24/2012; 12(1):1471-230X; 149",QALY,Not Stated,Not Stated,Not Stated,Acupuncture plus usual care vs. Usual care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,1 Year,Not Stated,Not Stated,-14801.25,United Kingdom,2010,-27120.66
10444,Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised controlled trial in primary care,"ABSTRACT: BACKGROUND: There is insufficient evidence to determine whether acupuncture is a cost-effective treatment for irritable bowel syndrome. The objective of this study is to assess the cost-effectiveness of acupuncture as an adjunct to usual care versus usual care alone for the treatment of Irritable Bowel Syndrome (IBS). METHODS: Cost-utility analysis conducted alongside a pragmatic, multicentre, randomised controlled trial. 233 patients with irritable bowel syndrome were randomly allocated to either acupuncture plus usual care, or usual care alone. Cost-effectiveness outcomes are expressed in terms of incremental cost per quality adjusted life year (QALY) at one year after randomisation. Costs were estimated from the UK National Health Service perspective for a time horizon of one year. Cost-utility ratios were estimated based on complete case analysis for the base case analysis, where only patients with available EQ-5D and cost data were included. Sensitivity analyses comprised a multiple imputation approach for missing data and a subgroup analysis for the more severe cases of IBS. RESULTS: The base case analysis showed acupuncture to be marginally more effective than usual care (gain of 0.0035 QALYs, 95% CI: -0.00395 to 0.0465) and more expensive (incremental cost of GBP218 per patient (95% CI: 55.87 to 492.87) resulting in an incremental cost-effectiveness ratio of approximately GBP62,500. Sensitivity analysis using multiple imputation for missing data resulted in acupuncture appearing less effective and more costly than usual care, so usual care is dominant. Subgroup analysis selecting the most severe cases of IBS (Symptom Severity Score of over 300) suggested that acupuncture may be a cost-effective treatment option for this group, with a cost-per-QALY of GBP6,500. CONCLUSIONS: Acupuncture as an adjunct to usual care is not a cost-effective option for the whole IBS population; however it may be cost-effective for those with more severe irritable bowel syndrome. Trial Registration Current Controlled Trials ISRCTN08827905.",2012-01-09960,23095351,BMC Gastroenterol,Eugena Stamuli,2012,12 / 1,149,No,23095351,"Eugena Stamuli; Karen Bloor; Hugh Macpherson; Helen Tilbrook; Tracy Stuardi; Sally Brabyn; David Torgerson; Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised controlled trial in primary care, BMC Gastroenterol, Oct/24/2012; 12(1):1471-230X; 149",QALY,Not Stated,Not Stated,Not Stated,Acupuncture plus usual care vs. Usual care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,1 Year,Not Stated,Not Stated,-15382.24,United Kingdom,2010,-28185.21
10445,Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised controlled trial in primary care,"ABSTRACT: BACKGROUND: There is insufficient evidence to determine whether acupuncture is a cost-effective treatment for irritable bowel syndrome. The objective of this study is to assess the cost-effectiveness of acupuncture as an adjunct to usual care versus usual care alone for the treatment of Irritable Bowel Syndrome (IBS). METHODS: Cost-utility analysis conducted alongside a pragmatic, multicentre, randomised controlled trial. 233 patients with irritable bowel syndrome were randomly allocated to either acupuncture plus usual care, or usual care alone. Cost-effectiveness outcomes are expressed in terms of incremental cost per quality adjusted life year (QALY) at one year after randomisation. Costs were estimated from the UK National Health Service perspective for a time horizon of one year. Cost-utility ratios were estimated based on complete case analysis for the base case analysis, where only patients with available EQ-5D and cost data were included. Sensitivity analyses comprised a multiple imputation approach for missing data and a subgroup analysis for the more severe cases of IBS. RESULTS: The base case analysis showed acupuncture to be marginally more effective than usual care (gain of 0.0035 QALYs, 95% CI: -0.00395 to 0.0465) and more expensive (incremental cost of GBP218 per patient (95% CI: 55.87 to 492.87) resulting in an incremental cost-effectiveness ratio of approximately GBP62,500. Sensitivity analysis using multiple imputation for missing data resulted in acupuncture appearing less effective and more costly than usual care, so usual care is dominant. Subgroup analysis selecting the most severe cases of IBS (Symptom Severity Score of over 300) suggested that acupuncture may be a cost-effective treatment option for this group, with a cost-per-QALY of GBP6,500. CONCLUSIONS: Acupuncture as an adjunct to usual care is not a cost-effective option for the whole IBS population; however it may be cost-effective for those with more severe irritable bowel syndrome. Trial Registration Current Controlled Trials ISRCTN08827905.",2012-01-09960,23095351,BMC Gastroenterol,Eugena Stamuli,2012,12 / 1,149,No,23095351,"Eugena Stamuli; Karen Bloor; Hugh Macpherson; Helen Tilbrook; Tracy Stuardi; Sally Brabyn; David Torgerson; Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised controlled trial in primary care, BMC Gastroenterol, Oct/24/2012; 12(1):1471-230X; 149",QALY,Not Stated,Not Stated,Not Stated,Acupuncture plus usual care vs. Usual care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,1 Year,Not Stated,Not Stated,7503.88,United Kingdom,2010,13749.53
10446,Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland,"Introduction: Invasive pneumococcal disease is associated with substantial morbidity, mortality and cost implications, which could be reduced by vaccination. Aim: To assess the cost-effectiveness of a 23-valent pneumococcal vaccine in the elderly (65 and older) in Poland. Methods: A Markov model with a 1-year cycle length was developed, allowing up to 10 cohorts to enter the model over the lifetime horizon (35 years). In the base case, costs and benefits were assessed using the public health care payer (NFZ) perspective. The analysis included routine vaccination of all elderly and high-risk (HR) elderly versus no vaccination. The analysis assumed that the government would reimburse 50% of the vaccine price. Costs and benefits were discounted 5%, with costs expressed in 2009 Polish Zloty (PLN). Extensive sensitivity analyses were carried out. Results: PPV23 vaccination targeting all elderly and HR elderly in Poland would avoid 8,935 pneumococcal infections, 2,542 hospitalisations, 671 deaths and 5,886 infections, 1,673 hospitalisations and 441 deaths respectively. The incremental cost per QALY gained would be PLN 3,382 in all elderly and PLN2,148 in HR elderly. Conclusion: Vaccinating adults 65 and older regardless of risk status with a 23-valent pneumococcal vaccine, is cost-effective, resulting in clinical and economic benefits including a non-negligible reduction of ambulatory doctor visits, hospitalizations and, deaths in Poland.",2012-01-09962,23095867,Hum Vaccin Immunother,Pawel Grzesiowski,2012,8 / 10,,No,23095867,"Pawel Grzesiowski; Raquel Aguiar-Ib??ez; Aleksandra Kobryn; Laure Durand; Pierre-Emmanuel Puig; Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland, Hum Vaccin Immunother , Oct/1/2012; 8(10):2164-554X",QALY,Not Stated,Not Stated,Not Stated,Pneumococcal vaccination program with pneumococcal polysaccharide vaccine covering 23 serotypes (PPV23) vs. None,Not Stated,Not Stated,65 Years,"Female, Male",Full,Lifetime,5.00,5.00,2255,Poland,2009,940.97
10447,Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland,"Introduction: Invasive pneumococcal disease is associated with substantial morbidity, mortality and cost implications, which could be reduced by vaccination. Aim: To assess the cost-effectiveness of a 23-valent pneumococcal vaccine in the elderly (65 and older) in Poland. Methods: A Markov model with a 1-year cycle length was developed, allowing up to 10 cohorts to enter the model over the lifetime horizon (35 years). In the base case, costs and benefits were assessed using the public health care payer (NFZ) perspective. The analysis included routine vaccination of all elderly and high-risk (HR) elderly versus no vaccination. The analysis assumed that the government would reimburse 50% of the vaccine price. Costs and benefits were discounted 5%, with costs expressed in 2009 Polish Zloty (PLN). Extensive sensitivity analyses were carried out. Results: PPV23 vaccination targeting all elderly and HR elderly in Poland would avoid 8,935 pneumococcal infections, 2,542 hospitalisations, 671 deaths and 5,886 infections, 1,673 hospitalisations and 441 deaths respectively. The incremental cost per QALY gained would be PLN 3,382 in all elderly and PLN2,148 in HR elderly. Conclusion: Vaccinating adults 65 and older regardless of risk status with a 23-valent pneumococcal vaccine, is cost-effective, resulting in clinical and economic benefits including a non-negligible reduction of ambulatory doctor visits, hospitalizations and, deaths in Poland.",2012-01-09962,23095867,Hum Vaccin Immunother,Pawel Grzesiowski,2012,8 / 10,,No,23095867,"Pawel Grzesiowski; Raquel Aguiar-Ib??ez; Aleksandra Kobryn; Laure Durand; Pierre-Emmanuel Puig; Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland, Hum Vaccin Immunother , Oct/1/2012; 8(10):2164-554X",QALY,Not Stated,Not Stated,Not Stated,Pneumococcal vaccination program with pneumococcal polysaccharide vaccine covering 23 serotypes (PPV23) vs. None,Not Stated,Not Stated,65 Years,"Female, Male",Full,Lifetime,5.00,5.00,939,Poland,2009,391.83
10448,Cost-effectiveness of supplementing a broth-enriched culture test with the Xpert meticillin-resistant Staphylococcus aureus (MRSA) assay for screening inpatients at high risk of MRSA,"Meticillin-resistant Staphylococcus aureus (MRSA) represents a considerable challenge for health care in terms of complications and costs. Whilst bacteriological culture remains the most common method for detecting MRSA, the polymerase-chain-reaction-based Xpert MRSA assay was introduced to Ullev?l Oslo University Hospital, Norway in 2009.To estimate the cost-effectiveness of supplementing a broth-enriched culture test with the Xpert MRSA assay in comparison with using the culture test alone as part of an active surveillance strategy.A decision-tree model was developed to compare the current strategy (broth-enriched culture test) with two new strategies using the Xpert MRSA assay (daytime and 24 h). Costs and outcomes (length of pre-emptive isolation, number of unavailable room-hours, quality of life) were measured.The current strategy was more expensive (NOK16,984 per patient) than the daytime Xpert strategy and 24 h Xpert strategy (NOK7360 and NOK3690 per patient, respectively). The new strategies reduced the length of pre-emptive isolation per patient (by 43.9 h and 57.5 h for the daytime Xpert strategy and 24 h Xpert strategy, respectively), and also the number of unavailable room-hours per case (by 57.1 h and 77.7 h, respectively). The improvement in patients' quality-adjusted life years (QALYs) was nominal (2.4*10(-4) and 3.0*10(-4) QALYs per patient for the daytime Xpert strategy and 24 h Xpert strategy, respectively). The sensitivity analyses indicated that these results were robust to reasonable changes in the model parameters.The 24 h Xpert strategy appears to be the best strategy for active surveillance as it reduces costs and unfavourable outcomes compared with the other strategies, while improving favourable outcomes under reasonable assumptions.",2012-01-09965,23098683,J Hosp Infect,J Li,2012,82 / 4,227-33,No,23098683,"J Li; K Ulvin; H Biboh; I S Kristiansen; Cost-effectiveness of supplementing a broth-enriched culture test with the Xpert meticillin-resistant Staphylococcus aureus (MRSA) assay for screening inpatients at high risk of MRSA, J Hosp Infect, ; 82(4):0195-6701; 227-33",QALY,Not Stated,Not Stated,Not Stated,Supplementing a broth-enriched culture test with the Xpert MRSA assay on a daytime basis vs. Culture test alone,Not Stated,Not Stated,Not Stated,"Female, Male",Full,12 Months,Not Stated,Not Stated,5879999.5,Norway,2009,1133871.04
10449,Cost-effectiveness of supplementing a broth-enriched culture test with the Xpert meticillin-resistant Staphylococcus aureus (MRSA) assay for screening inpatients at high risk of MRSA,"Meticillin-resistant Staphylococcus aureus (MRSA) represents a considerable challenge for health care in terms of complications and costs. Whilst bacteriological culture remains the most common method for detecting MRSA, the polymerase-chain-reaction-based Xpert MRSA assay was introduced to Ullev?l Oslo University Hospital, Norway in 2009.To estimate the cost-effectiveness of supplementing a broth-enriched culture test with the Xpert MRSA assay in comparison with using the culture test alone as part of an active surveillance strategy.A decision-tree model was developed to compare the current strategy (broth-enriched culture test) with two new strategies using the Xpert MRSA assay (daytime and 24 h). Costs and outcomes (length of pre-emptive isolation, number of unavailable room-hours, quality of life) were measured.The current strategy was more expensive (NOK16,984 per patient) than the daytime Xpert strategy and 24 h Xpert strategy (NOK7360 and NOK3690 per patient, respectively). The new strategies reduced the length of pre-emptive isolation per patient (by 43.9 h and 57.5 h for the daytime Xpert strategy and 24 h Xpert strategy, respectively), and also the number of unavailable room-hours per case (by 57.1 h and 77.7 h, respectively). The improvement in patients' quality-adjusted life years (QALYs) was nominal (2.4*10(-4) and 3.0*10(-4) QALYs per patient for the daytime Xpert strategy and 24 h Xpert strategy, respectively). The sensitivity analyses indicated that these results were robust to reasonable changes in the model parameters.The 24 h Xpert strategy appears to be the best strategy for active surveillance as it reduces costs and unfavourable outcomes compared with the other strategies, while improving favourable outcomes under reasonable assumptions.",2012-01-09965,23098683,J Hosp Infect,J Li,2012,82 / 4,227-33,No,23098683,"J Li; K Ulvin; H Biboh; I S Kristiansen; Cost-effectiveness of supplementing a broth-enriched culture test with the Xpert meticillin-resistant Staphylococcus aureus (MRSA) assay for screening inpatients at high risk of MRSA, J Hosp Infect, ; 82(4):0195-6701; 227-33",QALY,Not Stated,Not Stated,Not Stated,Supplementing a broth-enriched culture test with the Xpert MRSA assay on a 24 hr basis vs. Culture test alone,Not Stated,Not Stated,Not Stated,"Female, Male",Full,12 Months,Not Stated,Not Stated,-785416.63,Norway,2009,-151455.99
10450,Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis,"To estimate the cost effectiveness of vaccinating people with high risk conditions against invasive pneumococcal disease using the 13 valent pneumococcal conjugate vaccine.Economic evaluation using a cohort model from the perspective of healthcare providers.England.People aged 2 years and older at increased risk of invasive pneumococcal disease due to chronic kidney disease; splenic dysfunction; HIV infection; a compromised immune system; chronic heart, liver, or respiratory disease; or diabetes.Costs, gains in life years and quality adjusted life years (QALYs), and incremental cost effectiveness ratios.Increasing indirect protection resulting from the vaccination programme of infants using the 13 valent pneumococcal conjugate vaccine means that the burden of disease preventable by targeting high risk groups will diminish in time. Under base case assumptions--that is, no overall impact on non bacteraemic pneumonia in high risk groups and assuming the high risk vaccination programme would be launched two to three years after the infant programme--the incremental cost effectiveness ratio was estimated to be more than ?30,000 (?37,216; $48,210) per QALY gained for most risk groups. If, however, the vaccine does not offer protection against non-bacteraemic pneumococcal pneumonia or the vaccine was introduced concomitantly with the infant 13 valent pneumococcal conjugate vaccination programme then vaccinating high risk people would (more) likely be cost effective. Sensitivity analyses showed that the cost effectiveness was particularly sensitive to assumed herd benefits and vaccine efficacy estimates.Under base case assumptions it is unlikely that a pneumococcal vaccination programme aimed at risk groups could be considered cost effective. Uncertainty could be substantially reduced by establishing the effectiveness of the 13 valent pneumococcal conjugate vaccine against non-bacteraemic pneumococcal pneumonia, particularly in at risk groups.",2012-01-09969,23103369,BMJ,Mark H Rozenbaum,2012,345 /,e6879,No,23103369,"Mark H Rozenbaum; Albert Jan van Hoek; Douglas Fleming; Caroline L Trotter; Elizabeth Miller; W John Edmunds; Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis, BMJ, ; 345():0959-8138; e6879",QALY,Not Stated,Not Stated,Not Stated,13 valent pneumococcal conjugate vaccine vs. Usual care,Not Stated,Not Stated,2 Years,"Female, Male",Full,9 Years,3.50,3.50,183680,United Kingdom,2009,320840.54
10451,Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis,"To estimate the cost effectiveness of vaccinating people with high risk conditions against invasive pneumococcal disease using the 13 valent pneumococcal conjugate vaccine.Economic evaluation using a cohort model from the perspective of healthcare providers.England.People aged 2 years and older at increased risk of invasive pneumococcal disease due to chronic kidney disease; splenic dysfunction; HIV infection; a compromised immune system; chronic heart, liver, or respiratory disease; or diabetes.Costs, gains in life years and quality adjusted life years (QALYs), and incremental cost effectiveness ratios.Increasing indirect protection resulting from the vaccination programme of infants using the 13 valent pneumococcal conjugate vaccine means that the burden of disease preventable by targeting high risk groups will diminish in time. Under base case assumptions--that is, no overall impact on non bacteraemic pneumonia in high risk groups and assuming the high risk vaccination programme would be launched two to three years after the infant programme--the incremental cost effectiveness ratio was estimated to be more than ?30,000 (?37,216; $48,210) per QALY gained for most risk groups. If, however, the vaccine does not offer protection against non-bacteraemic pneumococcal pneumonia or the vaccine was introduced concomitantly with the infant 13 valent pneumococcal conjugate vaccination programme then vaccinating high risk people would (more) likely be cost effective. Sensitivity analyses showed that the cost effectiveness was particularly sensitive to assumed herd benefits and vaccine efficacy estimates.Under base case assumptions it is unlikely that a pneumococcal vaccination programme aimed at risk groups could be considered cost effective. Uncertainty could be substantially reduced by establishing the effectiveness of the 13 valent pneumococcal conjugate vaccine against non-bacteraemic pneumococcal pneumonia, particularly in at risk groups.",2012-01-09969,23103369,BMJ,Mark H Rozenbaum,2012,345 /,e6879,No,23103369,"Mark H Rozenbaum; Albert Jan van Hoek; Douglas Fleming; Caroline L Trotter; Elizabeth Miller; W John Edmunds; Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis, BMJ, ; 345():0959-8138; e6879",QALY,Not Stated,Not Stated,Not Stated,13 valent pneumococcal conjugate vaccine vs. Usual care,Not Stated,Not Stated,2 Years,"Female, Male",Full,9 Years,3.50,3.50,1204091,United Kingdom,2009,2103229.6
10452,Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis,"To estimate the cost effectiveness of vaccinating people with high risk conditions against invasive pneumococcal disease using the 13 valent pneumococcal conjugate vaccine.Economic evaluation using a cohort model from the perspective of healthcare providers.England.People aged 2 years and older at increased risk of invasive pneumococcal disease due to chronic kidney disease; splenic dysfunction; HIV infection; a compromised immune system; chronic heart, liver, or respiratory disease; or diabetes.Costs, gains in life years and quality adjusted life years (QALYs), and incremental cost effectiveness ratios.Increasing indirect protection resulting from the vaccination programme of infants using the 13 valent pneumococcal conjugate vaccine means that the burden of disease preventable by targeting high risk groups will diminish in time. Under base case assumptions--that is, no overall impact on non bacteraemic pneumonia in high risk groups and assuming the high risk vaccination programme would be launched two to three years after the infant programme--the incremental cost effectiveness ratio was estimated to be more than ?30,000 (?37,216; $48,210) per QALY gained for most risk groups. If, however, the vaccine does not offer protection against non-bacteraemic pneumococcal pneumonia or the vaccine was introduced concomitantly with the infant 13 valent pneumococcal conjugate vaccination programme then vaccinating high risk people would (more) likely be cost effective. Sensitivity analyses showed that the cost effectiveness was particularly sensitive to assumed herd benefits and vaccine efficacy estimates.Under base case assumptions it is unlikely that a pneumococcal vaccination programme aimed at risk groups could be considered cost effective. Uncertainty could be substantially reduced by establishing the effectiveness of the 13 valent pneumococcal conjugate vaccine against non-bacteraemic pneumococcal pneumonia, particularly in at risk groups.",2012-01-09969,23103369,BMJ,Mark H Rozenbaum,2012,345 /,e6879,No,23103369,"Mark H Rozenbaum; Albert Jan van Hoek; Douglas Fleming; Caroline L Trotter; Elizabeth Miller; W John Edmunds; Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis, BMJ, ; 345():0959-8138; e6879",QALY,Not Stated,Not Stated,Not Stated,13 valent pneumococcal conjugate vaccine vs. Usual care,Not Stated,Not Stated,2 Years,"Female, Male",Full,9 Years,3.50,3.50,90243,United Kingdom,2009,157630.73
10453,Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis,"To estimate the cost effectiveness of vaccinating people with high risk conditions against invasive pneumococcal disease using the 13 valent pneumococcal conjugate vaccine.Economic evaluation using a cohort model from the perspective of healthcare providers.England.People aged 2 years and older at increased risk of invasive pneumococcal disease due to chronic kidney disease; splenic dysfunction; HIV infection; a compromised immune system; chronic heart, liver, or respiratory disease; or diabetes.Costs, gains in life years and quality adjusted life years (QALYs), and incremental cost effectiveness ratios.Increasing indirect protection resulting from the vaccination programme of infants using the 13 valent pneumococcal conjugate vaccine means that the burden of disease preventable by targeting high risk groups will diminish in time. Under base case assumptions--that is, no overall impact on non bacteraemic pneumonia in high risk groups and assuming the high risk vaccination programme would be launched two to three years after the infant programme--the incremental cost effectiveness ratio was estimated to be more than ?30,000 (?37,216; $48,210) per QALY gained for most risk groups. If, however, the vaccine does not offer protection against non-bacteraemic pneumococcal pneumonia or the vaccine was introduced concomitantly with the infant 13 valent pneumococcal conjugate vaccination programme then vaccinating high risk people would (more) likely be cost effective. Sensitivity analyses showed that the cost effectiveness was particularly sensitive to assumed herd benefits and vaccine efficacy estimates.Under base case assumptions it is unlikely that a pneumococcal vaccination programme aimed at risk groups could be considered cost effective. Uncertainty could be substantially reduced by establishing the effectiveness of the 13 valent pneumococcal conjugate vaccine against non-bacteraemic pneumococcal pneumonia, particularly in at risk groups.",2012-01-09969,23103369,BMJ,Mark H Rozenbaum,2012,345 /,e6879,No,23103369,"Mark H Rozenbaum; Albert Jan van Hoek; Douglas Fleming; Caroline L Trotter; Elizabeth Miller; W John Edmunds; Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis, BMJ, ; 345():0959-8138; e6879",QALY,Not Stated,Not Stated,Not Stated,13 valent pneumococcal conjugate vaccine vs. Usual care,Not Stated,Not Stated,2 Years,"Female, Male",Full,9 Years,3.50,3.50,161063,United Kingdom,2009,281334.61
10454,Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis,"To estimate the cost effectiveness of vaccinating people with high risk conditions against invasive pneumococcal disease using the 13 valent pneumococcal conjugate vaccine.Economic evaluation using a cohort model from the perspective of healthcare providers.England.People aged 2 years and older at increased risk of invasive pneumococcal disease due to chronic kidney disease; splenic dysfunction; HIV infection; a compromised immune system; chronic heart, liver, or respiratory disease; or diabetes.Costs, gains in life years and quality adjusted life years (QALYs), and incremental cost effectiveness ratios.Increasing indirect protection resulting from the vaccination programme of infants using the 13 valent pneumococcal conjugate vaccine means that the burden of disease preventable by targeting high risk groups will diminish in time. Under base case assumptions--that is, no overall impact on non bacteraemic pneumonia in high risk groups and assuming the high risk vaccination programme would be launched two to three years after the infant programme--the incremental cost effectiveness ratio was estimated to be more than ?30,000 (?37,216; $48,210) per QALY gained for most risk groups. If, however, the vaccine does not offer protection against non-bacteraemic pneumococcal pneumonia or the vaccine was introduced concomitantly with the infant 13 valent pneumococcal conjugate vaccination programme then vaccinating high risk people would (more) likely be cost effective. Sensitivity analyses showed that the cost effectiveness was particularly sensitive to assumed herd benefits and vaccine efficacy estimates.Under base case assumptions it is unlikely that a pneumococcal vaccination programme aimed at risk groups could be considered cost effective. Uncertainty could be substantially reduced by establishing the effectiveness of the 13 valent pneumococcal conjugate vaccine against non-bacteraemic pneumococcal pneumonia, particularly in at risk groups.",2012-01-09969,23103369,BMJ,Mark H Rozenbaum,2012,345 /,e6879,No,23103369,"Mark H Rozenbaum; Albert Jan van Hoek; Douglas Fleming; Caroline L Trotter; Elizabeth Miller; W John Edmunds; Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis, BMJ, ; 345():0959-8138; e6879",QALY,Not Stated,Not Stated,Not Stated,13 valent pneumococcal conjugate vaccine vs. Usual care,Not Stated,Not Stated,2 Years,"Female, Male",Full,9 Years,3.50,3.50,493682,United Kingdom,2009,862332.33
10455,Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis,"To estimate the cost effectiveness of vaccinating people with high risk conditions against invasive pneumococcal disease using the 13 valent pneumococcal conjugate vaccine.Economic evaluation using a cohort model from the perspective of healthcare providers.England.People aged 2 years and older at increased risk of invasive pneumococcal disease due to chronic kidney disease; splenic dysfunction; HIV infection; a compromised immune system; chronic heart, liver, or respiratory disease; or diabetes.Costs, gains in life years and quality adjusted life years (QALYs), and incremental cost effectiveness ratios.Increasing indirect protection resulting from the vaccination programme of infants using the 13 valent pneumococcal conjugate vaccine means that the burden of disease preventable by targeting high risk groups will diminish in time. Under base case assumptions--that is, no overall impact on non bacteraemic pneumonia in high risk groups and assuming the high risk vaccination programme would be launched two to three years after the infant programme--the incremental cost effectiveness ratio was estimated to be more than ?30,000 (?37,216; $48,210) per QALY gained for most risk groups. If, however, the vaccine does not offer protection against non-bacteraemic pneumococcal pneumonia or the vaccine was introduced concomitantly with the infant 13 valent pneumococcal conjugate vaccination programme then vaccinating high risk people would (more) likely be cost effective. Sensitivity analyses showed that the cost effectiveness was particularly sensitive to assumed herd benefits and vaccine efficacy estimates.Under base case assumptions it is unlikely that a pneumococcal vaccination programme aimed at risk groups could be considered cost effective. Uncertainty could be substantially reduced by establishing the effectiveness of the 13 valent pneumococcal conjugate vaccine against non-bacteraemic pneumococcal pneumonia, particularly in at risk groups.",2012-01-09969,23103369,BMJ,Mark H Rozenbaum,2012,345 /,e6879,No,23103369,"Mark H Rozenbaum; Albert Jan van Hoek; Douglas Fleming; Caroline L Trotter; Elizabeth Miller; W John Edmunds; Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis, BMJ, ; 345():0959-8138; e6879",QALY,Not Stated,Not Stated,Not Stated,13 valent pneumococcal conjugate vaccine vs. Usual care,Not Stated,Not Stated,2 Years,"Female, Male",Full,9 Years,3.50,3.50,20324,United Kingdom,2009,35500.67
10456,Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis,"To estimate the cost effectiveness of vaccinating people with high risk conditions against invasive pneumococcal disease using the 13 valent pneumococcal conjugate vaccine.Economic evaluation using a cohort model from the perspective of healthcare providers.England.People aged 2 years and older at increased risk of invasive pneumococcal disease due to chronic kidney disease; splenic dysfunction; HIV infection; a compromised immune system; chronic heart, liver, or respiratory disease; or diabetes.Costs, gains in life years and quality adjusted life years (QALYs), and incremental cost effectiveness ratios.Increasing indirect protection resulting from the vaccination programme of infants using the 13 valent pneumococcal conjugate vaccine means that the burden of disease preventable by targeting high risk groups will diminish in time. Under base case assumptions--that is, no overall impact on non bacteraemic pneumonia in high risk groups and assuming the high risk vaccination programme would be launched two to three years after the infant programme--the incremental cost effectiveness ratio was estimated to be more than ?30,000 (?37,216; $48,210) per QALY gained for most risk groups. If, however, the vaccine does not offer protection against non-bacteraemic pneumococcal pneumonia or the vaccine was introduced concomitantly with the infant 13 valent pneumococcal conjugate vaccination programme then vaccinating high risk people would (more) likely be cost effective. Sensitivity analyses showed that the cost effectiveness was particularly sensitive to assumed herd benefits and vaccine efficacy estimates.Under base case assumptions it is unlikely that a pneumococcal vaccination programme aimed at risk groups could be considered cost effective. Uncertainty could be substantially reduced by establishing the effectiveness of the 13 valent pneumococcal conjugate vaccine against non-bacteraemic pneumococcal pneumonia, particularly in at risk groups.",2012-01-09969,23103369,BMJ,Mark H Rozenbaum,2012,345 /,e6879,No,23103369,"Mark H Rozenbaum; Albert Jan van Hoek; Douglas Fleming; Caroline L Trotter; Elizabeth Miller; W John Edmunds; Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis, BMJ, ; 345():0959-8138; e6879",QALY,Not Stated,Not Stated,Not Stated,13 valent pneumococcal conjugate vaccine vs. Usual care,Not Stated,Not Stated,2 Years,"Female, Male",Full,9 Years,3.50,3.50,269750,United Kingdom,2009,471182.15
10457,Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis,"To estimate the cost effectiveness of vaccinating people with high risk conditions against invasive pneumococcal disease using the 13 valent pneumococcal conjugate vaccine.Economic evaluation using a cohort model from the perspective of healthcare providers.England.People aged 2 years and older at increased risk of invasive pneumococcal disease due to chronic kidney disease; splenic dysfunction; HIV infection; a compromised immune system; chronic heart, liver, or respiratory disease; or diabetes.Costs, gains in life years and quality adjusted life years (QALYs), and incremental cost effectiveness ratios.Increasing indirect protection resulting from the vaccination programme of infants using the 13 valent pneumococcal conjugate vaccine means that the burden of disease preventable by targeting high risk groups will diminish in time. Under base case assumptions--that is, no overall impact on non bacteraemic pneumonia in high risk groups and assuming the high risk vaccination programme would be launched two to three years after the infant programme--the incremental cost effectiveness ratio was estimated to be more than ?30,000 (?37,216; $48,210) per QALY gained for most risk groups. If, however, the vaccine does not offer protection against non-bacteraemic pneumococcal pneumonia or the vaccine was introduced concomitantly with the infant 13 valent pneumococcal conjugate vaccination programme then vaccinating high risk people would (more) likely be cost effective. Sensitivity analyses showed that the cost effectiveness was particularly sensitive to assumed herd benefits and vaccine efficacy estimates.Under base case assumptions it is unlikely that a pneumococcal vaccination programme aimed at risk groups could be considered cost effective. Uncertainty could be substantially reduced by establishing the effectiveness of the 13 valent pneumococcal conjugate vaccine against non-bacteraemic pneumococcal pneumonia, particularly in at risk groups.",2012-01-09969,23103369,BMJ,Mark H Rozenbaum,2012,345 /,e6879,No,23103369,"Mark H Rozenbaum; Albert Jan van Hoek; Douglas Fleming; Caroline L Trotter; Elizabeth Miller; W John Edmunds; Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis, BMJ, ; 345():0959-8138; e6879",QALY,Not Stated,Not Stated,Not Stated,13 valent pneumococcal conjugate vaccine vs. Usual care,Not Stated,Not Stated,2 Years,"Female, Male",Full,9 Years,3.50,3.50,90720,United Kingdom,2009,158463.93
10458,Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis,"To estimate the cost effectiveness of vaccinating people with high risk conditions against invasive pneumococcal disease using the 13 valent pneumococcal conjugate vaccine.Economic evaluation using a cohort model from the perspective of healthcare providers.England.People aged 2 years and older at increased risk of invasive pneumococcal disease due to chronic kidney disease; splenic dysfunction; HIV infection; a compromised immune system; chronic heart, liver, or respiratory disease; or diabetes.Costs, gains in life years and quality adjusted life years (QALYs), and incremental cost effectiveness ratios.Increasing indirect protection resulting from the vaccination programme of infants using the 13 valent pneumococcal conjugate vaccine means that the burden of disease preventable by targeting high risk groups will diminish in time. Under base case assumptions--that is, no overall impact on non bacteraemic pneumonia in high risk groups and assuming the high risk vaccination programme would be launched two to three years after the infant programme--the incremental cost effectiveness ratio was estimated to be more than ?30,000 (?37,216; $48,210) per QALY gained for most risk groups. If, however, the vaccine does not offer protection against non-bacteraemic pneumococcal pneumonia or the vaccine was introduced concomitantly with the infant 13 valent pneumococcal conjugate vaccination programme then vaccinating high risk people would (more) likely be cost effective. Sensitivity analyses showed that the cost effectiveness was particularly sensitive to assumed herd benefits and vaccine efficacy estimates.Under base case assumptions it is unlikely that a pneumococcal vaccination programme aimed at risk groups could be considered cost effective. Uncertainty could be substantially reduced by establishing the effectiveness of the 13 valent pneumococcal conjugate vaccine against non-bacteraemic pneumococcal pneumonia, particularly in at risk groups.",2012-01-09969,23103369,BMJ,Mark H Rozenbaum,2012,345 /,e6879,No,23103369,"Mark H Rozenbaum; Albert Jan van Hoek; Douglas Fleming; Caroline L Trotter; Elizabeth Miller; W John Edmunds; Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis, BMJ, ; 345():0959-8138; e6879",QALY,Not Stated,Not Stated,Not Stated,13 valent pneumococcal conjugate vaccine vs. Usual care,Not Stated,Not Stated,2 Years,"Female, Male",Full,9 Years,3.50,3.50,61239,United Kingdom,2009,106968.39
10459,Economic evaluation of internet-based interventions for harmful alcohol use alongside a pragmatic randomized controlled trial,"Internet interventions with and without therapist support have been found to be effective treatment options for harmful alcohol users. Internet-based therapy (IT) leads to larger and longer-lasting positive effects than Internet-based self-help (IS), but it is also more costly to provide.To evaluate the cost effectiveness and cost utility of Internet-based interventions for harmful use of alcohol through the assessment of the incremental cost effectiveness of IT compared with IS.This study was performed in a substance abuse treatment center in Amsterdam, the Netherlands. We collected data over the years 2008-2009. A total of 136 participants were included, 70 (51%) were female, and mean age was 41.5 (SD 9.83) years. Reported alcohol consumption and Alcohol Use Disorders Identification Test (AUDIT) scores indicated harmful drinking behavior at baseline. We collected self-reported outcome data prospectively at baseline and 6 months after randomization. Cost data were extracted from the treatment center's cost records, and sex- and age-specific mean productivity cost data for the Netherlands.The median incremental cost-effectiveness ratio was estimated at ?3683 per additional treatment responder and ?14,710 per quality-adjusted life-year (QALY) gained. At a willingness to pay ?20,000 for 1 additional QALY, IT had a 60% likelihood of being more cost effective than IS. Sensitivity analyses attested to the robustness of the findings.IT offers better value for money than IS and might therefore be considered as a treatment option, either as first-line treatment in a matched-care approach or as a second-line treatment in the context of a stepped-care approach.Netherlands Trial Register NTR-TC1155; http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1155 (Archived by WebCite at http://www.webcitation.org/6AqnV4eTU).",2012-01-09971,23103771,J Med Internet Res,Matthijs Blankers,2012,14 / 5,e134,No,23103771,"Matthijs Blankers; Udo Nabitz; Filip Smit; Maarten W J Koeter; Gerard M Schippers; Economic evaluation of internet-based interventions for harmful alcohol use alongside a pragmatic randomized controlled trial, J Med Internet Res, ; 14(5):1438-8871; e134",QALY,Netherlands,Not Stated,Not Stated,Internet-based interventions (IT) (7 synchronous text-based chat-therapy sessions with a personal (Internet) cognitive behavioral therapy-trained therapist along with homework assignments) for harmful alcohol use vs. Internet-based self-help (IS) (various treatment exercises without therapists support),Not Stated,Not Stated,Not Stated,"Female, Male",Full,6 Months,Not Stated,Not Stated,14710,Euro,2010,23106.31
10460,The cost-effectiveness and budget impact of Vietnam's methadone maintenance treatment programme in HIV prevention and treatment among injection drug users,"Abstract We analysed the cost-effectiveness and budget impact of the methadone maintenance treatment (MMT) programme in HIV prevention and treatment among injection drug users (DUs) in Vietnam. The costs and health outcomes of providing MMT for opioid-dependent DUs versus non-MMT were estimated using a decision analytical model. Probabilistic sensitivity analysis using Monte Carlo simulation was conducted to justify uncertainties of model parameters simultaneously. The incremental cost-effectiveness ratio (ICER) of MMT in HIV prevention was US$3324 per one averted HIV case. The decision model showed that the cost-effectiveness ratio of MMT and non-MMT strategies was US$480 and US$204 per 1 quality-adjusted life year (QALY), equivalent to 0.43 and 0.18 times the gross domestic product per capita (GDPpc). The ICER for MMT versus non-MMT strategy was US$1964, approximately 1.76 times the GDPpc/QALY, classifying MMT as a cost-effective intervention. At the willingness to pay threshold of three times the GDPpc, the probability of MMT and non-MMT strategies being cost-effective was 80.3 and 19.7%, respectively. The budget impact of scaling up MMT from 2011 to 2015 will be US$97 million for 65% coverage or US$49 million for treating 80,000 DUs. The results indicated that MMT was cost-effective in HIV prevention and treatment among DUs who were opioid dependent.",2012-01-09974,23106230,Glob Public Health,Bach Xuan Tran,2012,7 / 5,1080-94,No,23106230,"Bach Xuan Tran; Arto Ohinmaa; Anh Thuy Duong; Long Thanh Nguyen; Phu Xuan Vu; Steve Mills; Stan Houston; Philip Jacobs; The cost-effectiveness and budget impact of Vietnam's methadone maintenance treatment programme in HIV prevention and treatment among injection drug users, Glob Public Health, ; 7(5):1744-1706; 1080-94",QALY,Not Stated,Not Stated,Not Stated,"Methadone maintenance treatment (MMT) for methadone-naive, opioid dependent users vs. Non-MMT",Not Stated,Not Stated,Not Stated,"Female, Male",Full,5 Years,5.00,5.00,1964.7,United States,2009,2370.16
10461,Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: a model-based evaluation,"Rotavirus gastroenteritis (RVGE) is associated with widespread morbidity and mortality in children worldwide. In high-income countries, including Canada, the burden of RVGE relates largely to morbidity and healthcare utilization. Two live rotavirus vaccines (RotaTeq(?) (Merck Frosst Canada Ltd.) and Rotarix? (GlaxoSmithKline Inc.)), are now approved for use in Canada, but their economic attractiveness has not been evaluated in the Canadian context.We performed a model-based economic analysis using a Markov chain Monte Carlo simulation of RVGE in populations of British Columbia children. Models were parameterized based on best available data on disease natural history and epidemiology, vaccine effectiveness and cost, and healthcare costs, and calibrated such that projections of healthcare utilization and vaccine coverage closely matched empirical estimates. Robustness of projections was evaluated in deterministic and probabilistic sensitivity analyses.Based on the best available data, childhood immunization against RVGE was projected to prevent 63-81 infections per 100 children vaccinated, and to prevent substantial numbers of outpatient medical visits. It was projected that either vaccine would prevent 1-2 hospitalizations per 100 children immunized. Vaccination was projected to increase healthcare costs: immunization with Rotarix? would prevent incident infections at a cost of approximately $10 per infection prevented or $2400 per quality-adjusted life-year gained. Vaccination with RotaTeq? would be more costly and less effective and would not be preferred. Projections were robust in the face of wide-ranging sensitivity analyses.The use of currently available vaccines against RVGE in British Columbia children is projected to result in a substantial reduction in the burden of illness and healthcare utilization associated with RVGE, with a modest increase in healthcare costs. RVGE vaccination should be considered ""highly cost-effective"" relative to other commonly available health interventions.",2012-01-09977,23107595,Vaccine,David N Fisman,2012,30 / 52,7601-7,Yes,23107595,"David N Fisman; Christina H Chan; Elizabeth Lowcock; Monika Naus; Victoria Lee; Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: a model-based evaluation, Vaccine, Dec/14/2012; 30(52):1873-2518; 7601-7",QALY,Canada,Not Stated,Not Stated,RotaTeq vaccine against rotavirus vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,5 Years,3.00,3.00,14300,Canada,2007,15713.86
10462,Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: a model-based evaluation,"Rotavirus gastroenteritis (RVGE) is associated with widespread morbidity and mortality in children worldwide. In high-income countries, including Canada, the burden of RVGE relates largely to morbidity and healthcare utilization. Two live rotavirus vaccines (RotaTeq(?) (Merck Frosst Canada Ltd.) and Rotarix? (GlaxoSmithKline Inc.)), are now approved for use in Canada, but their economic attractiveness has not been evaluated in the Canadian context.We performed a model-based economic analysis using a Markov chain Monte Carlo simulation of RVGE in populations of British Columbia children. Models were parameterized based on best available data on disease natural history and epidemiology, vaccine effectiveness and cost, and healthcare costs, and calibrated such that projections of healthcare utilization and vaccine coverage closely matched empirical estimates. Robustness of projections was evaluated in deterministic and probabilistic sensitivity analyses.Based on the best available data, childhood immunization against RVGE was projected to prevent 63-81 infections per 100 children vaccinated, and to prevent substantial numbers of outpatient medical visits. It was projected that either vaccine would prevent 1-2 hospitalizations per 100 children immunized. Vaccination was projected to increase healthcare costs: immunization with Rotarix? would prevent incident infections at a cost of approximately $10 per infection prevented or $2400 per quality-adjusted life-year gained. Vaccination with RotaTeq? would be more costly and less effective and would not be preferred. Projections were robust in the face of wide-ranging sensitivity analyses.The use of currently available vaccines against RVGE in British Columbia children is projected to result in a substantial reduction in the burden of illness and healthcare utilization associated with RVGE, with a modest increase in healthcare costs. RVGE vaccination should be considered ""highly cost-effective"" relative to other commonly available health interventions.",2012-01-09977,23107595,Vaccine,David N Fisman,2012,30 / 52,7601-7,Yes,23107595,"David N Fisman; Christina H Chan; Elizabeth Lowcock; Monika Naus; Victoria Lee; Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: a model-based evaluation, Vaccine, Dec/14/2012; 30(52):1873-2518; 7601-7",QALY,Canada,Not Stated,Not Stated,Rotatrix vaccine against rotavirus vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,5 Years,3.00,3.00,2400,Canada,2007,2637.29
10463,Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary,"ABSTRACT:The cervical cancer screening program implemented in Hungary to date has not been successful. Along with screening, vaccination is an effective intervention to prevent cervical cancer. The aim of this study was to assess the cost-effectiveness of adding vaccination with the human papillomavirus 16/18 vaccine to the current cervical cancer screening program in Hungary.We developed a cohort simulation state-transition Markov model to model the life course of 12-year-old girls. Eighty percent participation in the HPV vaccination program at 12 years of age was assumed. Transitional probabilities were estimated using data from the literature. Local data were used regarding screening participation rates, and the costs were estimated in US $. We applied the purchasing power parity exchange rate of 129 HUF/$ to the cost data. Only direct health care costs were considered. We used a 3.7% discount rate for both the cost and quality-adjusted life years (QALYs). The time horizon was 88 years.Inclusion of HPV vaccination at age 12 in the cervical cancer prevention program was predicted to be cost-effective. The incremental cost-effectiveness ratio (ICER) of adding HPV vaccination to the current national cancer screening program was estimated to be 27 588 $/QALY. The results were sensitive to the price of the vaccine, the discount rate, the screening participation rate and whether herd immunity was taken into account.Our modeling analysis showed that the vaccination of 12-year-old adolescent girls against cervical cancer with the AS04-adjuvanted human papillomavirus 16/18 vaccine would be a cost-effective strategy to prevent cervical cancer in Hungary.",2012-01-09982,23110361,BMC Public Health,Zolt?n Vok?,2012,12 /,924,No,23110361,"Zolt?n Vok?; L?szl? Nagyj?nosi; Zolt?n Kal?; Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary, BMC Public Health, ; 12():1471-2458; 924",QALY,Hungary,Not Stated,Not Stated,Participation in the HPV vaccination program (coverage=80%) vs. None,Not Stated,12 Years,12 Years,Female,Full,88 Years,3.70,3.70,27588,United States,2010,32744.24
10464,The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden,"ABSTRACT:This paper presents the model and results to evaluate the use of teriparatide as a first-line treatment of severe postmenopausal osteoporosis (PMO) and Glucocorticoid-induced osteoporosis (GIOP). The study's objective was to determine if teriparatide is cost effective against oral bisphosphonates for two large and high risk cohorts.A computer simulation model was created to model treatment, osteoporosis related fractures, and the remaining life of PMO and GIOP patients. Natural mortality and additional mortality from osteoporosis related fractures were included in the model. Costs for treatment with both teriparatide and oral bisphosphonates were included. Drug efficacy was modeled as a reduction to the relative fracture risk for subsequent osteoporosis related fractures. Patient health utilities associated with age, gender, and osteoporosis related fractures were included in the model. Patient costs and utilities were summarized and incremental cost-effectiveness ratios (ICERs) for teriparatide versus oral bisphosphonates and teriparatide versus no treatment were estimated.For each of the PMO and GIOP populations, two cohorts differentiated by fracture history were simulated. The first contained patients with both a historical vertebral fracture and an incident vertebral fracture. The second contained patients with only an incident vertebral fracture. The PMO cohorts simulated had an initial Bone Mineral Density (BMD) T-Score of -3.0. The GIOP cohorts simulated had an initial BMD T-Score of -2.5.The ICERs for teriparatide versus bisphosphonate use for the one and two fracture PMO cohorts were ?36,995 per QALY and ?19,371 per QALY. The ICERs for teriparatide versus bisphosphonate use for the one and two fracture GIOP cohorts were ?20,826 per QALY and ?15,155 per QALY, respectively.The selection of teriparatide versus oral bisphosphonates as a first-line treatment for the high risk PMO and GIOP cohorts evaluated is justified at a cost per QALY threshold of ?50,000.",2012-01-09985,23110626,BMC Musculoskelet Disord,Daniel R Murphy,2012,13 /,213,No,23110626,"Daniel R Murphy; Lee J Smolen; Timothy M Klein; Robert W Klein; The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden, BMC Musculoskelet Disord, ; 13 ():1471-2474; 213",QALY,Sweden,Not Stated,Not Stated,Teriparatide vs. Oral bisphosphonates,Not Stated,69 Years,69 Years,Female,Full,Lifetime,3.00,3.00,36995,Euro,2012,53624.55
10465,The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden,"ABSTRACT:This paper presents the model and results to evaluate the use of teriparatide as a first-line treatment of severe postmenopausal osteoporosis (PMO) and Glucocorticoid-induced osteoporosis (GIOP). The study's objective was to determine if teriparatide is cost effective against oral bisphosphonates for two large and high risk cohorts.A computer simulation model was created to model treatment, osteoporosis related fractures, and the remaining life of PMO and GIOP patients. Natural mortality and additional mortality from osteoporosis related fractures were included in the model. Costs for treatment with both teriparatide and oral bisphosphonates were included. Drug efficacy was modeled as a reduction to the relative fracture risk for subsequent osteoporosis related fractures. Patient health utilities associated with age, gender, and osteoporosis related fractures were included in the model. Patient costs and utilities were summarized and incremental cost-effectiveness ratios (ICERs) for teriparatide versus oral bisphosphonates and teriparatide versus no treatment were estimated.For each of the PMO and GIOP populations, two cohorts differentiated by fracture history were simulated. The first contained patients with both a historical vertebral fracture and an incident vertebral fracture. The second contained patients with only an incident vertebral fracture. The PMO cohorts simulated had an initial Bone Mineral Density (BMD) T-Score of -3.0. The GIOP cohorts simulated had an initial BMD T-Score of -2.5.The ICERs for teriparatide versus bisphosphonate use for the one and two fracture PMO cohorts were ?36,995 per QALY and ?19,371 per QALY. The ICERs for teriparatide versus bisphosphonate use for the one and two fracture GIOP cohorts were ?20,826 per QALY and ?15,155 per QALY, respectively.The selection of teriparatide versus oral bisphosphonates as a first-line treatment for the high risk PMO and GIOP cohorts evaluated is justified at a cost per QALY threshold of ?50,000.",2012-01-09985,23110626,BMC Musculoskelet Disord,Daniel R Murphy,2012,13 /,213,No,23110626,"Daniel R Murphy; Lee J Smolen; Timothy M Klein; Robert W Klein; The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden, BMC Musculoskelet Disord, ; 13 ():1471-2474; 213",QALY,Sweden,Not Stated,Not Stated,Teriparatide vs. Oral bisphosphonates,Not Stated,69 Years,69 Years,Female,Full,Lifetime,3.00,3.00,19371,Euro,2012,28078.42
10466,The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden,"ABSTRACT:This paper presents the model and results to evaluate the use of teriparatide as a first-line treatment of severe postmenopausal osteoporosis (PMO) and Glucocorticoid-induced osteoporosis (GIOP). The study's objective was to determine if teriparatide is cost effective against oral bisphosphonates for two large and high risk cohorts.A computer simulation model was created to model treatment, osteoporosis related fractures, and the remaining life of PMO and GIOP patients. Natural mortality and additional mortality from osteoporosis related fractures were included in the model. Costs for treatment with both teriparatide and oral bisphosphonates were included. Drug efficacy was modeled as a reduction to the relative fracture risk for subsequent osteoporosis related fractures. Patient health utilities associated with age, gender, and osteoporosis related fractures were included in the model. Patient costs and utilities were summarized and incremental cost-effectiveness ratios (ICERs) for teriparatide versus oral bisphosphonates and teriparatide versus no treatment were estimated.For each of the PMO and GIOP populations, two cohorts differentiated by fracture history were simulated. The first contained patients with both a historical vertebral fracture and an incident vertebral fracture. The second contained patients with only an incident vertebral fracture. The PMO cohorts simulated had an initial Bone Mineral Density (BMD) T-Score of -3.0. The GIOP cohorts simulated had an initial BMD T-Score of -2.5.The ICERs for teriparatide versus bisphosphonate use for the one and two fracture PMO cohorts were ?36,995 per QALY and ?19,371 per QALY. The ICERs for teriparatide versus bisphosphonate use for the one and two fracture GIOP cohorts were ?20,826 per QALY and ?15,155 per QALY, respectively.The selection of teriparatide versus oral bisphosphonates as a first-line treatment for the high risk PMO and GIOP cohorts evaluated is justified at a cost per QALY threshold of ?50,000.",2012-01-09985,23110626,BMC Musculoskelet Disord,Daniel R Murphy,2012,13 /,213,No,23110626,"Daniel R Murphy; Lee J Smolen; Timothy M Klein; Robert W Klein; The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden, BMC Musculoskelet Disord, ; 13 ():1471-2474; 213",QALY,Sweden,Not Stated,Not Stated,Teriparatide vs. None,Not Stated,69 Years,69 Years,Female,Full,Lifetime,3.00,3.00,5897,Euro,2012,8547.75
10467,The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden,"ABSTRACT:This paper presents the model and results to evaluate the use of teriparatide as a first-line treatment of severe postmenopausal osteoporosis (PMO) and Glucocorticoid-induced osteoporosis (GIOP). The study's objective was to determine if teriparatide is cost effective against oral bisphosphonates for two large and high risk cohorts.A computer simulation model was created to model treatment, osteoporosis related fractures, and the remaining life of PMO and GIOP patients. Natural mortality and additional mortality from osteoporosis related fractures were included in the model. Costs for treatment with both teriparatide and oral bisphosphonates were included. Drug efficacy was modeled as a reduction to the relative fracture risk for subsequent osteoporosis related fractures. Patient health utilities associated with age, gender, and osteoporosis related fractures were included in the model. Patient costs and utilities were summarized and incremental cost-effectiveness ratios (ICERs) for teriparatide versus oral bisphosphonates and teriparatide versus no treatment were estimated.For each of the PMO and GIOP populations, two cohorts differentiated by fracture history were simulated. The first contained patients with both a historical vertebral fracture and an incident vertebral fracture. The second contained patients with only an incident vertebral fracture. The PMO cohorts simulated had an initial Bone Mineral Density (BMD) T-Score of -3.0. The GIOP cohorts simulated had an initial BMD T-Score of -2.5.The ICERs for teriparatide versus bisphosphonate use for the one and two fracture PMO cohorts were ?36,995 per QALY and ?19,371 per QALY. The ICERs for teriparatide versus bisphosphonate use for the one and two fracture GIOP cohorts were ?20,826 per QALY and ?15,155 per QALY, respectively.The selection of teriparatide versus oral bisphosphonates as a first-line treatment for the high risk PMO and GIOP cohorts evaluated is justified at a cost per QALY threshold of ?50,000.",2012-01-09985,23110626,BMC Musculoskelet Disord,Daniel R Murphy,2012,13 /,213,No,23110626,"Daniel R Murphy; Lee J Smolen; Timothy M Klein; Robert W Klein; The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden, BMC Musculoskelet Disord, ; 13 ():1471-2474; 213",QALY,Sweden,Not Stated,Not Stated,Teriparatide vs. None,Not Stated,69 Years,69 Years,Female,Full,Lifetime,3.00,3.00,18701,Euro,2012,27107.25
10468,The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden,"ABSTRACT:This paper presents the model and results to evaluate the use of teriparatide as a first-line treatment of severe postmenopausal osteoporosis (PMO) and Glucocorticoid-induced osteoporosis (GIOP). The study's objective was to determine if teriparatide is cost effective against oral bisphosphonates for two large and high risk cohorts.A computer simulation model was created to model treatment, osteoporosis related fractures, and the remaining life of PMO and GIOP patients. Natural mortality and additional mortality from osteoporosis related fractures were included in the model. Costs for treatment with both teriparatide and oral bisphosphonates were included. Drug efficacy was modeled as a reduction to the relative fracture risk for subsequent osteoporosis related fractures. Patient health utilities associated with age, gender, and osteoporosis related fractures were included in the model. Patient costs and utilities were summarized and incremental cost-effectiveness ratios (ICERs) for teriparatide versus oral bisphosphonates and teriparatide versus no treatment were estimated.For each of the PMO and GIOP populations, two cohorts differentiated by fracture history were simulated. The first contained patients with both a historical vertebral fracture and an incident vertebral fracture. The second contained patients with only an incident vertebral fracture. The PMO cohorts simulated had an initial Bone Mineral Density (BMD) T-Score of -3.0. The GIOP cohorts simulated had an initial BMD T-Score of -2.5.The ICERs for teriparatide versus bisphosphonate use for the one and two fracture PMO cohorts were ?36,995 per QALY and ?19,371 per QALY. The ICERs for teriparatide versus bisphosphonate use for the one and two fracture GIOP cohorts were ?20,826 per QALY and ?15,155 per QALY, respectively.The selection of teriparatide versus oral bisphosphonates as a first-line treatment for the high risk PMO and GIOP cohorts evaluated is justified at a cost per QALY threshold of ?50,000.",2012-01-09985,23110626,BMC Musculoskelet Disord,Daniel R Murphy,2012,13 /,213,No,23110626,"Daniel R Murphy; Lee J Smolen; Timothy M Klein; Robert W Klein; The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden, BMC Musculoskelet Disord, ; 13 ():1471-2474; 213",QALY,Sweden,Not Stated,Not Stated,Teriparatide vs. None,Not Stated,69 Years,69 Years,"Female, Male",Full,Lifetime,3.00,3.00,3271,Euro,2012,4741.34
10469,The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden,"ABSTRACT:This paper presents the model and results to evaluate the use of teriparatide as a first-line treatment of severe postmenopausal osteoporosis (PMO) and Glucocorticoid-induced osteoporosis (GIOP). The study's objective was to determine if teriparatide is cost effective against oral bisphosphonates for two large and high risk cohorts.A computer simulation model was created to model treatment, osteoporosis related fractures, and the remaining life of PMO and GIOP patients. Natural mortality and additional mortality from osteoporosis related fractures were included in the model. Costs for treatment with both teriparatide and oral bisphosphonates were included. Drug efficacy was modeled as a reduction to the relative fracture risk for subsequent osteoporosis related fractures. Patient health utilities associated with age, gender, and osteoporosis related fractures were included in the model. Patient costs and utilities were summarized and incremental cost-effectiveness ratios (ICERs) for teriparatide versus oral bisphosphonates and teriparatide versus no treatment were estimated.For each of the PMO and GIOP populations, two cohorts differentiated by fracture history were simulated. The first contained patients with both a historical vertebral fracture and an incident vertebral fracture. The second contained patients with only an incident vertebral fracture. The PMO cohorts simulated had an initial Bone Mineral Density (BMD) T-Score of -3.0. The GIOP cohorts simulated had an initial BMD T-Score of -2.5.The ICERs for teriparatide versus bisphosphonate use for the one and two fracture PMO cohorts were ?36,995 per QALY and ?19,371 per QALY. The ICERs for teriparatide versus bisphosphonate use for the one and two fracture GIOP cohorts were ?20,826 per QALY and ?15,155 per QALY, respectively.The selection of teriparatide versus oral bisphosphonates as a first-line treatment for the high risk PMO and GIOP cohorts evaluated is justified at a cost per QALY threshold of ?50,000.",2012-01-09985,23110626,BMC Musculoskelet Disord,Daniel R Murphy,2012,13 /,213,No,23110626,"Daniel R Murphy; Lee J Smolen; Timothy M Klein; Robert W Klein; The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden, BMC Musculoskelet Disord, ; 13 ():1471-2474; 213",QALY,Sweden,Not Stated,Not Stated,Teriparatide vs. None,Not Stated,69 Years,69 Years,"Female, Male",Full,Lifetime,3.00,3.00,7330,Euro,2012,10624.89
10470,The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden,"ABSTRACT:This paper presents the model and results to evaluate the use of teriparatide as a first-line treatment of severe postmenopausal osteoporosis (PMO) and Glucocorticoid-induced osteoporosis (GIOP). The study's objective was to determine if teriparatide is cost effective against oral bisphosphonates for two large and high risk cohorts.A computer simulation model was created to model treatment, osteoporosis related fractures, and the remaining life of PMO and GIOP patients. Natural mortality and additional mortality from osteoporosis related fractures were included in the model. Costs for treatment with both teriparatide and oral bisphosphonates were included. Drug efficacy was modeled as a reduction to the relative fracture risk for subsequent osteoporosis related fractures. Patient health utilities associated with age, gender, and osteoporosis related fractures were included in the model. Patient costs and utilities were summarized and incremental cost-effectiveness ratios (ICERs) for teriparatide versus oral bisphosphonates and teriparatide versus no treatment were estimated.For each of the PMO and GIOP populations, two cohorts differentiated by fracture history were simulated. The first contained patients with both a historical vertebral fracture and an incident vertebral fracture. The second contained patients with only an incident vertebral fracture. The PMO cohorts simulated had an initial Bone Mineral Density (BMD) T-Score of -3.0. The GIOP cohorts simulated had an initial BMD T-Score of -2.5.The ICERs for teriparatide versus bisphosphonate use for the one and two fracture PMO cohorts were ?36,995 per QALY and ?19,371 per QALY. The ICERs for teriparatide versus bisphosphonate use for the one and two fracture GIOP cohorts were ?20,826 per QALY and ?15,155 per QALY, respectively.The selection of teriparatide versus oral bisphosphonates as a first-line treatment for the high risk PMO and GIOP cohorts evaluated is justified at a cost per QALY threshold of ?50,000.",2012-01-09985,23110626,BMC Musculoskelet Disord,Daniel R Murphy,2012,13 /,213,No,23110626,"Daniel R Murphy; Lee J Smolen; Timothy M Klein; Robert W Klein; The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden, BMC Musculoskelet Disord, ; 13 ():1471-2474; 213",QALY,Sweden,Not Stated,Not Stated,Teriparatide vs. Oral bisphosphonates,Not Stated,69 Years,69 Years,"Female, Male",Full,Lifetime,3.00,3.00,15155,Euro,2012,21967.3
10471,The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden,"ABSTRACT:This paper presents the model and results to evaluate the use of teriparatide as a first-line treatment of severe postmenopausal osteoporosis (PMO) and Glucocorticoid-induced osteoporosis (GIOP). The study's objective was to determine if teriparatide is cost effective against oral bisphosphonates for two large and high risk cohorts.A computer simulation model was created to model treatment, osteoporosis related fractures, and the remaining life of PMO and GIOP patients. Natural mortality and additional mortality from osteoporosis related fractures were included in the model. Costs for treatment with both teriparatide and oral bisphosphonates were included. Drug efficacy was modeled as a reduction to the relative fracture risk for subsequent osteoporosis related fractures. Patient health utilities associated with age, gender, and osteoporosis related fractures were included in the model. Patient costs and utilities were summarized and incremental cost-effectiveness ratios (ICERs) for teriparatide versus oral bisphosphonates and teriparatide versus no treatment were estimated.For each of the PMO and GIOP populations, two cohorts differentiated by fracture history were simulated. The first contained patients with both a historical vertebral fracture and an incident vertebral fracture. The second contained patients with only an incident vertebral fracture. The PMO cohorts simulated had an initial Bone Mineral Density (BMD) T-Score of -3.0. The GIOP cohorts simulated had an initial BMD T-Score of -2.5.The ICERs for teriparatide versus bisphosphonate use for the one and two fracture PMO cohorts were ?36,995 per QALY and ?19,371 per QALY. The ICERs for teriparatide versus bisphosphonate use for the one and two fracture GIOP cohorts were ?20,826 per QALY and ?15,155 per QALY, respectively.The selection of teriparatide versus oral bisphosphonates as a first-line treatment for the high risk PMO and GIOP cohorts evaluated is justified at a cost per QALY threshold of ?50,000.",2012-01-09985,23110626,BMC Musculoskelet Disord,Daniel R Murphy,2012,13 /,213,No,23110626,"Daniel R Murphy; Lee J Smolen; Timothy M Klein; Robert W Klein; The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden, BMC Musculoskelet Disord, ; 13 ():1471-2474; 213",QALY,Sweden,Not Stated,Not Stated,Teriparatide vs. Oral bisphosphonates,Not Stated,69 Years,69 Years,"Female, Male",Full,Lifetime,3.00,3.00,20826,Euro,2012,30187.46
10472,Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison,"About 7% of children and adolescents are diagnosed with attention-deficit/hyperactivity disorder (ADHD) in the US. Patients with ADHD who are intolerant of or do not have an optimal response to stimulants often use non-stimulants as alternative therapies. Guanfacine extended-release (GXR) and atomoxetine (ATX) are the only non-stimulants approved by the US Food and Drug Administration for once-daily use in the treatment of children and adolescents with ADHD in the US. ATX has been on the market since 2002 while GXR was recently approved in 2009. To date, there is no comparative effectiveness or cost-effectiveness study comparing the two drugs.The aim of this study was to assess the cost effectiveness of GXR versus ATX for the treatment of ADHD in children and adolescents, using the comparative efficacy results from a matching-adjusted indirect comparison (MAIC).The MAIC method was used to compare the efficacy between GXR (target dose and lower doses) and ATX (target dose) in the absence of head-to-head clinical trials. Individual patients in the GXR trials were weighted such that the summary baseline characteristics and the efficacy of the placebo arm of the GXR trials matched exactly with those from published ATX trials. After weighting, the efficacy (i.e. change in the ADHD rating scale, fourth edition [ADHD-RS-IV] total score from baseline) was compared between each GXR dosing group and the ATX group. The results from the MAIC analyses were used to populate a 1-year Markov model that is used to compare the cost effectiveness of GXR versus ATX from a US third-party payer perspective. Effectiveness outcomes for each treatment group were estimated as the proportion of responders, defined as patients with =25% reduction in ADHD-RS-IV total score from baseline, and average quality-adjusted life years (QALYs). Utilities associated with response/non-response and disutilities due to adverse events were applied in the model. Costs included drug and medical service costs and were inflated to 2011 US dollars ($US). Incremental cost/QALY and incremental cost/responder were estimated. Univariate sensitivity analyses were conducted by varying all model parameters, including costs, utilities, and response rate.The target dose of GXR was 0.12?mg/kg/day. In match-adjusted populations with balanced baseline characteristics, patients receiving GXR at the dose of 0.09-0.12 (p?=?0.0009) and 0.075-0.09?mg/kg/day (p?=?0.0248) had better efficacy, while those receiving GXR at the dose of 0.046-0.075?mg/kg/day had comparable efficacy (p?=?0.0699), compared with patients receiving ATX at the target dose of 1.2?mg/kg/day. In the base case of the cost-effectiveness analysis (CEA), GXR had incremental cost-effectiveness ratios of $US10?637/QALY and $US853/responder, compared with ATX (incremental costs: $US74; incremental effectiveness: 0.007 QALYs and 86 responders per 1000 patients treated). Results of all univariate sensitivity analyses showed that the model results were robust to changes in model inputs.To our knowledge, this is the first application of the novel comparative efficacy method of MAIC to a CEA model. The MAIC results indicate that GXR (0.075-0.12?mg/kg/day) was more effective than ATX (1.2?mg/kg/day) in the trial population. The CEA results indicate that GXR is cost effective compared with ATX for the treatment of ADHD in children and adolescents.",2012-01-09988,23113551,Appl Health Econ Health Policy,M Haim Erder,2012,10 / 6,381-95,Yes,23113551,"M Haim Erder; Jipan Xie; James E Signorovitch; Kristina S Chen; Paul Hodgkins; Mei Lu; Eric Q Wu; Vanja Sikirica; Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison, Appl Health Econ Health Policy, Nov/1/2012; 10(6):1179-1896; 381-95",QALY,Not Stated,Not Stated,Not Stated,Guanfacine extended-release (GXR) within weight-based dosing range of 0.075 - 0.12 mg/kg/day (target dose and lower doses) vs. Atomoxetine (ATX) with weight-based dose of 1.2 mg/kg/day (target dose),Not Stated,18 Years,6 Years,"Female, Male",Full,1 Year,Not Stated,Not Stated,10637,United States,2011,12238.75
10473,Cost-effectiveness at two years in the VA Open Versus Endovascular Repair Trial,"Long-term clinical outcomes have been similar for endovascular and open repair of abdominal aortic aneurysm (AAA), increasing the importance of comparing cost-effectiveness.We compared data to two years from a multicenter randomized trial of 881 patients. Quality-adjusted life years (QALYs) were calculated from EQ-5D questionnaires. Healthcare utilization data were obtained from patients and from national VA and Medicare sources. VA costs were obtained using methods previously developed by the VA Health Economics Resource Center. Costs for non-VA care were determined from Medicare or billing data.Mean life-years were 1.78 in the endovascular and 1.74 in the open repair group (P?=?0.29), and mean QALYs were 1.462 in the endovascular and 1.461 in the open group (P?=?0.78). Although graft costs were higher in the endovascular group ($14,052 vs. $1363; P?<?0.001), length of stay was shorter (5.0 vs. 10.5 days; P?<?0.001), resulting in lower cost of AAA repair hospitalization in the endovascular group ($37,068 vs. $42,970; P?=?0.04). Costs remained lower after 2 years in the endovascular group but the difference was no longer significant (-$5019; 95% CI:?-$16,720 to $4928; P?=?0.35). The probability that endovascular repair was both more effective and less costly was 70.9% for life-years and 51.4% for QALYs.Endovascular repair is a cost-effective alternative to open repair in the US VA healthcare system for at least the first two years.",2012-01-09992,23116986,Eur J Vasc Endovasc Surg,F A Lederle,2012,44 / 6,543-8,No,23116986,"F A Lederle; K T Stroupe; Open Versus Endovascular Repair; Cost-effectiveness at two years in the VA Open Versus Endovascular Repair Trial, Eur J Vasc Endovasc Surg, ; 44(6):1078-5884; 543-8",QALY,Not Stated,Not Stated,Not Stated,Endovascular repair vs. Open repair,Not Stated,Not Stated,Not Stated,"Female, Male",Full,2 Years,3.00,3.00,-5019000,United States,2008,-6033229.49
10474,Brain damage treated with non proven intensive training 2003-2011: a Norwegian cost analysis,"There has been an increased request for intensive training and rehabilitation of patients with brain damage in Norway. These programs are demanding with regard to personnel, travelling, time and economic resources. We aimed to indicate cost and gain to make these programs cost-effective.A retrospective study included all patients referred to the Northern Norway Regional Health Authority (NNRHA) trust during the nine years period 2003-2011. All referrals to the NNRHA trust for the economic coverage of foreign based rehabilitation or habilitation programs (The Advanced Bio-Mechanical Rehabilitation (ABR), Institutes of Achievement of Human Potential program (IAHP) (Doman Method), Family Hope Center (FHC) program and the Kozijavkin Method) were included. 17 patients were detected and 15 fulfilled the inclusion criteria for funding. Median age was 8 years (1-31 years). Cost from the specialist health care point of view was calculated. A cut-off limit of ?57,000/quality adjusted life year (QALY) and a 4% discount rate was employed.The undiscounted cost per patient enrolled was calculated ?133,210 (discounted ?121,348). To make these therapies cost effective, a total of at least 2.13 QALYs (2.34 undiscounted QALYs) must be gained per patient enrolled. Such a gain could not be indicated and we doubt it is achievable.Non-proven intensive training programs for patients with brain damage are costly. As long as their effect has not been documented, health care services should not spend resources on these programs outside clinical trials.",2012-01-09994,23121754,Glob J Health Sci,Jan Norum,2012,4 / 6,179-84,No,23121754,"Jan Norum; Arnborg Ramsvik; Knut Tjeldnes; Brain damage treated with non proven intensive training 2003-2011: a Norwegian cost analysis, Glob J Health Sci, ; 4(6):1916-9736; 179-84",QALY,Not Stated,Not Stated,Not Stated,Intensive training and rehabilitation vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,9 Years,4.00,4.00,57000,Euro,2012,82621.96
10475,Cost-Effectiveness of Transcatheter Aortic Valve Replacement Compared With Surgical Aortic Valve Replacement in High-Risk Patients With Severe Aortic Stenosis: Results of the PARTNER (Placement of Aortic Transcatheter Valves) Trial (Cohort A),"The aim of this study was to evaluate the cost-effectiveness of transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement (AVR) for patients with severe aortic stenosis and high surgical risk.TAVR is an alternative to AVR for patients with severe aortic stenosis and high surgical risk.We performed a formal economic analysis based on cost, quality of life, and survival data collected in the PARTNER A (Placement of Aortic Transcatheter Valves) trial in which patients with severe aortic stenosis and high surgical risk were randomized to TAVR or AVR. Cumulative 12-month costs (assessed from a U.S. societal perspective) and quality-adjusted life-years (QALYs) were compared separately for the transfemoral (TF) and transapical (TA) cohorts.Although 12-month costs and QALYs were similar for TAVR and AVR in the overall population, there were important differences when results were stratified by access site. In the TF cohort, total 12-month costs were slightly lower with TAVR and QALYs were slightly higher such that TF-TAVR was economically dominant compared with AVR in the base case and economically attractive (incremental cost-effectiveness ratio <$50,000/QALY) in 70.9% of bootstrap replicates. In the TA cohort, 12-month costs remained substantially higher with TAVR, whereas QALYs tended to be lower such that TA-TAVR was economically dominated by AVR in the base case and economically attractive in only 7.1% of replicates.In the PARTNER trial, TAVR was an economically attractive strategy compared with AVR for patients suitable for TF access. Future studies are necessary to determine whether improved experience and outcomes with TA-TAVR can improve its cost-effectiveness relative to AVR. (THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial; NCT00530894).",2012-01-09996,23122802,J Am Coll Cardiol,Matthew R Reynolds,2012,60 / 25,2683-92,No,23122802,"Matthew R Reynolds; Elizabeth A Magnuson; Yang Lei; Kaijun Wang; Katherine Vilain; Haiyan Li; Joshua Walczak; Duane S Pinto; Vinod H Thourani; Lars G Svensson; Michael J Mack; D Craig Miller; Lowell E Satler; Joseph Bavaria; Craig R Smith; Martin B Leon; David J Cohen; PARTNER Investigators; Cost-Effectiveness of Transcatheter Aortic Valve Replacement Compared With Surgical Aortic Valve Replacement in High-Risk Patients With Severe Aortic Stenosis: Results of the PARTNER (Placement of Aortic Transcatheter Valves) Trial (Cohort A), J Am Coll Cardiol, Dec/25/2012; 60(25):0735-1097; 2683-92",QALY,Not Stated,Not Stated,Not Stated,Transcatheter aortic valve replacement (TAVR) vs. Surgical aortic valve replacement (AVR),Not Stated,Not Stated,Not Stated,"Female, Male",Full,12 Months,Not Stated,Not Stated,-18382.35,United States,2010,-21818.04
10476,Cost-Effectiveness of Transcatheter Aortic Valve Replacement Compared With Surgical Aortic Valve Replacement in High-Risk Patients With Severe Aortic Stenosis: Results of the PARTNER (Placement of Aortic Transcatheter Valves) Trial (Cohort A),"The aim of this study was to evaluate the cost-effectiveness of transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement (AVR) for patients with severe aortic stenosis and high surgical risk.TAVR is an alternative to AVR for patients with severe aortic stenosis and high surgical risk.We performed a formal economic analysis based on cost, quality of life, and survival data collected in the PARTNER A (Placement of Aortic Transcatheter Valves) trial in which patients with severe aortic stenosis and high surgical risk were randomized to TAVR or AVR. Cumulative 12-month costs (assessed from a U.S. societal perspective) and quality-adjusted life-years (QALYs) were compared separately for the transfemoral (TF) and transapical (TA) cohorts.Although 12-month costs and QALYs were similar for TAVR and AVR in the overall population, there were important differences when results were stratified by access site. In the TF cohort, total 12-month costs were slightly lower with TAVR and QALYs were slightly higher such that TF-TAVR was economically dominant compared with AVR in the base case and economically attractive (incremental cost-effectiveness ratio <$50,000/QALY) in 70.9% of bootstrap replicates. In the TA cohort, 12-month costs remained substantially higher with TAVR, whereas QALYs tended to be lower such that TA-TAVR was economically dominated by AVR in the base case and economically attractive in only 7.1% of replicates.In the PARTNER trial, TAVR was an economically attractive strategy compared with AVR for patients suitable for TF access. Future studies are necessary to determine whether improved experience and outcomes with TA-TAVR can improve its cost-effectiveness relative to AVR. (THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial; NCT00530894).",2012-01-09996,23122802,J Am Coll Cardiol,Matthew R Reynolds,2012,60 / 25,2683-92,No,23122802,"Matthew R Reynolds; Elizabeth A Magnuson; Yang Lei; Kaijun Wang; Katherine Vilain; Haiyan Li; Joshua Walczak; Duane S Pinto; Vinod H Thourani; Lars G Svensson; Michael J Mack; D Craig Miller; Lowell E Satler; Joseph Bavaria; Craig R Smith; Martin B Leon; David J Cohen; PARTNER Investigators; Cost-Effectiveness of Transcatheter Aortic Valve Replacement Compared With Surgical Aortic Valve Replacement in High-Risk Patients With Severe Aortic Stenosis: Results of the PARTNER (Placement of Aortic Transcatheter Valves) Trial (Cohort A), J Am Coll Cardiol, Dec/25/2012; 60(25):0735-1097; 2683-92",QALY,Not Stated,Not Stated,Not Stated,Transcatheter aortic valve replacement (TAVR) vs. Surgical aortic valve replacement (AVR),Not Stated,Not Stated,Not Stated,"Female, Male",Full,12 Months,Not Stated,Not Stated,-141514.28,United States,2010,-167963.52
10477,Cost-Effectiveness of Transcatheter Aortic Valve Replacement Compared With Surgical Aortic Valve Replacement in High-Risk Patients With Severe Aortic Stenosis: Results of the PARTNER (Placement of Aortic Transcatheter Valves) Trial (Cohort A),"The aim of this study was to evaluate the cost-effectiveness of transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement (AVR) for patients with severe aortic stenosis and high surgical risk.TAVR is an alternative to AVR for patients with severe aortic stenosis and high surgical risk.We performed a formal economic analysis based on cost, quality of life, and survival data collected in the PARTNER A (Placement of Aortic Transcatheter Valves) trial in which patients with severe aortic stenosis and high surgical risk were randomized to TAVR or AVR. Cumulative 12-month costs (assessed from a U.S. societal perspective) and quality-adjusted life-years (QALYs) were compared separately for the transfemoral (TF) and transapical (TA) cohorts.Although 12-month costs and QALYs were similar for TAVR and AVR in the overall population, there were important differences when results were stratified by access site. In the TF cohort, total 12-month costs were slightly lower with TAVR and QALYs were slightly higher such that TF-TAVR was economically dominant compared with AVR in the base case and economically attractive (incremental cost-effectiveness ratio <$50,000/QALY) in 70.9% of bootstrap replicates. In the TA cohort, 12-month costs remained substantially higher with TAVR, whereas QALYs tended to be lower such that TA-TAVR was economically dominated by AVR in the base case and economically attractive in only 7.1% of replicates.In the PARTNER trial, TAVR was an economically attractive strategy compared with AVR for patients suitable for TF access. Future studies are necessary to determine whether improved experience and outcomes with TA-TAVR can improve its cost-effectiveness relative to AVR. (THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial; NCT00530894).",2012-01-09996,23122802,J Am Coll Cardiol,Matthew R Reynolds,2012,60 / 25,2683-92,No,23122802,"Matthew R Reynolds; Elizabeth A Magnuson; Yang Lei; Kaijun Wang; Katherine Vilain; Haiyan Li; Joshua Walczak; Duane S Pinto; Vinod H Thourani; Lars G Svensson; Michael J Mack; D Craig Miller; Lowell E Satler; Joseph Bavaria; Craig R Smith; Martin B Leon; David J Cohen; PARTNER Investigators; Cost-Effectiveness of Transcatheter Aortic Valve Replacement Compared With Surgical Aortic Valve Replacement in High-Risk Patients With Severe Aortic Stenosis: Results of the PARTNER (Placement of Aortic Transcatheter Valves) Trial (Cohort A), J Am Coll Cardiol, Dec/25/2012; 60(25):0735-1097; 2683-92",QALY,Not Stated,Not Stated,Not Stated,Transcatheter aortic valve replacement (TAVR) vs. Surgical aortic valve replacement (AVR),Not Stated,Not Stated,Not Stated,"Female, Male",Full,12 Months,Not Stated,Not Stated,76877,United States,2010,91245.43
10478,Should we invest in environmental interventions to encourage physical activity in England? An economic appraisal,"The Department of Health in England asked the National Institute for Health and Clinical Excellence (NICE) to develop guidance on environmental interventions that promote physical activity. The economic appraisals summarized in this study informed the development of that guidance. In view of the difficulties inherent in applying conventional health economic evaluation techniques to public health interventions, the economic appraisal employed a multi-faceted approach.The analyses comprised of three components. Two cost-utility analyses; the first used a life-time disease progression model which sought to take into account the long-term benefits of physical activity on health outcomes, whereas the second used data from a regression analysis which captured some of the short-term, process benefits of physical activity which might manifest themselves in terms of improved mental health and wellbeing. The third approach was a cost-benefit analysis that took into account benefits beyond healthcare.The cost-utility approaches generated cost-effectiveness estimates ranging between ?100 and ?10?000 per QALY depending on the level of effectiveness of the intervention and the proportion of the intervention cost that was deemed to be attributable to health. The standardized cost-benefit ratio was 11:1.The findings present a consistent case to support environmental interventions that promote increased physical activity in the sedentary adult population. However, some degree of caution should be taken in interpreting the findings due to the limitations of the evidence upon which they are based. Further consideration should also be given to the relative merits of alternative approaches to assessing the value of changes to the built environment that might also benefit health as a positive externality.",2012-01-10005,23132876,Eur J Public Health,Sophie J Beale,2012,22 / 6,869-73,No,23132876,"Sophie J Beale; Matthew W Bending; Paul Trueman; Bhash Naidoo; Should we invest in environmental interventions to encourage physical activity in England? An economic appraisal, Eur J Public Health, ; 22(6):1101-1262; 869-73",QALY,Not Stated,Not Stated,Not Stated,Physical activity for 1 session per week vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Not Stated / None,3.50,3.50,9439,United Kingdom,2007,23587.68
10479,Should we invest in environmental interventions to encourage physical activity in England? An economic appraisal,"The Department of Health in England asked the National Institute for Health and Clinical Excellence (NICE) to develop guidance on environmental interventions that promote physical activity. The economic appraisals summarized in this study informed the development of that guidance. In view of the difficulties inherent in applying conventional health economic evaluation techniques to public health interventions, the economic appraisal employed a multi-faceted approach.The analyses comprised of three components. Two cost-utility analyses; the first used a life-time disease progression model which sought to take into account the long-term benefits of physical activity on health outcomes, whereas the second used data from a regression analysis which captured some of the short-term, process benefits of physical activity which might manifest themselves in terms of improved mental health and wellbeing. The third approach was a cost-benefit analysis that took into account benefits beyond healthcare.The cost-utility approaches generated cost-effectiveness estimates ranging between ?100 and ?10?000 per QALY depending on the level of effectiveness of the intervention and the proportion of the intervention cost that was deemed to be attributable to health. The standardized cost-benefit ratio was 11:1.The findings present a consistent case to support environmental interventions that promote increased physical activity in the sedentary adult population. However, some degree of caution should be taken in interpreting the findings due to the limitations of the evidence upon which they are based. Further consideration should also be given to the relative merits of alternative approaches to assessing the value of changes to the built environment that might also benefit health as a positive externality.",2012-01-10005,23132876,Eur J Public Health,Sophie J Beale,2012,22 / 6,869-73,No,23132876,"Sophie J Beale; Matthew W Bending; Paul Trueman; Bhash Naidoo; Should we invest in environmental interventions to encourage physical activity in England? An economic appraisal, Eur J Public Health, ; 22(6):1101-1262; 869-73",QALY,Not Stated,Not Stated,Not Stated,Physical activity for 2 sessions per week vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Not Stated / None,3.50,3.50,4719,United Kingdom,2007,11792.59
10480,Should we invest in environmental interventions to encourage physical activity in England? An economic appraisal,"The Department of Health in England asked the National Institute for Health and Clinical Excellence (NICE) to develop guidance on environmental interventions that promote physical activity. The economic appraisals summarized in this study informed the development of that guidance. In view of the difficulties inherent in applying conventional health economic evaluation techniques to public health interventions, the economic appraisal employed a multi-faceted approach.The analyses comprised of three components. Two cost-utility analyses; the first used a life-time disease progression model which sought to take into account the long-term benefits of physical activity on health outcomes, whereas the second used data from a regression analysis which captured some of the short-term, process benefits of physical activity which might manifest themselves in terms of improved mental health and wellbeing. The third approach was a cost-benefit analysis that took into account benefits beyond healthcare.The cost-utility approaches generated cost-effectiveness estimates ranging between ?100 and ?10?000 per QALY depending on the level of effectiveness of the intervention and the proportion of the intervention cost that was deemed to be attributable to health. The standardized cost-benefit ratio was 11:1.The findings present a consistent case to support environmental interventions that promote increased physical activity in the sedentary adult population. However, some degree of caution should be taken in interpreting the findings due to the limitations of the evidence upon which they are based. Further consideration should also be given to the relative merits of alternative approaches to assessing the value of changes to the built environment that might also benefit health as a positive externality.",2012-01-10005,23132876,Eur J Public Health,Sophie J Beale,2012,22 / 6,869-73,No,23132876,"Sophie J Beale; Matthew W Bending; Paul Trueman; Bhash Naidoo; Should we invest in environmental interventions to encourage physical activity in England? An economic appraisal, Eur J Public Health, ; 22(6):1101-1262; 869-73",QALY,Not Stated,Not Stated,Not Stated,Physical activity for 3 sessions per week vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Not Stated / None,3.50,3.50,3146,United Kingdom,2007,7861.73
10481,Should we invest in environmental interventions to encourage physical activity in England? An economic appraisal,"The Department of Health in England asked the National Institute for Health and Clinical Excellence (NICE) to develop guidance on environmental interventions that promote physical activity. The economic appraisals summarized in this study informed the development of that guidance. In view of the difficulties inherent in applying conventional health economic evaluation techniques to public health interventions, the economic appraisal employed a multi-faceted approach.The analyses comprised of three components. Two cost-utility analyses; the first used a life-time disease progression model which sought to take into account the long-term benefits of physical activity on health outcomes, whereas the second used data from a regression analysis which captured some of the short-term, process benefits of physical activity which might manifest themselves in terms of improved mental health and wellbeing. The third approach was a cost-benefit analysis that took into account benefits beyond healthcare.The cost-utility approaches generated cost-effectiveness estimates ranging between ?100 and ?10?000 per QALY depending on the level of effectiveness of the intervention and the proportion of the intervention cost that was deemed to be attributable to health. The standardized cost-benefit ratio was 11:1.The findings present a consistent case to support environmental interventions that promote increased physical activity in the sedentary adult population. However, some degree of caution should be taken in interpreting the findings due to the limitations of the evidence upon which they are based. Further consideration should also be given to the relative merits of alternative approaches to assessing the value of changes to the built environment that might also benefit health as a positive externality.",2012-01-10005,23132876,Eur J Public Health,Sophie J Beale,2012,22 / 6,869-73,No,23132876,"Sophie J Beale; Matthew W Bending; Paul Trueman; Bhash Naidoo; Should we invest in environmental interventions to encourage physical activity in England? An economic appraisal, Eur J Public Health, ; 22(6):1101-1262; 869-73",QALY,Not Stated,Not Stated,Not Stated,Physical activity for 4 sessions per week vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Not Stated / None,3.50,3.50,2360,United Kingdom,2007,5897.54
10482,Should we invest in environmental interventions to encourage physical activity in England? An economic appraisal,"The Department of Health in England asked the National Institute for Health and Clinical Excellence (NICE) to develop guidance on environmental interventions that promote physical activity. The economic appraisals summarized in this study informed the development of that guidance. In view of the difficulties inherent in applying conventional health economic evaluation techniques to public health interventions, the economic appraisal employed a multi-faceted approach.The analyses comprised of three components. Two cost-utility analyses; the first used a life-time disease progression model which sought to take into account the long-term benefits of physical activity on health outcomes, whereas the second used data from a regression analysis which captured some of the short-term, process benefits of physical activity which might manifest themselves in terms of improved mental health and wellbeing. The third approach was a cost-benefit analysis that took into account benefits beyond healthcare.The cost-utility approaches generated cost-effectiveness estimates ranging between ?100 and ?10?000 per QALY depending on the level of effectiveness of the intervention and the proportion of the intervention cost that was deemed to be attributable to health. The standardized cost-benefit ratio was 11:1.The findings present a consistent case to support environmental interventions that promote increased physical activity in the sedentary adult population. However, some degree of caution should be taken in interpreting the findings due to the limitations of the evidence upon which they are based. Further consideration should also be given to the relative merits of alternative approaches to assessing the value of changes to the built environment that might also benefit health as a positive externality.",2012-01-10005,23132876,Eur J Public Health,Sophie J Beale,2012,22 / 6,869-73,No,23132876,"Sophie J Beale; Matthew W Bending; Paul Trueman; Bhash Naidoo; Should we invest in environmental interventions to encourage physical activity in England? An economic appraisal, Eur J Public Health, ; 22(6):1101-1262; 869-73",QALY,Not Stated,Not Stated,Not Stated,Physical activity for 5 sessions per week vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Not Stated / None,3.50,3.50,1888,United Kingdom,2007,4718.04
10483,Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China,"Several rescue therapies have been used in patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB); however, the economic outcome of these therapies is unclear. The object of the current analysis was to evaluate the lifetime cost-effectiveness of rescue therapies among patients with LAM-resistant CHB.A Markov model was developed to simulate the clinical course of patients with LAM-resistant CHB. From the perspective of Chinese health care, a lifetime cost-utility analysis was performedfor 4 rescue strategies: adefovir (ADV), entecavir (ETV) or tenofovir (TDF) monotherapy and combination therapy using LAM and ADV. A hypothetical cohort of 45-year-old patients with genotypic or clinical LAM-resistant CHB entered the model, and the beginning health state was LAM-resistant CHB without other complications. The transition probabilities, efficacy and resistance data for each rescue therapy as well as the costs and utility data were estimated from the literature. The discount rate (3%) utilized for costs and benefits. Sensitivity analyses were used to explore the impact of uncertainty on the results.In LAM-resistant HBeAg-positive and HBeAg-negative CHB cohorts, TDF monotherapy and combination therapy were on the efficiency frontier for both positive and negative populations. Compared with no treatment, the use of combination therapy cost an additional $6,531.7 to gain 1 additional quality-adjusted life year (QALY) for HBeAg-positive patients and $4,571.7 to gain 1 additional QALY for HBeAg-negative patients. TDF monotherapy for HBeAg-positive patients, shows greater increase in QALYs but higher incremental cost-effectiveness ratio (ICER) in comparison with combination therapy. In probabilistic sensitivity analyses, combination therapy was the preferred option for health care systems with limited health resources, such as Chinese health care system.In Chinese patients with LAM-resistant CHB, combination therapy is a more cost-effective option than the competing rescue therapies.",2012-01-10008,23137013,BMC Health Serv Res,Bin Wu,2012,12 /,385,Yes,23137013,"Bin Wu; Jinfang Shen; Huafeng Cheng; Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China, BMC Health Serv Res, ; 12():1472-6963; 385",QALY,China,Not Stated,Not Stated,"Adefovir (ADV), 10 mg/day vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,7468,United States,2011,8592.55
10484,Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China,"Several rescue therapies have been used in patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB); however, the economic outcome of these therapies is unclear. The object of the current analysis was to evaluate the lifetime cost-effectiveness of rescue therapies among patients with LAM-resistant CHB.A Markov model was developed to simulate the clinical course of patients with LAM-resistant CHB. From the perspective of Chinese health care, a lifetime cost-utility analysis was performedfor 4 rescue strategies: adefovir (ADV), entecavir (ETV) or tenofovir (TDF) monotherapy and combination therapy using LAM and ADV. A hypothetical cohort of 45-year-old patients with genotypic or clinical LAM-resistant CHB entered the model, and the beginning health state was LAM-resistant CHB without other complications. The transition probabilities, efficacy and resistance data for each rescue therapy as well as the costs and utility data were estimated from the literature. The discount rate (3%) utilized for costs and benefits. Sensitivity analyses were used to explore the impact of uncertainty on the results.In LAM-resistant HBeAg-positive and HBeAg-negative CHB cohorts, TDF monotherapy and combination therapy were on the efficiency frontier for both positive and negative populations. Compared with no treatment, the use of combination therapy cost an additional $6,531.7 to gain 1 additional quality-adjusted life year (QALY) for HBeAg-positive patients and $4,571.7 to gain 1 additional QALY for HBeAg-negative patients. TDF monotherapy for HBeAg-positive patients, shows greater increase in QALYs but higher incremental cost-effectiveness ratio (ICER) in comparison with combination therapy. In probabilistic sensitivity analyses, combination therapy was the preferred option for health care systems with limited health resources, such as Chinese health care system.In Chinese patients with LAM-resistant CHB, combination therapy is a more cost-effective option than the competing rescue therapies.",2012-01-10008,23137013,BMC Health Serv Res,Bin Wu,2012,12 /,385,Yes,23137013,"Bin Wu; Jinfang Shen; Huafeng Cheng; Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China, BMC Health Serv Res, ; 12():1472-6963; 385",QALY,China,Not Stated,Not Stated,"Adefovir (ADV), 10 mg/day vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,3552.6,United States,2011,4087.56
10485,Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China,"Several rescue therapies have been used in patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB); however, the economic outcome of these therapies is unclear. The object of the current analysis was to evaluate the lifetime cost-effectiveness of rescue therapies among patients with LAM-resistant CHB.A Markov model was developed to simulate the clinical course of patients with LAM-resistant CHB. From the perspective of Chinese health care, a lifetime cost-utility analysis was performedfor 4 rescue strategies: adefovir (ADV), entecavir (ETV) or tenofovir (TDF) monotherapy and combination therapy using LAM and ADV. A hypothetical cohort of 45-year-old patients with genotypic or clinical LAM-resistant CHB entered the model, and the beginning health state was LAM-resistant CHB without other complications. The transition probabilities, efficacy and resistance data for each rescue therapy as well as the costs and utility data were estimated from the literature. The discount rate (3%) utilized for costs and benefits. Sensitivity analyses were used to explore the impact of uncertainty on the results.In LAM-resistant HBeAg-positive and HBeAg-negative CHB cohorts, TDF monotherapy and combination therapy were on the efficiency frontier for both positive and negative populations. Compared with no treatment, the use of combination therapy cost an additional $6,531.7 to gain 1 additional quality-adjusted life year (QALY) for HBeAg-positive patients and $4,571.7 to gain 1 additional QALY for HBeAg-negative patients. TDF monotherapy for HBeAg-positive patients, shows greater increase in QALYs but higher incremental cost-effectiveness ratio (ICER) in comparison with combination therapy. In probabilistic sensitivity analyses, combination therapy was the preferred option for health care systems with limited health resources, such as Chinese health care system.In Chinese patients with LAM-resistant CHB, combination therapy is a more cost-effective option than the competing rescue therapies.",2012-01-10008,23137013,BMC Health Serv Res,Bin Wu,2012,12 /,385,Yes,23137013,"Bin Wu; Jinfang Shen; Huafeng Cheng; Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China, BMC Health Serv Res, ; 12():1472-6963; 385",QALY,China,Not Stated,Not Stated,Combination therapy using lamivudine (LAM) and adefovir (ADV) vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,6531.7,United States,2011,7515.26
10486,Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China,"Several rescue therapies have been used in patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB); however, the economic outcome of these therapies is unclear. The object of the current analysis was to evaluate the lifetime cost-effectiveness of rescue therapies among patients with LAM-resistant CHB.A Markov model was developed to simulate the clinical course of patients with LAM-resistant CHB. From the perspective of Chinese health care, a lifetime cost-utility analysis was performedfor 4 rescue strategies: adefovir (ADV), entecavir (ETV) or tenofovir (TDF) monotherapy and combination therapy using LAM and ADV. A hypothetical cohort of 45-year-old patients with genotypic or clinical LAM-resistant CHB entered the model, and the beginning health state was LAM-resistant CHB without other complications. The transition probabilities, efficacy and resistance data for each rescue therapy as well as the costs and utility data were estimated from the literature. The discount rate (3%) utilized for costs and benefits. Sensitivity analyses were used to explore the impact of uncertainty on the results.In LAM-resistant HBeAg-positive and HBeAg-negative CHB cohorts, TDF monotherapy and combination therapy were on the efficiency frontier for both positive and negative populations. Compared with no treatment, the use of combination therapy cost an additional $6,531.7 to gain 1 additional quality-adjusted life year (QALY) for HBeAg-positive patients and $4,571.7 to gain 1 additional QALY for HBeAg-negative patients. TDF monotherapy for HBeAg-positive patients, shows greater increase in QALYs but higher incremental cost-effectiveness ratio (ICER) in comparison with combination therapy. In probabilistic sensitivity analyses, combination therapy was the preferred option for health care systems with limited health resources, such as Chinese health care system.In Chinese patients with LAM-resistant CHB, combination therapy is a more cost-effective option than the competing rescue therapies.",2012-01-10008,23137013,BMC Health Serv Res,Bin Wu,2012,12 /,385,Yes,23137013,"Bin Wu; Jinfang Shen; Huafeng Cheng; Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China, BMC Health Serv Res, ; 12():1472-6963; 385",QALY,China,Not Stated,Not Stated,Combination therapy using lamivudine (LAM) and adefovir (ADV) vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,4571.7,United States,2011,5260.12
10487,Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China,"Several rescue therapies have been used in patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB); however, the economic outcome of these therapies is unclear. The object of the current analysis was to evaluate the lifetime cost-effectiveness of rescue therapies among patients with LAM-resistant CHB.A Markov model was developed to simulate the clinical course of patients with LAM-resistant CHB. From the perspective of Chinese health care, a lifetime cost-utility analysis was performedfor 4 rescue strategies: adefovir (ADV), entecavir (ETV) or tenofovir (TDF) monotherapy and combination therapy using LAM and ADV. A hypothetical cohort of 45-year-old patients with genotypic or clinical LAM-resistant CHB entered the model, and the beginning health state was LAM-resistant CHB without other complications. The transition probabilities, efficacy and resistance data for each rescue therapy as well as the costs and utility data were estimated from the literature. The discount rate (3%) utilized for costs and benefits. Sensitivity analyses were used to explore the impact of uncertainty on the results.In LAM-resistant HBeAg-positive and HBeAg-negative CHB cohorts, TDF monotherapy and combination therapy were on the efficiency frontier for both positive and negative populations. Compared with no treatment, the use of combination therapy cost an additional $6,531.7 to gain 1 additional quality-adjusted life year (QALY) for HBeAg-positive patients and $4,571.7 to gain 1 additional QALY for HBeAg-negative patients. TDF monotherapy for HBeAg-positive patients, shows greater increase in QALYs but higher incremental cost-effectiveness ratio (ICER) in comparison with combination therapy. In probabilistic sensitivity analyses, combination therapy was the preferred option for health care systems with limited health resources, such as Chinese health care system.In Chinese patients with LAM-resistant CHB, combination therapy is a more cost-effective option than the competing rescue therapies.",2012-01-10008,23137013,BMC Health Serv Res,Bin Wu,2012,12 /,385,Yes,23137013,"Bin Wu; Jinfang Shen; Huafeng Cheng; Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China, BMC Health Serv Res, ; 12():1472-6963; 385",QALY,China,Not Stated,Not Stated,Entecavir (ETV) vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,24268.9,United States,2011,27923.38
10488,Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China,"Several rescue therapies have been used in patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB); however, the economic outcome of these therapies is unclear. The object of the current analysis was to evaluate the lifetime cost-effectiveness of rescue therapies among patients with LAM-resistant CHB.A Markov model was developed to simulate the clinical course of patients with LAM-resistant CHB. From the perspective of Chinese health care, a lifetime cost-utility analysis was performedfor 4 rescue strategies: adefovir (ADV), entecavir (ETV) or tenofovir (TDF) monotherapy and combination therapy using LAM and ADV. A hypothetical cohort of 45-year-old patients with genotypic or clinical LAM-resistant CHB entered the model, and the beginning health state was LAM-resistant CHB without other complications. The transition probabilities, efficacy and resistance data for each rescue therapy as well as the costs and utility data were estimated from the literature. The discount rate (3%) utilized for costs and benefits. Sensitivity analyses were used to explore the impact of uncertainty on the results.In LAM-resistant HBeAg-positive and HBeAg-negative CHB cohorts, TDF monotherapy and combination therapy were on the efficiency frontier for both positive and negative populations. Compared with no treatment, the use of combination therapy cost an additional $6,531.7 to gain 1 additional quality-adjusted life year (QALY) for HBeAg-positive patients and $4,571.7 to gain 1 additional QALY for HBeAg-negative patients. TDF monotherapy for HBeAg-positive patients, shows greater increase in QALYs but higher incremental cost-effectiveness ratio (ICER) in comparison with combination therapy. In probabilistic sensitivity analyses, combination therapy was the preferred option for health care systems with limited health resources, such as Chinese health care system.In Chinese patients with LAM-resistant CHB, combination therapy is a more cost-effective option than the competing rescue therapies.",2012-01-10008,23137013,BMC Health Serv Res,Bin Wu,2012,12 /,385,Yes,23137013,"Bin Wu; Jinfang Shen; Huafeng Cheng; Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China, BMC Health Serv Res, ; 12():1472-6963; 385",QALY,China,Not Stated,Not Stated,Entecavir (ETV) vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,19157.1,United States,2011,22041.83
10489,Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China,"Several rescue therapies have been used in patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB); however, the economic outcome of these therapies is unclear. The object of the current analysis was to evaluate the lifetime cost-effectiveness of rescue therapies among patients with LAM-resistant CHB.A Markov model was developed to simulate the clinical course of patients with LAM-resistant CHB. From the perspective of Chinese health care, a lifetime cost-utility analysis was performedfor 4 rescue strategies: adefovir (ADV), entecavir (ETV) or tenofovir (TDF) monotherapy and combination therapy using LAM and ADV. A hypothetical cohort of 45-year-old patients with genotypic or clinical LAM-resistant CHB entered the model, and the beginning health state was LAM-resistant CHB without other complications. The transition probabilities, efficacy and resistance data for each rescue therapy as well as the costs and utility data were estimated from the literature. The discount rate (3%) utilized for costs and benefits. Sensitivity analyses were used to explore the impact of uncertainty on the results.In LAM-resistant HBeAg-positive and HBeAg-negative CHB cohorts, TDF monotherapy and combination therapy were on the efficiency frontier for both positive and negative populations. Compared with no treatment, the use of combination therapy cost an additional $6,531.7 to gain 1 additional quality-adjusted life year (QALY) for HBeAg-positive patients and $4,571.7 to gain 1 additional QALY for HBeAg-negative patients. TDF monotherapy for HBeAg-positive patients, shows greater increase in QALYs but higher incremental cost-effectiveness ratio (ICER) in comparison with combination therapy. In probabilistic sensitivity analyses, combination therapy was the preferred option for health care systems with limited health resources, such as Chinese health care system.In Chinese patients with LAM-resistant CHB, combination therapy is a more cost-effective option than the competing rescue therapies.",2012-01-10008,23137013,BMC Health Serv Res,Bin Wu,2012,12 /,385,Yes,23137013,"Bin Wu; Jinfang Shen; Huafeng Cheng; Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China, BMC Health Serv Res, ; 12():1472-6963; 385",QALY,China,Not Stated,Not Stated,Tenofovir (TDF) vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,9359.8,United States,2011,10769.23
10490,Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China,"Several rescue therapies have been used in patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB); however, the economic outcome of these therapies is unclear. The object of the current analysis was to evaluate the lifetime cost-effectiveness of rescue therapies among patients with LAM-resistant CHB.A Markov model was developed to simulate the clinical course of patients with LAM-resistant CHB. From the perspective of Chinese health care, a lifetime cost-utility analysis was performedfor 4 rescue strategies: adefovir (ADV), entecavir (ETV) or tenofovir (TDF) monotherapy and combination therapy using LAM and ADV. A hypothetical cohort of 45-year-old patients with genotypic or clinical LAM-resistant CHB entered the model, and the beginning health state was LAM-resistant CHB without other complications. The transition probabilities, efficacy and resistance data for each rescue therapy as well as the costs and utility data were estimated from the literature. The discount rate (3%) utilized for costs and benefits. Sensitivity analyses were used to explore the impact of uncertainty on the results.In LAM-resistant HBeAg-positive and HBeAg-negative CHB cohorts, TDF monotherapy and combination therapy were on the efficiency frontier for both positive and negative populations. Compared with no treatment, the use of combination therapy cost an additional $6,531.7 to gain 1 additional quality-adjusted life year (QALY) for HBeAg-positive patients and $4,571.7 to gain 1 additional QALY for HBeAg-negative patients. TDF monotherapy for HBeAg-positive patients, shows greater increase in QALYs but higher incremental cost-effectiveness ratio (ICER) in comparison with combination therapy. In probabilistic sensitivity analyses, combination therapy was the preferred option for health care systems with limited health resources, such as Chinese health care system.In Chinese patients with LAM-resistant CHB, combination therapy is a more cost-effective option than the competing rescue therapies.",2012-01-10008,23137013,BMC Health Serv Res,Bin Wu,2012,12 /,385,Yes,23137013,"Bin Wu; Jinfang Shen; Huafeng Cheng; Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China, BMC Health Serv Res, ; 12():1472-6963; 385",QALY,China,Not Stated,Not Stated,Tenofovir (TDF) vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,7370.4,United States,2011,8480.26
10491,Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model,"ABSTRACT:Streptococcus pneumoniae infections, which place a considerable burden on healthcare resources, can be reduced in a cost-effective manner using a 7-valent pneumococcal conjugate vaccine (PCV-7). We compare the cost effectiveness of a 13-valent PCV (PCV-13) and a 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with that of PCV-7 in Turkey.A cost-utility analysis was conducted and a decision analytical model was used to estimate the proportion of the Turkish population <10 years old that would experience 10 mutually exclusive outcomes over the course of 1 year from a perspective of a healthcare system. Model outcomes were adjusted according to the population demographics and region-specific serotype distribution in Turkey. Health outcomes and direct healthcare costs were simulated for PCV-7, PCV-13 and PHiD-CV.PCV-13 and PHiD-CV are projected to have a substantial impact on pneumococcal disease in Turkey versus PCV-7, with 2,223 and 3,156 quality-adjusted life years (QALYs) and 2,146 and 2,081 life years, respectively, being saved under a 3+1 schedule. Projections of direct medical costs showed that a PHiD-CV vaccination programme would provide the greatest cost savings, offering additional savings of US$11,718,813 versus PCV-7 and US$8,235,010 versus PCV-13. Probabilistic sensitivity analysis showed that PHiD-CV dominated PCV-13 in terms of QALYs gained and cost savings in 58.3% of simulations.Under the modeled conditions, PHiD-CV would provide the most cost-effective intervention for reducing pneumococcal disease in Turkish children.",2012-01-10009,23137037,BMC Health Serv Res,Mustafa Bakir,2012,12 /,386,Yes,23137037,"Mustafa Bakir; Ozden T?rel; Oleksandr Topachevskyi; Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model, BMC Health Serv Res, ; 12():1472-6963; 386",QALY,Not Stated,Not Stated,Not Stated,13-valent pneumococcal conjugate vaccine (PCV-13) vs. 7-valent pneumococcal conjugate vaccine (PCV-7),Not Stated,Not Stated,Not Stated,"Female, Male",Full,1 Year,Not Stated,Not Stated,Not Stated,United States,2010,Not Stated
10492,Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model,"ABSTRACT:Streptococcus pneumoniae infections, which place a considerable burden on healthcare resources, can be reduced in a cost-effective manner using a 7-valent pneumococcal conjugate vaccine (PCV-7). We compare the cost effectiveness of a 13-valent PCV (PCV-13) and a 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with that of PCV-7 in Turkey.A cost-utility analysis was conducted and a decision analytical model was used to estimate the proportion of the Turkish population <10 years old that would experience 10 mutually exclusive outcomes over the course of 1 year from a perspective of a healthcare system. Model outcomes were adjusted according to the population demographics and region-specific serotype distribution in Turkey. Health outcomes and direct healthcare costs were simulated for PCV-7, PCV-13 and PHiD-CV.PCV-13 and PHiD-CV are projected to have a substantial impact on pneumococcal disease in Turkey versus PCV-7, with 2,223 and 3,156 quality-adjusted life years (QALYs) and 2,146 and 2,081 life years, respectively, being saved under a 3+1 schedule. Projections of direct medical costs showed that a PHiD-CV vaccination programme would provide the greatest cost savings, offering additional savings of US$11,718,813 versus PCV-7 and US$8,235,010 versus PCV-13. Probabilistic sensitivity analysis showed that PHiD-CV dominated PCV-13 in terms of QALYs gained and cost savings in 58.3% of simulations.Under the modeled conditions, PHiD-CV would provide the most cost-effective intervention for reducing pneumococcal disease in Turkish children.",2012-01-10009,23137037,BMC Health Serv Res,Mustafa Bakir,2012,12 /,386,Yes,23137037,"Mustafa Bakir; Ozden T?rel; Oleksandr Topachevskyi; Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model, BMC Health Serv Res, ; 12():1472-6963; 386",QALY,Not Stated,Not Stated,Not Stated,10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) vs. 7-valent pneumococcal conjugate vaccine (PCV-13),Not Stated,Not Stated,Not Stated,"Female, Male",Full,1 Year,Not Stated,Not Stated,Not Stated,United States,2010,Not Stated
10493,Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model,"ABSTRACT:Streptococcus pneumoniae infections, which place a considerable burden on healthcare resources, can be reduced in a cost-effective manner using a 7-valent pneumococcal conjugate vaccine (PCV-7). We compare the cost effectiveness of a 13-valent PCV (PCV-13) and a 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with that of PCV-7 in Turkey.A cost-utility analysis was conducted and a decision analytical model was used to estimate the proportion of the Turkish population <10 years old that would experience 10 mutually exclusive outcomes over the course of 1 year from a perspective of a healthcare system. Model outcomes were adjusted according to the population demographics and region-specific serotype distribution in Turkey. Health outcomes and direct healthcare costs were simulated for PCV-7, PCV-13 and PHiD-CV.PCV-13 and PHiD-CV are projected to have a substantial impact on pneumococcal disease in Turkey versus PCV-7, with 2,223 and 3,156 quality-adjusted life years (QALYs) and 2,146 and 2,081 life years, respectively, being saved under a 3+1 schedule. Projections of direct medical costs showed that a PHiD-CV vaccination programme would provide the greatest cost savings, offering additional savings of US$11,718,813 versus PCV-7 and US$8,235,010 versus PCV-13. Probabilistic sensitivity analysis showed that PHiD-CV dominated PCV-13 in terms of QALYs gained and cost savings in 58.3% of simulations.Under the modeled conditions, PHiD-CV would provide the most cost-effective intervention for reducing pneumococcal disease in Turkish children.",2012-01-10009,23137037,BMC Health Serv Res,Mustafa Bakir,2012,12 /,386,Yes,23137037,"Mustafa Bakir; Ozden T?rel; Oleksandr Topachevskyi; Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model, BMC Health Serv Res, ; 12():1472-6963; 386",QALY,Not Stated,Not Stated,Not Stated,10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) vs. 13-valent pneumococcal conjugate vaccine (PCV-13),Not Stated,Not Stated,Not Stated,"Female, Male",Full,1 Year,Not Stated,Not Stated,Not Stated,United States,2010,Not Stated
10494,Cost analysis of enhancing linkages to HIV care following jail: a cost-effective intervention,"We are not aware of published cost-effectiveness studies addressing community transitional programs for HIV-infected jail detainees. To address this gap, data from 9 sites of EnhanceLink, a project that enrolled HIV-infected releasees from jails across the US, were examined. Figures on the number of clients served, cost of linkage services, number of linkages and 6-month sustained linkages to community HIV care, and number of clients achieving viral suppression were assessed for subjects released in the first quarter of 2010 (n = 543). The cost analysis included all costs that participating service agencies incurred. A cost-effectiveness analysis was conducted to estimate the new HIV cases averted by EnhanceLink and the cost per quality-adjusted life year saved by the program. The mean cost per linked client was $4,219; the mean cost per 6-month sustained linkage was $4,670; and the mean cost per client achieving viral suppression was $8,432. Compared to standard care, the cost per additional quality-adjusted life year saved was $72,285, suggesting that the EnhanceLink interventions were cost-effective from the societal perspective.",2012-01-10013,23138877,AIDS Behav,Anne C Spaulding,2013,17 Suppl 2 /,,No,23138877,"Anne C Spaulding; Steven D Pinkerton; Hillary Superak; Marc J Cunningham; Stephen Resch; Alison O Jordan; Zhou Yang; Cost analysis of enhancing linkages to HIV care following jail: a cost-effective intervention, AIDS Behav, 2013 Oct; 17 Suppl 2():1573-3254",QALY,Not Stated,Not Stated,Not Stated,EnhanceLink: community transitional program vs. Standard of care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,10 Years,3.00,3.00,72285,United States,2010,85795.18
10495,Dynamic modelling of costs and health consequences of school closure during an influenza pandemic,"ABSTRACT:The purpose of this article is to evaluate the cost-effectiveness of school closure during a potential influenza pandemic and to examine the trade-off between costs and health benefits for school closure involving different target groups and different closure durations.We developed two models: a dynamic disease model capturing the spread of influenza and an economic model capturing the costs and benefits of school closure. Decisions were based on quality-adjusted life years gained using incremental cost-effectiveness ratios. The disease model is an age-structured SEIR compartmental model based on the population of Oslo. We studied the costs and benefits of school closure by varying the age targets (kindergarten, primary school, secondary school) and closure durations (1-10 weeks), given pandemics with basic reproductive number of 1.5, 2.0 or 2.5.The cost-effectiveness of school closure varies depending on the target group, duration and whether indirect costs are considered. Using a case fatality rate (CFR) of 0.1-0.2% and with current cost-effectiveness threshold for Norway, closing secondary school is the only cost-effective strategy, when indirect costs are included. The most cost-effective strategies would be closing secondary schools for 8 weeks if R0=1.5, 6 weeks if R0=2.0, and 4 weeks if R0= 2.5. For severe pandemics with case fatality rates of 1-2%, similar to the Spanish flu, or when indirect costs are disregarded, the optimal strategy is closing kindergarten, primary and secondary school for extended periods of time. For a pandemic with 2009 H1N1 characteristics (mild severity and low transmissibility), closing schools would not be cost-effective, regardless of the age target of school children.School closure has moderate impact on the epidemic's scope, but the resulting disruption to society imposes a potentially great cost in terms of lost productivity from parents' work absenteeism.",2012-01-10017,23140513,BMC Public Health,Yiting Xue,2012,12 /,962,No,23140513,"Yiting Xue; Ivar S?nb? Kristiansen; Birgitte Freiesleben de Blasio; Dynamic modelling of costs and health consequences of school closure during an influenza pandemic, BMC Public Health, ; 12():1471-2458; 962",QALY,Not Stated,Not Stated,Not Stated,School closure for 8 weeks during a potential influenza pandemic vs. School closure for 7 weeks,Not Stated,Not Stated,Not Stated,"Female, Male",Full,10 Weeks,4.00,4.00,28929,United States,2008,34774.91
10496,Dynamic modelling of costs and health consequences of school closure during an influenza pandemic,"ABSTRACT:The purpose of this article is to evaluate the cost-effectiveness of school closure during a potential influenza pandemic and to examine the trade-off between costs and health benefits for school closure involving different target groups and different closure durations.We developed two models: a dynamic disease model capturing the spread of influenza and an economic model capturing the costs and benefits of school closure. Decisions were based on quality-adjusted life years gained using incremental cost-effectiveness ratios. The disease model is an age-structured SEIR compartmental model based on the population of Oslo. We studied the costs and benefits of school closure by varying the age targets (kindergarten, primary school, secondary school) and closure durations (1-10 weeks), given pandemics with basic reproductive number of 1.5, 2.0 or 2.5.The cost-effectiveness of school closure varies depending on the target group, duration and whether indirect costs are considered. Using a case fatality rate (CFR) of 0.1-0.2% and with current cost-effectiveness threshold for Norway, closing secondary school is the only cost-effective strategy, when indirect costs are included. The most cost-effective strategies would be closing secondary schools for 8 weeks if R0=1.5, 6 weeks if R0=2.0, and 4 weeks if R0= 2.5. For severe pandemics with case fatality rates of 1-2%, similar to the Spanish flu, or when indirect costs are disregarded, the optimal strategy is closing kindergarten, primary and secondary school for extended periods of time. For a pandemic with 2009 H1N1 characteristics (mild severity and low transmissibility), closing schools would not be cost-effective, regardless of the age target of school children.School closure has moderate impact on the epidemic's scope, but the resulting disruption to society imposes a potentially great cost in terms of lost productivity from parents' work absenteeism.",2012-01-10017,23140513,BMC Public Health,Yiting Xue,2012,12 /,962,No,23140513,"Yiting Xue; Ivar S?nb? Kristiansen; Birgitte Freiesleben de Blasio; Dynamic modelling of costs and health consequences of school closure during an influenza pandemic, BMC Public Health, ; 12():1471-2458; 962",QALY,Not Stated,Not Stated,Not Stated,School closure for 9 weeks during a potential influenza pandemic vs. School closure for 8 weeks,Not Stated,Not Stated,Not Stated,"Female, Male",Full,10 Weeks,4.00,4.00,77819,United States,2008,93544.51
10497,Dynamic modelling of costs and health consequences of school closure during an influenza pandemic,"ABSTRACT:The purpose of this article is to evaluate the cost-effectiveness of school closure during a potential influenza pandemic and to examine the trade-off between costs and health benefits for school closure involving different target groups and different closure durations.We developed two models: a dynamic disease model capturing the spread of influenza and an economic model capturing the costs and benefits of school closure. Decisions were based on quality-adjusted life years gained using incremental cost-effectiveness ratios. The disease model is an age-structured SEIR compartmental model based on the population of Oslo. We studied the costs and benefits of school closure by varying the age targets (kindergarten, primary school, secondary school) and closure durations (1-10 weeks), given pandemics with basic reproductive number of 1.5, 2.0 or 2.5.The cost-effectiveness of school closure varies depending on the target group, duration and whether indirect costs are considered. Using a case fatality rate (CFR) of 0.1-0.2% and with current cost-effectiveness threshold for Norway, closing secondary school is the only cost-effective strategy, when indirect costs are included. The most cost-effective strategies would be closing secondary schools for 8 weeks if R0=1.5, 6 weeks if R0=2.0, and 4 weeks if R0= 2.5. For severe pandemics with case fatality rates of 1-2%, similar to the Spanish flu, or when indirect costs are disregarded, the optimal strategy is closing kindergarten, primary and secondary school for extended periods of time. For a pandemic with 2009 H1N1 characteristics (mild severity and low transmissibility), closing schools would not be cost-effective, regardless of the age target of school children.School closure has moderate impact on the epidemic's scope, but the resulting disruption to society imposes a potentially great cost in terms of lost productivity from parents' work absenteeism.",2012-01-10017,23140513,BMC Public Health,Yiting Xue,2012,12 /,962,No,23140513,"Yiting Xue; Ivar S?nb? Kristiansen; Birgitte Freiesleben de Blasio; Dynamic modelling of costs and health consequences of school closure during an influenza pandemic, BMC Public Health, ; 12():1471-2458; 962",QALY,Not Stated,Not Stated,Not Stated,School closure for 10 weeks during a potential influenza pandemic vs. School closure for 9 weeks,Not Stated,Not Stated,Not Stated,"Female, Male",Full,10 Weeks,4.00,4.00,187991,United States,2008,225979.85
10498,Dynamic modelling of costs and health consequences of school closure during an influenza pandemic,"ABSTRACT:The purpose of this article is to evaluate the cost-effectiveness of school closure during a potential influenza pandemic and to examine the trade-off between costs and health benefits for school closure involving different target groups and different closure durations.We developed two models: a dynamic disease model capturing the spread of influenza and an economic model capturing the costs and benefits of school closure. Decisions were based on quality-adjusted life years gained using incremental cost-effectiveness ratios. The disease model is an age-structured SEIR compartmental model based on the population of Oslo. We studied the costs and benefits of school closure by varying the age targets (kindergarten, primary school, secondary school) and closure durations (1-10 weeks), given pandemics with basic reproductive number of 1.5, 2.0 or 2.5.The cost-effectiveness of school closure varies depending on the target group, duration and whether indirect costs are considered. Using a case fatality rate (CFR) of 0.1-0.2% and with current cost-effectiveness threshold for Norway, closing secondary school is the only cost-effective strategy, when indirect costs are included. The most cost-effective strategies would be closing secondary schools for 8 weeks if R0=1.5, 6 weeks if R0=2.0, and 4 weeks if R0= 2.5. For severe pandemics with case fatality rates of 1-2%, similar to the Spanish flu, or when indirect costs are disregarded, the optimal strategy is closing kindergarten, primary and secondary school for extended periods of time. For a pandemic with 2009 H1N1 characteristics (mild severity and low transmissibility), closing schools would not be cost-effective, regardless of the age target of school children.School closure has moderate impact on the epidemic's scope, but the resulting disruption to society imposes a potentially great cost in terms of lost productivity from parents' work absenteeism.",2012-01-10017,23140513,BMC Public Health,Yiting Xue,2012,12 /,962,No,23140513,"Yiting Xue; Ivar S?nb? Kristiansen; Birgitte Freiesleben de Blasio; Dynamic modelling of costs and health consequences of school closure during an influenza pandemic, BMC Public Health, ; 12():1471-2458; 962",QALY,Not Stated,Not Stated,Not Stated,School closure for 7 weeks during a potential influenza pandemic vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,10 Weeks,4.00,4.00,3648,United States,2008,4385.18
10499,Primary prevention of pediatric abusive head trauma: A cost audit and cost-utility analysis,"To obtain comprehensive, reliable data on the direct cost of pediatric abusive head trauma in New Zealand, and to use this data to evaluate the possible cost-benefit of a national primary prevention program.A 5 year cohort of infants with abusive head trauma admitted to hospital in Auckland, New Zealand was reviewed. We determined the direct costs of hospital care (from hospital and Ministry of Health financial records), community rehabilitation (from the Accident Compensation Corporation), special education (from the Ministry of Education), investigation and child protection (from the Police and Child Protective Services), criminal trials (from the Police, prosecution and defence), punishment of offenders (from the Department of Corrections) and life-time care for moderate or severe disability (from the Accident Compensation Corporation). Analysis of the possible cost-utility of a national primary prevention program was undertaken, using the costs established in our cohort, recent New Zealand national data on the incidence of pediatric abusive head trauma, international data on quality of life after head trauma, and published international literature on prevention programs.There were 52 cases of abusive head trauma in the sample. Hospital costs totaled $NZ2,433,340, child protection $NZ1,560,123, police investigation $NZ1,842,237, criminal trials $NZ3,214,020, punishment of offenders $NZ4,411,852 and community rehabilitation $NZ2,895,848. Projected education costs for disabled survivors were $NZ2,452,148, and the cost of projected lifetime care was $NZ33,624,297. Total costs were $NZ52,433,864, averaging $NZ1,008,344 per child. Cost-utility analysis resulted in a strongly positive economic argument for primary prevention, with expected case scenarios showing lowered net costs with improved health outcomes.Pediatric abusive head trauma is very expensive, and on a conservative estimate the costs of acute hospitalization represent no more than 4% of lifetime direct costs. If shaken baby prevention programs are effective, there is likely to be a strong economic argument for their implementation. This study also provides robust data for future cost-benefit analysis in the field of abusive head trauma prevention.",2012-01-10020,23141137,Child Abuse Negl,Joshua Friedman,2012,36 / 11-12,760-70,No,23141137,"Joshua Friedman; Peter Reed; Peter Sharplin; Patrick Kelly; Primary prevention of pediatric abusive head trauma: A cost audit and cost-utility analysis, Child Abuse Negl, ; 36(11-12):0145-2134; 760-70",QALY,New Zealand,Not Stated,Not Stated,National newborn-based intervention program to reduce pediatric abusive head trauma (AHT) (20% national reduction of AHT) vs. None,Not Stated,2 Years,2 Years,"Female, Male",Full,Lifetime,3.50,3.50,36100,New Zealand,2012,32980.6
10500,Economic evaluation of different treatment modalities in acute kidney injury,"Major controversy exists regarding the preferred treatment option for acute kidney injury (AKI). The purpose of this study was to assess the incremental cost-effectiveness of continuous renal replacement therapy (CRRT) versus intermittent renal replacement therapy (IRRT) and conservative (CONS) AKI treatment in Belgium.An area-under-the-curve model based on survival analysis was used to estimate costs and health outcomes using a 2-year time horizon. Input data were derived from the multi-centre Stuivenberg Hospital Acute Renal Failure 4 study.Analyses indicated that in-hospital mortality, hospitalization costs and hospital length of stay differed significantly between treatment modes. Follow-up mortality rates and follow-up cost per day showed no significant difference between the treatment modes. Utility values, which improved gradually after admission to the hospital, revealed no significant differences between the three treatment strategies. CONS treatment was associated with a 2-year cost of 33,802? and 0.54 quality-adjusted life years (QALYs). The CRRT was the most expensive therapy with a cost of 51,365? leading to 0.57 QALYs. The cost and QALYs associated with IRRT were 43,445? and 0.50, respectively. One-way sensitivity analyses indicated the 'in-hospital mortality' as the variable with the greatest influence on the results. Probabilistic sensitivity analysis resulted in a significant difference in treatment costs but no significant difference in QALY gain.This study has indicated that the most expensive treatment (CRRT) associated with an incremental cost of approximately ?7920 generates only a minor non-significant increase in QALYs of 0.07 compared with IRRT. Additionally, the results revealed that the RRTs did not result in a significant increase in QALYs despite their higher cost compared with the CONS treatment. From a health economic perspective, the latter seems to be the preferred treatment strategy.",2012-01-10024,23144072,Nephrol Dial Transplant,Delphine M De Smedt,2012,27 / 11,4095-101,No,23144072,"Delphine M De Smedt; Monique M Elseviers; Robert L Lins; Lieven Annemans; Economic evaluation of different treatment modalities in acute kidney injury, Nephrol Dial Transplant, ; 27(11):0931-0509; 4095-101",QALY,Belgium,Not Stated,Not Stated,Continuous renal replacement therapy (CRRT) vs. Conservative (CONS) acute kidney injury (AKI) treatment,Not Stated,Not Stated,19 Years,"Female, Male",Full,2 Years,3.00,Not Stated,590410,Euro,2010,927409.79
